Search Result
Results for "
antitumor
" in MedChemExpress (MCE) Product Catalog:
5362
Inhibitors & Agonists
42
Biochemical Assay Reagents
128
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-115995
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-50 (compound 1a), a thiazolidinone, is a potent antitumor agent. Antitumor agent-50 has the potential for osteosarcoma (OS) research .
|
-
-
- HY-N8975
-
|
|
Others
|
Cancer
|
|
Antitumor agent-137 (Compound M12) is a linear diarylheptanoid compound with antitumor activity .
|
-
-
- HY-159811
-
|
|
Others
|
Cancer
|
|
Antitumor agent-187 (compound I) is an isoflavone derivative with antitumor activity. Antitumor agent-187 shows IC50 values of 5.23 μM and 2.63 μM on A2780 and SKOV3, respectily .
|
-
-
- HY-149839
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-112 (compound 3a) is a potent antitumor agent. Antitumor agent-112 induces apoptosis. Antitumor agent-112 has cytotoxic activity on A549 cells with an IC50 value of 91.35 μM .
|
-
-
- HY-152538
-
|
|
G-quadruplex
|
Cancer
|
|
Antitumor agent-85 is a G-quadruplex (G4)-ligand with the ability to stabilize different G4-DNA structures. Antitumor agent-85 has highly effective anti-tumor properties .
|
-
-
- HY-152537
-
|
|
G-quadruplex
|
Cancer
|
|
Antitumor agent-84 (compound 21a) is a G-quadruplex (G4)-ligand with the ability to stabilize different G4-DNA structures. Antitumor agent-84 has highly effective anti-tumor properties .
|
-
-
- HY-162462
-
|
|
Apoptosis
|
Cancer
|
Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC50 = 0.79 μM) and antitumor activity in vitro (IC50 = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis .
|
-
-
- HY-151295
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC50 value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .
|
-
-
- HY-162131
-
-
-
- HY-146409
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-59 (Compound 13b) is a potent antitumor agent. Antitumor agent-59 effectively inhibits the proliferation and migration of HCT116 cells. Antitumor agent-59 induces HCT116 cell apoptosis and arrests the cell cycle at the G2/M phase .
|
-
-
- HY-117708
-
|
|
Others
|
Cancer
|
|
Antitumor agent-144 (16) is an antitumor agent, with IC50 values of 2.6 μM and 8.4 μM in L1210 and KB cells, respectively .
|
-
-
- HY-162560
-
|
|
Others
|
Cancer
|
|
Antitumor agent-162 (compound 52a) is a potent and orally active antitumor agent. Antitumor agent-162 shows cytotoxicity .
|
-
-
- HY-139975
-
|
|
Fluorescent Dye
|
Cancer
|
|
Antitumor agent-31 is a nanosized chelates of anchoring bisazo dye. Antitumor agent-31 can be used for an antioxidant and antitumor agent .
|
-
-
- HY-146094
-
|
|
Topoisomerase
|
Cancer
|
|
Antitumor agent-63 (Compound 40), a 20 (S)-O-linked camptothecin (CPT) glycoconjugate, is an antitumor agent without toxicity towards normal cells. Antitumor agent-63 shows high stability and very weak direct topoisomerase I (Topo I) inhibition .
|
-
-
- HY-146048
-
-
-
- HY-155038
-
|
|
PARP
CDK
|
Cancer
|
|
Antitumor agent-104 (Compound 9) is an antitumor agent by inhibiting DNA damage repair in tumors. Antitumor agent-104 inhibits PARP1 enzymatic activity and the PAR protein level. Antitumor agent-104 also inhibits the expression of CDK12 .
|
-
-
- HY-176738
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor agent-204 (compound 15a) is a potent antitumor agent. Antitumor agent-204 shows cytotoxicity. Antitumor agent-204 induces nitric oxide (NO) release and reactive oxygen species (ROS) generation. Antitumor agent-204 induces apoptosis and induces cell cycle arrest at G2/M phase. Antitumor agent-204 shows antitumor activity .
|
-
-
- HY-168587
-
|
|
Others
|
Cancer
|
|
Antitumor agent-189 (Compound DN4) is a potent antitumor agent. Antitumor agent-189 inhibits A498 cells proliferation, adhesion and invasion with an IC50 of 1.94 μM. Antitumor agent-189 also inhibits angiogenesis and tumor growth in the xenograft model of A498 cells .
|
-
-
- HY-149019
-
|
|
c-Kit
Apoptosis
|
Cancer
|
|
Antitumor agent-70 (compound 8b) has anti-tumor activity and can induce cell apoptosis. Antitumor agent-70 inhibits multiple myeloma with an IC50 value of 0.12 μM. Antitumor agent-70 is a potential multi-targeted kinase inhibitor especially for c-Kit .
|
-
-
- HY-151618
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-79 shows good antiproliferative activities against hepatocellular carcinoma and breast cancer cells with IC50 values of 0.7-7.9 μM. Antitumor agent-79 induces cancer cells apoptosis and shows in vivo antitumor effects. Antitumor agent-79 can be used for the research of cancer .
|
-
-
- HY-115949
-
|
|
HSP
|
Cancer
|
|
Antitumor agent-47 (Compound 3e) is a silibinin derivative with an antitumor activity. Antitumor agent-47 shows cytotoxic activity against NCI-H1299 and HT29 cells with IC50 values of 8.07 µM and 6.27 µM, respectively .
|
-
-
- HY-W194107
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Antitumor agent-152 (Compound 5) is a specific substrate and inhibitor of deoxycytidine kinase (dCK) with anticancer activity. Antitumor agent-152 can inhibit the uptake of 3H-dC in L1210 leukemia cells with an IC50 value of 1.12 μM .
|
-
-
- HY-151404
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-76 (Compound TP-P1) is an orally active, rapid-release and water-soluble Triptolide (HY-32735) proagent with antitumor activity .
|
-
-
- HY-162129
-
|
|
Photosensitizer
|
Cancer
|
|
Antitumor agent-131 (Compound 2-p) is an ER fluorescent probe with an IC50 value of 23 nM for HepG2 tumor cells. Antitumor agent-131 can be used as a photosensitizer for the study of cancer photodynamics .
|
-
-
- HY-146046
-
|
|
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-56 (Compound 33) is a triptolide derivative with antitumor, anti-inflammatory and NO release activities. Antitumor agent-56 significantly inhibits the growth of melanoma. Antitumor agent-56 is orally active .
|
-
-
- HY-157564
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-135 (Compound 13) is a potent antitumor agent. Antitumor agent-135 induces cell apoptosis, with IC50s of 3.79 , 10.55, 1.14, and 4.14 μM for NSCLC cell lines (A549, H460, PC-9, and PC-9/GR) .
|
-
-
- HY-161840
-
|
|
FGFR
|
Cancer
|
|
Antitumor agent-176 (Compound 22), an antitumor agent, can effectively bind to FGF2 and inhibit the activation of fibroblast growth factor receptor (FGFR) in multiple myeloma (MM) cells, exhibiting significant antitumor activity both in vivo and in vitro against MM .
|
-
-
- HY-151620
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-80 (compound 11) is an orally active and potent antitumor agent. Antitumor agent-80 induces apoptosis in tumor cells .
|
-
-
- HY-161332
-
|
|
Ferroptosis
Pyroptosis
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor agent-143 (compound 2c) is an antitumor agent that blocks cell proliferation of A549 cells during the S phase and induces an early apoptosis. Antitumor agent-143 induces cell death via ferroptosis, apoptosis by a ROS-mediated mitochondrial dysfunction pathway and GSDMD-mediated pyroptosis .
|
-
-
- HY-115950
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-48 (Compound 4a) is a 2,3-dehydrosilybin derivative with an antitumor activity. Antitumor agent-48 shows cytotoxic activity against MCF-7, NCI-H1299, HepG2 and HT29 cells with IC50 values of 8.06 µM, 13.1 µM, 16.51 µM and 12.44 µM, respectively .
|
-
-
- HY-146432
-
|
|
Apoptosis
Raf
Ras
ROS Kinase
MDM-2/p53
|
Cancer
|
|
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model .
|
-
-
- HY-156775
-
|
|
Others
|
Cancer
|
|
Antitumor agent-119 (compound 13K) is a 2-benzoxazolyl hydrazone derivative with anticancer activities. Antitumor agent-119 inhibits the cell growth of Butkitt, CCRF-CEM, HeLa, and HT-29 with IC50 values of 30 nM, 140 nM, 100 nM, and 40 nM, respectively .
|
-
-
- HY-170483
-
|
|
HSV
HIV
|
Infection
Cancer
|
|
Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV with EC50 of 0.03 μM and 0.81 μM. Antitumor agent-191 exhibits potential antitumor efficacy, that inhibits cancer cell HepG2, WI-38, Vero and MCF-7, with IC50s of 19.6, 39.3, 18.3 and 28 μM, respectively .
|
-
-
- HY-146025
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-F10 (Compound F10) is a camptothecin derivative. Antitumor agent-F10 is an orally–bioavailable and potent antitumor agent. Antitumor agent-F10 displays lower acute toxicity than SN-38 does and the solubility of F10 reached 9.86 μg/mL .
|
-
-
- HY-N11442
-
|
|
Others
|
Cancer
|
|
Antitumor agent-89 (Compd OTS-5), a natural compound, weakly suppresses fMLP-induced superoxide generation .
|
-
-
- HY-145438
-
|
|
Others
|
Cancer
|
|
Antitumor agent-38 is a potent antitumor agents. Antitumor agent-38 shows antiproliferative activity for cancer cells. Antitumor agent-38 induces cell cycle arrest at the late S and G2/M phase without interfering with microtubule formation or cell morphology[1].
|
-
-
- HY-151429
-
|
|
Apoptosis
Ferroptosis
Bcl-2 Family
COX
|
Cancer
|
|
Antitumor agent-77 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-77 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-77 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
|
-
-
- HY-151428
-
|
|
Ferroptosis
Apoptosis
Bcl-2 Family
COX
|
Cancer
|
|
Antitumor agent-78 is an antitumor agent, inhibits cancer cells growth and migration. Antitumor agent-78 triggers ferroptosis by inhibiting GPx-4 and elevating COX2. Antitumor agent-78 also activates intrinsic apoptotic pathway (Bax-Bcl-2-caspase-3) and hinders Epithelial-mesenchymal transition (EMT) process of cancer cells .
|
-
-
- HY-151286
-
|
|
STAT
|
Cancer
|
|
Antitumor agent-73 is a Diosgenin (HY-N0177) derivative, which inhibits STAT3 signaling and activates Pdia3/ERp57 exogenously. Antitumor agent-73 shows potent anti-tumor activity against various cancer cell lines, 7.9-341.7-fold stronger than Diosgenin .
|
-
-
- HY-144331
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Antitumor agent-42 (Compound 15h) is a bifunctional agent exhibiting both tubulin polymerized inhibition and NO-releasing activities, resulting in potent anti-angiogenesis, colony formation inhibition, cell cycle arrest and apoptosis induction effects .
|
-
-
- HY-157548
-
|
|
p62
Atg8/LC3
Autophagy
|
Cancer
|
|
Antitumor agent-133 (compound 4d) is a bis-isatin derivative, with activities against Huh1 (IC50=17.13 μM) and Huh7 (IC50=8.27 μM). Antitumor agent-133 induces cell autophagy and inhibits tumor growth through regulation of LC3BII, ATG5 and p62 proteins .
|
-
-
- HY-149717
-
|
|
Others
|
Cancer
|
|
Antitumor agent-122 (Compound 5j) is an antitumor agent with good efficacy, limited toxicity and low resistance. Antitumor agent-122 has antiproliferative activity for MGC-803 cell, HepG2 cell, SKOV3 cell and T24 cell with IC50 values of 5.23 μM, 3.60 μM, 1.43 μM, 3.03 μM, respectively .
|
-
-
- HY-152774
-
|
|
Akt
PI3K
|
Cancer
|
|
Antitumor agent-86 (compound 5a) inhibits MCF-7 breast cancer cells with an IC50 value of 2.62 µM. Antitumor agent-86 induces cell apoptosis and cell cycle arrest, and shows antineoplastic activity by targeting RAS/PI3K/Akt/JNK signaling cascades .
|
-
-
- HY-146080
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC50s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways .
|
-
-
- HY-142086
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-40 is an antitumor agent. Antitumor agent-40 can be used for the research of cancer .
|
-
-
- HY-139735
-
|
|
Drug Intermediate
|
Cancer
|
|
Antitumor agent-29 is a novel hepatocyte-targeting antitumor proagent, which exhibits good antitumor activity and low toxic side effects.
|
-
-
- HY-148592
-
|
|
Cytochrome P450
|
Cancer
|
|
Antitumor agent-87 is a potent antitumor agent. Antitumor agent-87 shows a high affinity for CYP1A1 with a Ki value of 0.23 µM. Antitumor agent-87 shows antiproliferative activity. Antitumor agent-87 induces cell cycle arrest at the G2/M phase. Antitumor agent-87 show antitumoral activity .
|
-
-
- HY-146250
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Antitumor Agent-71 is an antiproliferative activity antitumor agent and against tumor cell lines with IC50 values ranging from 3.98-15.70 μM. Antitumor Agent-71 is an antitumor agent that can inhibit tubulin polymerization.
|
-
-
- HY-161821
-
|
|
Interleukin Related
TNF Receptor
MMP
|
Cancer
|
|
Antitumor agent-173 (Compound 4b) is a prodrug of Cycloicaritin (HY-N1940). Antitumor agent-173 is a substrate for OATP2B1. Antitumor agent-173 selectively inhibits the growth of tumor Antitumor agent-173 significantly increases the oral bioavailability of Cycloicaritin and exerts good antitumor activity and safety .
|
-
-
- HY-161831
-
|
|
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor agent-175 (Compound Ru2) is an antitumor agent with photocytotoxicity, demonstrating selective antitumor effects against triple-negative breast cancer (TNBC) cells .
|
-
- HY-151914
-
|
|
Atg7
Autophagy
|
Cancer
|
|
Antitumor agent-82 (compound 6g) is a potent anti-tumor agent. Antitumor agent-82 shows anti-proliferative activity. Antitumor agent-82 induces cell Autophagy by the ATG5/ATG7 signaling pathway .
|
-
- HY-146038
-
|
|
Apoptosis
ROS Kinase
MDM-2/p53
Bcl-2 Family
|
Cancer
|
|
Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC50 of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3. Antitumor agent-55 induces G1/S phase arrest and apoptosis in PC3 .
|
-
- HY-146743
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-53 is a potent antitumor agent. Antitumor agent-53 induces cell cycle arrest at the G2/M phase. Antitumor agent-53 inhibits the PI3K/AKT pathway to induce the apoptosis of HGC-27 cells. Antitumor agent-53 has the potential for the research of gastrointestinal tumors .
|
-
- HY-145908
-
|
|
NO Synthase
|
Cancer
|
|
Antitumor agent-49 (Compound 10) is a Harmine derivative-furoxan hybrids containing NO donor, with antitumor activities. Antitumor agent-49 shows cytotoxic activity against HepG2 cells with an IC50 of 1.79 µM. Antitumor agent-49 produces high levels of NO in vitro .
|
-
- HY-146114
-
|
|
Microtubule/Tubulin
Quinone Reductase
|
Cancer
|
|
Antitumor agent-67 (compound 3) is a potent antitumor agent. Antitumor agent-67 has highly selective toxicity to cancer cells and lower damage to normal cells. Antitumor agent-67 can be activated by NQO1 and effectively liberate podophyllotoxin and kill tumor cells. Antitumor agent-67 significantly suppresses cancer growth in HepG2 xenograft models without obvious toxicity .
|
-
- HY-146093
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-62 (Compound 47) is a NO-releasing antitumor agent. Antitumor agent-62 shows antiproliferative activity against four cancer cell lines. Antitumor agent-62 activates mitochondrial apoptosis pathway and arrests cell cycle at G2/M phase .
|
-
- HY-155748
-
|
|
MELK
Apoptosis
|
Cancer
|
|
Antitumor agent-116 (compound 6C) is an anti-tumor agent with anti-proliferative activities. Antitumor agent-11 induces cell apoptosis, and shows the binding affinity against the MELK receptor .
|
-
- HY-169292
-
|
|
Glycosidase
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor agent-188 (compound C6) exerts α-glucosidase inhibitory activity, and antitumor effects.Antitumor agent-188 induces excessive production of ROS to trigger oxidative stress .
|
-
- HY-146323
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-58 (Compound C18) is an anti-tumor agent. Antitumor agent-58 effectively inhibits colony formation and cell migration of MGC-803 cells. Antitumor agent-58 induces apoptosis of MGC-803 cells through activation of the p38 and JNK signaling pathways. Antitumor agent-58 induces mitochondrial dysfunction of MGC-803 cells. Antitumor agent-58 effectively inhibits tumor growth of xenograft model bearing MGC-803 cells .
|
-
- HY-149829
-
|
|
Apoptosis
Autophagy
|
Cancer
|
|
Antitumor agent-97 (compound 42) is an anticancer agent. Antitumor agent-97 can effectively inhibit the proliferation and autophagy of MGC 803 cells, and induce apoptosis. Antitumor agent-97 also enhances ROS accumulation in MGC 803 cells. Antitumor agent-97 can be used in cancer research .
|
-
- HY-115948
-
|
|
Others
|
Cancer
|
|
Antitumor agent-46 (Compound 2h) is an anti-tumor agent. Antitumor agent-46 demonstrates markedly higher antiproliferative activity on MCF-7 cells with an IC50 value of 2.08 µM .
|
-
- HY-161425
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-149 (Compound 3) is an analogue of Echinomycin (HY-106101). Antitumor agent-149 inhibits HIF-1α-mediated transcription. Antitumor agent-149 induces cancer cell apoptosis. Antitumor agent-149 inhibits tumor growth in SW620 xenograft mice model .
|
-
- HY-173133
-
|
|
Autophagy
Atg7
|
Cancer
|
|
Antitumor agent-199 (Compound 4b) is an antitumor agent. Antitumor agent-199 exhibits significant antiproliferative activity against multiple tumor cell lines. Antitumor agent-199 can induce autophagy in cancer cells via the ATG5/ATG7 pathway and can be used in the study of cancer .
|
-
- HY-155039
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-105 (Compound 37) is an antitumor agent. Antitumor agent-105 has antitumor activity against A549, H1299, H460, HCT116, MDA-MB-231 cells, with IC50 values of 6.7, 8.3, 4.3, 4.4, 6.7 μM respectively .
|
-
- HY-15961
-
|
|
Others
|
Cancer
|
|
Antitumor agent-3 is a potent compound which comprises a new imidazopyridine having excellent antitumor activity as an active ingredient.
|
-
- HY-146416
-
|
|
Photosensitizer
|
Cancer
|
|
Antitumor photosensitizer-2 (Compound 11) is a potent photosensitizer. Antitumor photosensitizer-2 has outstanding photodynamic anti-tumor effects without obvious skin photo-toxicity, and can act as new agent candidates for photodynamic research .
|
-
- HY-146414
-
|
|
Photosensitizer
|
Cancer
|
|
Antitumor photosensitizer-1 (Compound 8) is a potent photosensitizer. Antitumor photosensitizer-1 has outstanding photodynamic anti-tumor effects without obvious skin photo-toxicity, and can act as new agent candidates for photodynamic research .
|
-
- HY-163767
-
|
|
β-catenin
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-171 (Compound 35) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 1.61 μM. Antitumor agent-171 exhibits high affinity to β-catenin with Kd of 0.63 μM. Antitumor agent-171 inhibits the gene expression of axin2 with IC50 of 0.84 μM. Antitumor agent-171 inhibits cell viability of HCT116 with IC50 of 4.39 μM. Antitumor agent-171 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
|
-
- HY-157222
-
|
|
Apoptosis
Ferroptosis
|
Cancer
|
|
Antitumor agent-125 (compound 17A) is a novel platinum(IV) prodrug. Antitumor agent-125 can activate the mitochondrion-dependent apoptosis pathway. Antitumor agent-125 induces ferroptosis in HCT-116/OXA .
|
-
- HY-163768
-
|
|
β-catenin
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-172 (Compound 28) is an inhibitor for β-catenin/BCL9 interaction with IC50 of 3.92 μM. Antitumor agent-172 exhibits high affinity to β-catenin with Kd of 82 nM. Antitumor agent-172 activates T cells, promotes antigen presentation, and exhibits antitumor efficacy and good pharmacokinetic characteristics in mouse models .
|
-
- HY-159176
-
|
|
Cytochrome P450
|
Cancer
|
|
Antitumor agent-183 (compound 3f) has antitumor activity with metabolic stability. Antitumor agent-183 inhibits cancer cell growth, with IC50s less than 5 nM for A549, HCT116, and HS578T cells. The albumin-bound nanoparticle formulation of Antitumor agent-183 has prolonged retention in the tumor tissues .
|
-
- HY-W781271
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-160 (compound Ia) is a derivative of the antifungal agent PHENALENONE (HY-W286805) and has antitumor activity .
|
-
- HY-155109
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research .
|
-
- HY-144125
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-41 (compound N-12), a potent antitumor agent, enhibits excellent antimigration and anti-invasion activity. Antitumor agent-41 (compound N-12) induces tumor inhibition via tumor necrosis and inflammatory response .
|
-
- HY-155544
-
|
|
c-Met/HGFR
|
Cancer
|
|
Antitumor agent-111 (compound 46) is an c-Met kinase inhibitor (IC50=46 nM) with antitumor and antiproliferative activity. Antitumor agent-111 arrests cell cycle at G0/G1 phase, and induces apoptosis .
|
-
- HY-150696
-
|
|
Apoptosis
Caspase
PARP
|
Cancer
|
|
Antitumor agent-72 (compound 6w) is a potent anticancer agent. Antitumor agent-72 has anticancer activity and induces apoptosis through activation of caspase-3 and cleavage of PARP. Antitumor agent-72 can be used for cancer research .
|
-
- HY-149972
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-96 (Compound D34) is a potent MRE11 inhibitor. Antitumor agent-96 down-regulates the HR pathway by binding with MRE11 and suppressing its endonuclease functions. Antitumor agent-96 induces CM cells apoptosis .
|
-
- HY-155503
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-103 (compound 24l) is an apoptosis inducer with antiproliferative and anti-clony formation activities. Antitumor agent-103 arrests cell cycle at G0/G1 phase, enhances NO production, and exhibits anti-tumor activity .
|
-
- HY-147540
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-66 (Compound 4) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-66 has the potential for the research of cancer diseases .
|
-
- HY-163841
-
|
|
Others
|
Cancer
|
|
Antitumor agent-181 (HJ1) is an anticancer agent. Antitumor agent-181 inhibits tumor cell growth in vivo and in vitro .
|
-
- HY-W669548
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-193 (Compound 13) has antitumor effect, but has no activity against normal cell line MRC-5 .
|
-
- HY-147539
-
|
|
Others
|
Cancer
|
|
Antitumor agent-65 (Compound 5) is an analogue/derivative of (-)-cleistenolide. Antitumor agent-65 has the potential for the research of cancer diseases .
|
-
- HY-162644
-
|
|
PD-1/PD-L1
PARP
|
Cancer
|
|
Antitumor agent-170 (Compound C6) exhibits inhibitory activities against PD-1/PD-L1 interaction and PARP7, with IC50 of 0.342 μM and 7.05 nM. Antitumor agent-170 exhibits a high affinity to human PD-L1, with a Ki of 9.31 nM. Antitumor agent-170 restores the T cell function and increases IFN-γ secretion. Antitumor agent-170 exhibits antitumor efficacy against melanoma in mouse models and good pharmacokinetic characteristics .
|
-
- HY-161647
-
|
|
Reactive Oxygen Species (ROS)
Apoptosis
Autophagy
Ferroptosis
|
Cancer
|
|
Antitumor agent-156 (Compound 20) causes DNA damage and mitochondrial dysfunction, promotes reactive oxygen species
generation, activates endoplasmic reticulum stress, and induce apoptosis, autophagy and ferroptosis. Antitumor agent-156 shows superior antitumor activity against cancer cells including Cisplatin (HY-17394) resistance cells. Antitumor agent-156 displayS good liver-targeting ability .
|
-
- HY-116447
-
|
|
Mitochondrial Metabolism
Apoptosis
|
Cancer
|
|
Antitumor agent-159 (Compound 13b) targets the mitochondria and downregulates cardiolipin levels. Antitumor agent-159 inhibits the proliferation of cancer cell MDA-MB-231, arrests the cell cycle at sub-G1 phase, and induces apoptosis in MDA-MB-231. Antitumor agent-159 exhibits antitumor efficacy in MDA-MB-231 xenograft mouse models .
|
-
- HY-161180
-
|
|
NAMPT
|
Cancer
|
|
Antitumor Agent-136 (Compound 17) is a potent broad-spectrum antitumor agent and a NAMPT inhibitor with an IC50 of 9.5 nM. Antitumor Agent-136 can reduce the levels of intracellular and extracellular NAMPT protein through the ubiquitin proteasome pathway, thus achieving tumor inhibition .
|
-
- HY-147538
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-64 (Compound 8d) is a diosgenin derivative. Antitumor agent-64 exhibits potent cytotoxic activity against A549 cell line. Antitumor agent-64 induces A549 cells apoptosis via the mitochondria-related pathway .
|
-
- HY-163965
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
Antitumor agent-185 (compound 3) shows antitumor activity that could effectively reduce the growth of tumors and prolong the survival time of mice in vivo .
|
-
- HY-128934
-
-
- HY-144361
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-44 (Compound 5n) disrupts the mitochondrial homeostasis, induces cell cycle arrest and apoptosis in human adenocarcinoma cells. Antitumor agent-44 (Compound 5n) possesses good anti-tumor activity in a lung-cancer-cell xenograft mice model .
|
-
- HY-144340
-
|
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Antitumor agent-43 (Compound 4B) is a potent antitumor agent, with an IC50of 0.5 µM for (T-24 cell). Antitumor agent-43 (Compound 4B) induces cell cycle arrest at G2/M phase .
|
-
- HY-147521
-
|
|
Necroptosis
|
Cancer
|
|
Antitumor photosensitizer-3 (Compound I) is a chlorin derivative. Antitumor photosensitizer-3 induces tumor cells apoptosis and necrosis under 650 nm laser irradiation. Antitumor photosensitizer-3 exhibits lower skin photo-toxicity than positive reference m-THPC in vivo .
|
-
- HY-170947
-
|
|
STAT
Quinone Reductase
|
Cancer
|
|
Antitumor agent-195 (compound 16c) is a dual targeting agent of STAT3 and NQO1. Antitumor agent-195 significantly inhibits phosphorylation of STAT3 at Tyr705 at a concentration of 1 μM and effectively induce Apoptosis in MDAMB-231 and MDA-MB-468 breast cancer cells. Antitumor agent-195 as a NQO1 substrate strongly increases ROS generation and causes severe DNA damage in a dose-dependent manner. Antitumor agent-195 shows encouraging anti-tumor efficacy in the MDA-MB-231 xenograft model .
|
-
- HY-155020
-
|
|
Histone Methyltransferase
GLP Receptor
|
Cancer
|
|
Antitumor agent-101 is a selective covalent inhibitor of lysine methyltransferases G9a/GLP, with IC50s of 8.5 nM and 5.5 nM for G9a and GLP, respectively. Antitumor agent-101 shows antitumor efficacy in the PANC-1 xenograft model .
|
-
- HY-170594
-
|
|
Atg7
Autophagy
|
Cancer
|
|
Antitumor agent-192 (Compound 2f) is a β-carboline antitumor agent. Antitumor agent-192 induces autophagy in HCT116 cells via the ATG5/ATG7 pathway. Antitumor agent-192 has an IC50 of less than 5 μM for human tumor cell lines and significantly inhibits tumor development and reduces tumor weight in a mouse colorectal cancer model transplanted with allografts [1].
|
-
- HY-157317
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-126 (Compound II4) is a photoactive (IC50= 0.149) anticancer agent with significant near-infrared fluorescence emission at 650-760 nm. Antitumor agent-126 has antiproliferative activity and can induce apoptosis after laser irradiation. Antitumor agent-126 effectively inhibits tumor growth in mouse xenograft models exposed to 650 nm laser irradiation. Antitumor agent-126 can be used in cancer research .
|
-
- HY-161841
-
|
|
FGFR
|
Cancer
|
|
Antitumor agent-177 (compound 57), a non-steroidal NSC12 derivative, shows potent FGF2 binding affinity with a Kd of 24 μM by SPR. Antitumor agent-177 significantly inhibits the formation of HSPG/FGF2/FGFR1 ternary complexes. Antitumor agent-177 inhibits FGFR activation and exerts a potent anti-tumor activity on multiple myeloma (MM) cell lines in vitro and in vivo .
|
-
- HY-162643
-
|
|
PD-1/PD-L1
PARP
|
Cancer
|
|
Antitumor agent-169 (Compound B3) is a dual inhibitor PD-1/PD-L1 interaction and PARP7, with IC50s of 0.426 μM and 2.50 nM. Antitumor agent-169 exhibits an affinity to human PD-L1, with Ki of 20.2 nM. Antitumor agent-169 restores the T cell function, increases IFN-γ secretion. Antitumor agent-169 inhibits cell viability of MDA-MB-231 and Jurkat T, exhibits antitumor efficacy against melanoma in mouse model and good pharmacokinetic characteristics .
|
-
- HY-151292
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Antitumor agent-74 (compound 13da) is a quinoxalines derivative, an antitumor agent. Antitumor agent-74 exhibits more potent efficacy on tumor inhibition, mixed with regioisomer Antitumor agent-75 (HY-151295, compound 14 da) (mriBIQ 13da/14da). mriBIQ 13da/14da attests cell cycle at S phase, inhibits DNA synthesis, and induces mithochondrial apoptosis .
|
-
- HY-128776
-
|
|
TNF Receptor
|
Cancer
|
|
Antitumor agent-19 is an antitumor agent that targets tumor-associated macrophages (TAMs) and can be used as a potent TAMs modulator. Antitumor agent-19 can increase TNF-alpha levels in tumor cells with EC50 values???of 17.18 μM and 18.87 μM in RAW 264.7 cells and BMDM cells, respectively .
|
-
- HY-163691
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Antitumor agent-163 (Compound 3) is a photosensitizer used in Molecular-Targeted Photodynamic Therapy (MT-PDT) targeting carbonic anhydrase IX (CAIX). Antitumor agent-163 inactivates CAIX protein via singlet oxygen under 540 nm wavelength light, without affecting internal standard proteins such as α-tubulin, β-actin, and proliferating cell nuclear antigen (PCNA). Antitumor agent-163 induces cell membrane damage, inhibits cell viability (IC50 is 0.2 and 0.05 μM for A549 and U87MG). Antitumor agent-163 exhibits antitumor efficacy in mouse model .
|
-
- HY-153051
-
|
|
Others
|
Cancer
|
|
Antitumor agent-90 (Compound 17) has cytotoxicity against PC 14 cell and MKN 45 cell. Antitumor agent-90 can be used for cancer research .
|
-
- HY-161865
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-180 (Compound 13a) is an inhibitor for BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B). Antitumor agent-180 inhibits the proliferation of ccRCC cell Caki-1 with IC50 of 2.047 µM. Antitumor agent-180 induces necrosis and apoptosis in Caki-1 .
|
-
- HY-141478
-
|
|
ATM/ATR
|
Cancer
|
|
Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .
|
-
- HY-149927
-
|
|
Drug Derivative
|
Cancer
|
|
Antitumor agent-91 is a cyclic phosphate ester derivative with anticancer and anti-proliferative activities. Antitumor agent-91 has potential application in human castration resistant prostate cancer and pancreatic cancer .
|
-
- HY-155745
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-115 (SS-12) is an effective anti-tumor compound with an IC50 value of 0.34 μM-24.14 μM for cell line 4T1. Antitumor agent-115 can block the cell cycle of mouse breast cancer cell line 4T1, reduce the mitochondrial membrane potential, and induce apoptosis, and the IC50 value is 8-25 μmol/L for cell viability. Antitumor agent-115 can be used for breast cancer research .
|
-
- HY-146169
-
|
|
Reactive Oxygen Species (ROS)
Microtubule/Tubulin
|
Cancer
|
|
Antitumor agent-68 is a potent tubulin inhibitor. Antitumor agent-68 shows potent anticancer activity with IC50s of 3.6 and 3.8 μM for HeLa and MCF-7 cells, respectively. Antitumor agent-68 exhibits good scavenging activity of ROS and DPPH radical in a dose-dependent manner . Antitumor agent-68 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-161826
-
|
|
Wnt
β-catenin
HSP
CDK
c-Myc
|
Cancer
|
|
Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity .
|
-
- HY-162108
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-128 (compound 1a) is an antitumor agent that elicits cell cycle arrest in both the G2/M and S phases, triggering apoptosis in A549 cells .
|
-
- HY-148595
-
|
|
Cytochrome P450
|
Cancer
|
|
Antitumor agent-88 exhibits potent antimitotic activity and arrests cell in the G2/M phase. Antitumor agent-88 disrupts the microtubule and the cytoskeleton in CYP1A1-expressing breast cancer cells. Antitumor agent-88 is also a competitive inhibitor of CYP1A1 (Ki: 1.4 μM) .
|
-
- HY-153802A
-
|
|
Apoptosis
Phosphodiesterase (PDE)
Molecular Glues
|
Cancer
|
|
Antitumor agent-100 (compound A6) hydrochloride is an orally potent apoptosis inducer and molecular gel targeting PDE3A-SLFN12 (IC50: 0.3 μM) with antitumor activity. Antitumor agent-100 hydrochloride binds to the PDE3A enzyme pocket to recruit and stabilize SLFN12, thereby preventing protein translation and leading to apoptosis .
|
-
- HY-161981
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-187 (compound I3) is a photosensitizer based on 5,15-diaryltetrabenzoporphyrin with a maximum absorption wavelength of ~668 nm and anticancer activity. Antitumor agent-187 can induce apoptosis and can be used in photodynamic therapy (PDP). Antitumor agent-187 selectively accumulates at tumor sites and has real-time fluorescence imaging capabilities .
|
-
- HY-153802
-
|
|
Apoptosis
Phosphodiesterase (PDE)
|
Cancer
|
|
Antitumor agent-100 (compound A6) is an orally available apoptosis inducer and molecular gel targeting PDE3A-SLFN12 (IC50: 0.3 μM) with antitumor activity. Antitumor agent-100 binds to the PDE3A enzyme pocket to recruit and stabilize SLFN12, thereby preventing protein translation and leading to apoptosis .
|
-
- HY-162227
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Antitumor agent-138 (compound 5b) is an inhibitor against tubulin polymerization at tubulin colchicine-binding sites, with IC50 of 1.87 μM. Antitumor agent-138 arrests the cell cycle at G2/M phase and induces an apoptosis in MCF-7 cells. Antitumor agent-138 inhibits cells migration and angiogenesis .
|
-
- HY-155541
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-110 (compound 13) is an anticancer imidazotetrazine with good permeability properties. Antitumor agent-110 arrests cell cycel at G2/M phase, and induces apoptosis . Antitumor agent-110 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-149896
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Antitumor agent-107 (compound 5h) is an anticancer agent that shows excellent inhibitory activity against leukemia cell lines (GI50=0.32-1.34 μM). Antitumor agent-107 also shows antitumor activity against various other human cancer cell lines (GI50 range 0.35-9.43 μM) .
|
-
- HY-162594
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Antitumor agent-164 (compound 60c) is a colchicine-binding site inhibitor (CBSI) with potency against taxane-sensitive TNBC. Antitumor agent-164 is a next-generation derivative of VERU-111 .
|
-
- HY-115996
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-51 possesses potent and selective inhibitory for osteosarcoma cell growth and migration with IC50 of 21.9 nM in MNNG/HOS cells. Antitumor agent-51 has a considerable bioavailability and a low toxicity .
|
-
- HY-162825
-
|
|
Photosensitizer
|
Cancer
|
|
Antitumor photosensitizer-7 (compound 15) is a photosensitizer with anti-cancer activity. Antitumor photosensitizer-7 exhibits significant cytotoxicity against the G361 melanoma cell line under 414 nm blue light irradiation .
|
-
- HY-149840
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-113 shows cytotoxic effects on A549 cells with IC50 value of 46.60 μM and induces apoptosis. Antitumor agent-113 can be used in non-small cell lung cancer study .
|
-
- HY-156092
-
|
|
BCRP
Apoptosis
|
Cancer
|
|
Antitumor photosensitizer-4 (compound 10b) is a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. Antitumor photosensitizer-4 is a photosensitizer (PS) consisting of a conjugate of dasatinib (HY-10181) and imatinib (HY-15463). Antitumor photosensitizer-4 induces apoptosis and ROS production and exhibits strong phototoxicity to HepG2 and B16-F10 cells .
|
-
- HY-145289
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
|
-
- HY-145288
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
|
-
- HY-168717
-
|
|
Hexokinase
Microtubule/Tubulin
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor agent-190 (Compound 26) is a Hexokinase 2 inhibitor that demonstrates significant anti-tumor activity by targeting microtubules and Hexokinase 2, with an IC50 value of 0.764 μM against MD-MBA-231 cells. Antitumor agent-190 effectively inhibits the activity of Hexokinase 2, leading to the accumulation of Reactive Oxygen Species and dysfunction of the mitochondrial membrane potential (MMP), thereby promoting apoptosis and blocking the cell cycle .
|
-
- HY-156778
-
|
|
Others
|
Cancer
|
|
Antitumor agent-120 (compound 1) is a flavonoid compound isolated from Kudzu root.Antitumor agent-120 has no significant inhibitory activity against LNCaP and PC3 cancer cells, with IC50s >50 μM .
|
-
- HY-159149
-
|
|
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
Antitumor agent-182 (Compound 12a) decreases mitochondrial membrane potential (MMP) and enhances ROS levels. Antitumor agent-182 arrests the cell cycle at G0/G1 phase, induces apoptosis in HeLa. Antitumor agent-182 inhibits the proliferation of HeLa, PC-3 and HCT-15 with IC50s of 8.83, 10.07 and 7.84 μM, respectively .
|
-
- HY-170999
-
|
|
Caspase
Apoptosis
Ferroptosis
|
Cancer
|
|
Antitumor agent-196 (Compound 6a (β, β, β)) is an artemisinin-based oligomer with anticancer activity, showing an IC50 of 90 nM against MCF-7 breast cancer cells.
Antitumor agent-196 promotes Apoptosis by regulating the Bax-caspase 3 signaling pathway, and induces Ferroptosis through the modulation of key signaling molecules, including GPX4.
Antitumor agent-196 holds promising potential for further research in the field of cancer therapy .
|
-
- HY-161096
-
|
|
ROR
|
Cancer
|
|
Antitumor agent-127 (compound 1) is a parent macrocyclic peptide. Antitumor agent-127 displays nanomolar cell-based binding to ROR1 and relatively good internalization in 786-O and MDA-MB-231 tumor cell lines .
|
-
- HY-163301
-
|
|
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor agent-139 (compound 9b) is a liver - and mitochondria-targeting gold(I) complexe, and produces reactive oxygen species (ROS) and facilitates DNA excretion. Antitumor agent-139 inhibits tumor growth in a patient-derived xenograft model of hepatocellular carcinoma .
|
-
- HY-U00414
-
|
|
Others
|
Cancer
|
|
Antitumor agent-4, a butenylphenyl phosphate derivative, is a agent for mammary cancer and anovulatory sterility.
|
-
- HY-162128
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
Antitumor agent-130 (Compound 7b) is a p300 histone acetyltransferases (HAT) inhibitor with an IC50 of 1.51 μM. Antitumor agent-130 combinates with doxorubicin (HY-15142A) can significantly inhibit tumor growth and invasion in vitro and in vivo .
|
-
- HY-155034
-
|
|
Topoisomerase
GLUT
|
Cancer
|
|
Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .
|
-
- HY-149063
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-92, an Icaritin (HY-N0678) derivative, causes arrest at the G0/G1 phase in the cell cycle and induces cell apoptosis. Antitumor agent-92 has the potential for hepatocellular carcinoma (HCC) research .
|
-
- HY-146187
-
|
|
Histone Methyltransferase
|
Cancer
|
|
Antitumor agent-69 (compound 12) is a potent inhibitor of protein-protein interaction between DOT1L and MLL-AF9/MLL-ENL, with Kis of 9 nM and 109 nM for AF9 and ENL, respectively. Antitumor agent-69 exhibits anticancer cellular activitiy .
|
-
- HY-162695
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Antitumor agent-168 (compound 21b) disrupts the microtubule network in tumor cells leading to G2/M cell cycle arrest and apoptosis induction. Antitumor agent-168 inhibits MCF-7 growth with an IC50 value of 1.4 nM .
|
-
- HY-173182
-
|
|
Microtubule/Tubulin
P-glycoprotein
|
Cancer
|
|
Antitumor agent-200 (Compound 2g) is a microtubule synthesis inhibitor. By binding to the colchicine site of tubulin, it causes G2/M cell cycle arrest and generates reactive oxygen species (ROS). Antitumor agent-200 exhibits significant inhibitory activity against MCF7/ADR and KBV200 cell lines with overexpression of P-glycoprotein (P-gp), with drug resistance indices (DRI) of 0.83 and 0.58 respectively. In the MCF-7 xenograft model, Antitumor agent-200 (25 mg/kg, intraperitoneal injection) can achieve a tumor growth inhibition rate of 57.2%. Antitumor agent-200 can be used in the research of the anti-cancer field .
|
-
- HY-163034
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Antitumor photosensitizer-5 (Ru2) is a photosensitizer which effectively target tumor mitochondria with an IC50 of 0.3 μM for phototoxicity to A549 cells. Under 460 nm light irradiation, antitumor photosensitizer-5 induces the generation of reactive oxygen species and NADH depletion, causes mitochondrial damage and activation of caspase-3, inducing apoptosis and suppressing cell migration. Antitumor photosensitizer-5 has the potential to prevent the growth of malignant tumors, therefore, shows the potential to be applied to photodynamic therapy .
|
-
- HY-163518
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Antitumor agent-153 (compound 11b) is an optimized H2A histone ubiquitination inhibitor based on PRT4165 (HY-19817). Antitumor agent-153 inhibits the viability of human osteosarcoma U2OS cells and reduces histone H2A monoubiquitination, exhibiting anticancer activity .
|
-
- HY-144394
-
|
|
Apoptosis
c-Met/HGFR
|
Cancer
|
|
Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells .
|
-
- HY-162824
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor photosensitizer-6 (Compound Ru2) shows synergetic type I/II photosensitization and photocatalytic activity upon 595 nm light excitation. Ru2 induces intracellular redox imbalance and affects the biosynthetic and metabolic processes, leading to cell apoptosis. Antitumor photosensitizer-6 can be used for research of photodynamic therapy (PDT) .
|
-
- HY-158436
-
|
|
Microtubule/Tubulin
Autophagy
Apoptosis
|
Cancer
|
|
Antitumor agent-155 (Compound 13) inhibits microtubule polymerization, induces autophagy and apoptosis. Antitumor agent-155 shows cytotoxicity against HCT116, A549, AGS, SK-MES-1 cells with IC50s of 0.227, 0.253, 0.574, 0.423 μM respectively .
|
-
- HY-162121
-
|
|
Others
|
Cancer
|
|
Antitumor agent-129 (Compound 68) is a thiazolidin-4-one sulfone derivative and an Osteosarcoma (OS) inhibitor with an IC50 value of 0.217 μM, a half-life of 73.8 min (mouse liver microsome) and an excellent pharmacokinetic profile (in vivo bioavailability F = 115%, intraperitoneal administration). Antitumor agent-129 is a potential candidate for OS research .
|
-
- HY-170843
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-198 (Compound A3) exhibits cytotoxicity in head and neck squamous cell carcinoma (HNSCC) cells, that inhibits the proliferation of CAL27, HN6, HN30, SCC9 and SCC25 with IC50 of 4 nM-77 nM. Antitumor agent-198 inhibits the HNSCC cell migration, arrests the cell cycle, and induces apoptosis .
|
-
- HY-149718
-
|
|
JAK
HDAC
|
Cancer
|
|
Antitumor agent-123 (Copmound 4d) effectively inhibits multiple kinase targets with anti-cancer effects, including JAK2, JAK3, HDAC1 and HDAC6, with IC50 values of 34.6 and 2.6 μM for JAK2 and JAK3, respectively. Antitumor agent-123 exhibits moderate activity in solid tumor models .
|
-
- HY-157217
-
|
|
Antifolate
|
Cancer
|
|
Antitumor agent-99 (compound 7) is an anticancer agent targeting FRα/β and PCFT. Antitumor agent-99 inhibits R2/PCFT4 (PCFT), RT16(FRα), and D4(FRβ) cells with IC50s of 51.46 nM, 2.53 nM, and 2.98 nM, respectively .
|
-
- HY-163715
-
|
|
FAK
|
Cancer
|
|
Antitumor agent-165 (Compound 10l) is a potent focal adhesion kinase (FAK) inhibitor. Antitumor agent-165 exhibits effective antiproliferative activity against CAPAN-1, PANC-1, PATU-T, SUIT-2, BxPC-3, PDAC-3 and PANC-1 GR with IC50s in the range of 1.04-3.44 μM .
|
-
- HY-173331
-
|
|
Chloride Channel
Apoptosis
Autophagy
|
Cancer
|
|
Antitumor agent-201 (Compound 10) is a chloride transport activator that targets the Golgi apparatus. Its EC50 for promoting the transmembrane transport of chloride ions is 1.53 mol%, and its IC50 against HepG2 cells is 7.13 μM. Antitumor agent-201 exerts its anti-cancer activity by selectively acting on the Golgi apparatus, disrupting the chloride ion homeostasis within it, reducing the expression of key proteins such as GM130 and GRASP55, altering the structure and function of the Golgi apparatus, triggering Autophagy of the Golgi apparatus, and further inducing Apoptosis of cancer cells and arresting cancer cells in the G2/M phase. Antitumor agent-201 can be used in the research field of cancer diseases .
|
-
- HY-107470
-
|
|
Drug Derivative
|
Inflammation/Immunology
Cancer
|
|
Antitumor agent-21 is an aryl-quinolin derivative, with potential anticancer, anti-inflammatory, anti-proliferative, anti-hormonal effects and inhibition of vasculogenic mimicry .
|
-
- HY-174277
-
|
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
|
Antitumor agent-203 (compound 26) is a derivative of Exatecan (DX-8951) (HY-13631) and can be used to prepare antibody-drug conjugates (ADCs), as the ADC Cytotoxin .
|
-
- HY-162348
-
|
|
Necroptosis
|
Cancer
|
|
Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which exerts anti-cancer effects by inducing necroptosis and activating the necroptosis-related immune response .
|
-
- HY-153272
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Antitumor agent-93 (compound 7D) is an anticancer agent that can effectively inhibit the growth of several tumor cell lines, such as MDA-MB-231 and HCT-116 cell lines .
|
-
- HY-162450
-
|
|
PROTACs
MDM-2/p53
Apoptosis
|
Cancer
|
Antitumor agent-150 (V10), an anti-breast cancer agent, is a PROTAC-based MDM2 protein degrader (Red: Ganoderic acid A; Black: 4O-PEG linker; Blue: VHL ligand) .
|
-
- HY-155040
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
Antitumor agent-106 (compound 42) is an anticancer agent that exhibits good inhibitory activity (IC50=4.2-6.6 µM) against both lung cancer and colon cancer cell lines .
|
-
- HY-136342
-
|
|
Others
|
Cancer
|
|
Antitumor agent-23 is a potent anti-cancer agent with GI50s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity .
|
-
- HY-W287494
-
|
|
MDM-2/p53
|
Cancer
|
|
Antitumor agent-202 is a stabilizer of the p53 Y220C mutant. It exhibits a selective inhibitory effect on the proliferation of tumor cells carrying the p53 Y220C mutation and can be applied to the research of cancers associated with the p53 Y220C mutation .
|
-
- HY-162766
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-184 (compound 12aa) induces cell apoptosis, with the IC50s of 2.35 μM, 7.32 μM and 10.31 μM in B16-F10 cells, 4T1 cells and CT26 cells, respectively .
|
-
- HY-152468
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-83 is an activator of pro-apoptotic protein BAX and has significant anti-proliferation effect on tumor cells. Antiumor agent-83 mediates cell Apoptosis by inducing the conformational activation of BAX and has inhibitory effect on A549 cell cycle. Antiumor agent-83 has good metabolic stability and CYPs spectrum in vitro .
|
-
- HY-159093
-
|
|
Others
|
Cancer
|
|
GSCs-IN-1 (compound 4 h) is a potent and selective GSCs inhibitor. GSCs-IN-1 has the potential for the research of cancer .
|
-
- HY-131790
-
|
|
Others
|
Cancer
|
|
3'-Amino-3'-deoxyadenosine is an antitumor agent extracted from Helminthosporium .
|
-
- HY-155313
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE (compound 20) is auristatins-glucuronide conjugate. Antitumor agent-122 shows in vitro antiproliferative activities against β-glucuronidase pretreated and untreated cancer cells with an IC50 value of 5.7 nM - 9.7 nM. Antitumor agent-122 shows potent antitumor efficacy in HCT-116 xenograft mouse model without inducing side effects .
|
-
![β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE](//file.medchemexpress.com/product_pic/hy-155313.gif)
- HY-129312
-
-
- HY-122384
-
-
- HY-159844
-
-
- HY-136486
-
|
|
Others
|
Cancer
|
|
Lasiocarpine N-oxide is a natural compound with antitumor activity .
|
-
- HY-159833
-
-
- HY-119527
-
-
- HY-124262
-
-
- HY-105890
-
-
- HY-N7994
-
|
|
Others
|
Cancer
|
|
Hellebrigenol is a metabolite of bufadienolides with antitumor activity .
|
-
- HY-N12371
-
|
|
Others
|
Others
|
|
5,8-Dihydroxy-6,7-dimethoxyflavone, isolated from aerial parts of Gnaphalium gaudichaudianum, has antitumor activity .
|
-
- HY-146970
-
|
|
Antibiotic
|
Cancer
|
|
Lankacyclinone C is a lankacidin C congener lacking the δ-lactone moiety, with antitumor activity .
|
-
- HY-159838
-
|
EI‐1071
|
c-Fms
|
Cancer
|
|
Enrupatinib is a colony-stimulating factor 1 receptor (CSF1R) inhibitor with antitumor activity .
|
-
- HY-121350
-
|
|
Apoptosis
|
Cancer
|
|
Merodantoin has significant antitumor activity in vitro and in vivo, and has less toxicity to normal cells and tissues .
|
-
- HY-121176
-
|
Cifelin
|
Others
|
Cancer
|
|
Asalin (Cifelin) is an antitumor agent that can be used for the study of cervical cancer, laryngeal cancer, and other cancers .
|
-
- HY-124343
-
|
DEHSPM
|
Drug Derivative
|
Cancer
|
|
Diethylhomospermine is a polyamine analogue. Diethylhomospermine has antitumor and antidiarrheal activity .
|
-
- HY-13726
-
|
Oxantrazole; NCS 349174
|
Topoisomerase
|
Cancer
|
|
Piroxantrone (Oxantrazole) is a potent DNA topoisomerase II-targeting anthrapyrazole antitumor agent. Piroxantrone displays cardiotoxicity .
|
-
- HY-160915
-
-
- HY-149547
-
|
|
Others
|
Cancer
|
|
DRF-4015 (Compound 22) is a betulinic acid derivative with antitumor activity .
|
-
- HY-N1366A
-
|
|
Others
|
Cancer
|
|
Herniarin (Standard) is a standard product of Herniarin. Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect .
|
-
- HY-120185
-
|
UCT-1003
|
Topoisomerase
|
Infection
Cancer
|
|
Saintopin is an antitumor antibiotic. Saintopin is also an inhibitor of DNA topoisomerases I and II. Saintopin induces DNA cleavage .
|
-
- HY-172244
-
-
- HY-115843
-
-
- HY-19459A
-
-
- HY-164718
-
|
|
EGFR
|
Cancer
|
|
Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity .
|
-
- HY-149584
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
CIDD-0149897 is a potent, selective and brain-penetrant ERβ agonist. CIDD-0149897 exert antitumor functions in glioblastoma .
|
-
- HY-N7685
-
-
- HY-N0827
-
-
- HY-13656
-
|
KOS-1803
|
Microtubule/Tubulin
|
Cancer
|
|
Isofludelone (KOS-1803) is a potential microtubule stabilizer for the treatment of solid tumors. Isofludelone has antitumor activity .
|
-
- HY-156411
-
|
|
Bacterial
|
Cancer
|
|
NR-NO2 is a potential drug with targeted release and imaging-based guidance in antitumor research. NR-NO2 has an anti-bacterial effect .
|
-
- HY-162773
-
|
|
c-Met/HGFR
|
Cancer
|
|
MET-IN-1 (Compound 13) is an orally active MET inhibitor. MET-IN-1 has antitumor activity .
|
-
- HY-121569
-
|
|
Kinesin
|
Cancer
|
|
Syntelin is a selective centromere protein E (CENP-E) inhibitor with IC50 at 160 nM. Syntelin has antitumor activity .
|
-
- HY-172879
-
|
|
Aminopeptidase
|
Cancer
|
|
Aminopeptidase N inhibitor 2 (Compound 2k) is an APN inhibitor (IC50: 4.3 μM) and has antitumor activity.
|
-
- HY-17565A
-
|
|
DNA/RNA Synthesis
Antibiotic
|
Cancer
|
|
Bleomycin hydrochloride is a DNA synthesis inhibitor. Bleomycin hydrochloride is a DNA damaging agent. Bleomycin hydrochloride is an antitumor antibiotic .
|
-
- HY-N7595
-
|
|
Others
|
Cancer
|
|
Microhelenin C is a sesquiterpene lactone that can be isolated from Helenium microcephalum, with antitumor activity .
|
-
- HY-123363
-
|
F-11782
|
Topoisomerase
|
Cancer
|
|
Tafluposide (F-11782) is a DNA topoisomerase inhibitor. Tafluposide has antitumor activity .
|
-
- HY-N8449
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
Ailanthoidol is a natural occurring neolignan, with anti-inflammatory and antitumor activities. Ailanthoidol has chemopreventive activity against tumor promotion .
|
-
- HY-164382
-
|
|
TAM Receptor
|
Cancer
|
|
ER-851 is a selective AXL inhibitor with oral activity with IC50 of 100 nM. ER-851 has antitumor activity .
|
-
- HY-N14410
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Clecarmycin C is an antitumor antibiotic. Clecarmycin C shows cytotoxicity and antitumor activity. Clecarmycin C shows antimicrobial activity .
|
-
- HY-126048
-
|
|
MEK
|
Cancer
|
|
JTP-70902, a p15 INK4b-inductive compound, is a MEK1/2 inhibitor. JTP-70902 exhibits potent antitumor effect .
|
-
- HY-156336
-
|
|
Polo-like Kinase (PLK)
|
Cancer
|
|
PLK1-IN-7 (compound 30e) is a potent PLK1 inhibitor, with an IC50 of 0.66 nM. PLK1-IN-7 exhibits antiproliferative and antitumor activities .
|
-
- HY-14115
-
|
|
Hedgehog
|
Cancer
|
|
Hedgehog IN-10 (compound 24) is a potent Hedgehog inhibitor. Hedgehog IN-10 exhibits significant antitumor effect .
|
-
- HY-111999A
-
|
|
STING
|
Cancer
|
|
E7766 diammonium salt is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 diammonium salt shows potent pan-genotypic and antitumor activities .
|
-
- HY-111999B
-
|
|
STING
|
Cancer
|
|
E7766 disodium is a macrocycle-bridged STING agonist with a Kd of 40 nM. E7766 disodium shows potent pan-genotypic and antitumor activities .
|
-
- HY-105530
-
|
CL 286558
|
Biochemical Assay Reagents
|
Cancer
|
|
Zeniplatin is a third-generation, water-soluble platinum compound that has shown broad antitumor activity. Zeniplatin can be used for cancer research .
|
-
- HY-139096
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
4-Pentadecylbenzylphosphonic acid is an Autotaxin (ATX) inhibitor. 4-Pentadecylbenzylphosphonic acid has antitumor activity .
|
-
- HY-N12145
-
|
Ao58A; NSC 66645
|
Bacterial
|
Infection
Cancer
|
|
Streptimidone (Ao58A) is a bacterial metabolite found in Streptomyces. Streptimidone has antitumor activity .
|
-
- HY-125395
-
-
- HY-W040046
-
|
Nafoxidene hydrochloride
|
Estrogen Receptor/ERR
|
Cancer
|
|
Nafoxidine hydrochloride is a non-steroidal estrogen receptor antagonist with antitumor activity for breast cancer .
|
-
- HY-10939
-
|
|
Bacterial
Fluorescent Dye
|
Cancer
|
|
(-)-15-Deoxyspergualin is a potent antitumor agent. (-)-15-Deoxyspergualin shows strong inhibition against mouse leukemia L-1210 .
|
-
- HY-10939A
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
(-)-15-Deoxyspergualin trihydrochloride is a potent antitumor agent. (-)-15-Deoxyspergualin trihydrochloride shows strong inhibition against mouse leukemia L-1210 .
|
-
- HY-162410
-
|
|
MDM-2/p53
|
Cancer
|
|
Fluplatin is a prodrug composed of cisplatin and fluvastatin. Fluplatin has antitumor activity .
|
-
- HY-41004
-
|
|
Drug Intermediate
|
Cancer
|
|
3-Isoquinolinecarboxylic acid (compound 2) is a synthetic intermediate that has been used to design antitumor compounds .
|
-
- HY-143359
-
|
|
Ras
|
Cancer
|
|
COTI-219 is an orally active inhibitor of KRAS. COTI-219 has antitumor activity .
|
-
- HY-N8533
-
|
|
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Sodium Camptothecin is a plant alkaloid, with antitumor activity. Sodium Camptothecin is a reversible inhibitor of RNA synthesis. Sodium Camptothecin is an effective inhibitor of adenovirus replication. Sodium Camptothecin inhibits DNA synthesis and causes breaks in intracellular preformed viral DNA .
|
-
- HY-155172
-
|
|
Cyclophilin
|
Cancer
|
|
ZX-J-19j (Compound ZX-J-19j) is a cyclophilin J inhibitor. ZX-J-19j showes potent antitumor activity .
|
-
- HY-129234
-
-
- HY-Z3832
-
|
|
Apoptosis
p38 MAPK
Autophagy
|
Cancer
|
|
N-Methylparoxetine is a derivative of Paroxetine that induces Apoptosis NSCLC cells by activating mitogen-activated protein kinase ( MAPK). N-Methylparoxetine has antitumor activity .
|
-
- HY-113793
-
|
|
Others
|
Cancer
|
|
BPH-742 (compound 9) is a Geranylgeranyl diphosphate synthase inhibitor with IC50 of 0.1 μM. BPH-742 has antitumor activity .
|
-
- HY-P10418
-
|
|
c-Myc
|
Cancer
|
|
VGN50 is a bioactive molecule that mimics the function of K-Rta and down-regulates MYC-mediated gene transcription. VGN50 has antitumor activity .
|
-
- HY-146141
-
|
|
Ephrin Receptor
|
Cancer
|
|
EphA2 agonist 2 (Lead compound) is a selective EphA2 agonist with antitumor activities. EphA2 agonist 2 can cross the BBB .
|
-
- HY-16059
-
|
(+)-Arglabin
|
NOD-like Receptor (NLR)
Farnesyl Transferase
Autophagy
|
Inflammation/Immunology
Cancer
|
|
Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities . The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene .
|
-
- HY-N3741
-
|
Didrovaltratum
|
Others
|
Cancer
|
|
Didrovaltrate (Didrovaltratum) can be isolated from the roots of Valeriana wallichii D.C. Didrovaltrate is an antitumor agent with cytotoxicity .
|
-
- HY-160417
-
|
|
PARP
|
Cancer
|
|
PARP1-IN-19 is a PARP1 inhibitor with antitumor effects (CN107955001A; Embodiment 3) .
|
-
- HY-119956
-
-
- HY-147359
-
|
|
Antibiotic
Apoptosis
|
Cancer
|
|
Boanmycin is an antibiotic with antitumor activity that induces cellular senescence and apoptosis .
|
-
- HY-N3378
-
|
|
Farnesyl Transferase
Parasite
|
Infection
|
|
Lipiferolide is an antiplasmodial agent (IC50: 1.8 μg/mL) that can be isolated from Liriodendron tulipifera. Lipiferolide also inhibits FPTase, and has antitumor activity .
|
-
- HY-123675
-
|
|
Mps1
|
Cancer
|
|
CFI-400936 is a potent TTK inhibitor with an IC50 of 3.6 nM. CFI-400936 has antitumor activity .
|
-
- HY-169284
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Polθ-IN-5 (Compound 139) is a DNA polymerase theta (Polθ) inhibitor. Polθ-IN-5 has antitumor activity .
|
-
- HY-111783
-
|
|
DNA-PK
ATM/ATR
PI3K
Apoptosis
|
Cancer
|
|
AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
|
-
- HY-N10469
-
|
Phleomycin F
|
Antibiotic
|
Cancer
|
|
Bleomycin B4 (Phleomycin F) is an antibiotic. Bleomycin B4 has antitumor activity. Bleomycin B4 can be used for the research of cancer .
|
-
- HY-N14781
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
10-Decarbamoyloxy-9-dehydromitomycin B is a mitomycin. 10-Decarbamoyloxy-9-dehydromitomycin B has antibacterial and antitumor activity .
|
-
- HY-169285
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Polθ-IN-6 (Compound 89) is a DNA polymerase theta (Polθ) inhibitor. Polθ-IN-6 has antitumor activity .
|
-
- HY-122474
-
|
|
Drug Derivative
|
Cancer
|
|
Acetylaranotin is a metabolite produced by the fungus Arachniotus aureus, exhibiting antitumor activity. Acetylaranotin is utilized in research within the field of oncology for its potential in anti-cancer applications .
|
-
- HY-145852
-
-
- HY-34590
-
|
|
Drug Intermediate
|
Cancer
|
|
3-Amino-2,6-piperidinedione is a synthetic intermediate that has been used to design antitumor compounds .
|
-
- HY-121076
-
-
- HY-157941
-
|
|
ATM/ATR
|
Cancer
|
|
ART0380 is a potent and selective ATR kinase inhibitor. ART0380 has selective antitumor activity that can be used for the research of Ataxia-Telangiectasia Mutated (ATM) aberrant cancers .
|
-
- HY-156467
-
-
- HY-145623
-
|
ANDES-1537
|
DNA/RNA Synthesis
|
Cancer
|
|
Mulnitorsen is an antisense non-coding mitochondrial RNA (ASncmtRNA) synthesis reducer. Mulnitorsen is an antitumor agent .
|
-
- HY-159874
-
|
|
Interleukin Related
|
Cancer
|
|
KRN7000 analog 2 is a iNKT agonist, which is promising for research of antitumor agents and vaccine adjuvants.
|
-
- HY-105237
-
|
|
Antibiotic
DNA/RNA Synthesis
|
Cancer
|
|
Esperamicin A1, as an extremely potent antitumor antibiotic, is isolated from cultures of Actinomadura verrucosospora. Esperamicin A1 can be used for the research of antitumor . Eesperamicin A1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-136327
-
|
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Phenylacetic acid mustard is the major metabolite of the cancer chemotherapeutic agent Chlorambucil (HY-13593). Chlorambucil is an alkylating agent with antitumor activity .
|
-
- HY-138623
-
-
- HY-N11654
-
|
Cardol monoene
|
Insecticide
|
Infection
Cancer
|
|
Bilobol is a potent insecticide against Aedes aegypti with a LC50 of 7.67 mg/L. Bilobol also has antitumor activity .
|
-
- HY-113102B
-
|
|
Endogenous Metabolite
|
Cancer
|
|
9(Z),11(Z)-octadecadienoic acid is an isomer of linoleic acid and has antitumor activity (EC 50 = 446.1 µM) .
|
-
- HY-168111
-
-
- HY-133571A
-
|
AHGDM hydrochloride
|
HSP
ADC Cytotoxin
|
Cancer
|
|
Aminohexylgeldanamycin (AHGDM) hydrochloride, a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin hydrochloride shows antiangiogenic and antitumor activities .
|
-
- HY-130115
-
|
|
STING
|
Cancer
|
|
IACS-8803 is a highly potent cyclic dinucleotide STING agonist with robust systemic antitumor efficacy .
|
-
- HY-133571
-
|
AHGDM
|
HSP
ADC Cytotoxin
|
Cancer
|
|
Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities .
|
-
- HY-P991140
-
|
|
Claudin
|
Cancer
|
|
Garetatug is a humanized monoclonal antibody targeting human CLDN18 (claudin-18). Garetatug specifically binds to CLDN18, interfering with relevant cell signaling pathways and exerting antitumor activity .
|
-
- HY-162163
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR7 agonist 19 (Compound 14) is a Toll-like receptor 7 (TLR7) agonist with excellent pharmacokinetic properties and synergistic antitumor activity.
|
-
- HY-169101
-
|
|
Apoptosis
|
Cancer
|
|
KSRP-IN-1 (compound 8) is a KSRP inhibitor that induces Apoptosis and cell cycle arrest. KSRP-IN-1 has antitumor activity .
|
-
- HY-147894
-
|
|
Histone Acetyltransferase
|
Cancer
|
|
PCAF-IN-1 is a highly selective PCAF inhibitor. PCAF-IN-1 is a antitumor agents, which can be used in tumor research research .
|
-
- HY-146646
-
|
|
Antibiotic
|
Infection
Cancer
|
|
Bleomycin A2, an antitumor antibiotic promoting DNA-degradation, is an aspartate/asparagine-β-hydroxylase (AspH) inhibitor with an IC50 of 1.47 μM .
|
-
- HY-164263
-
|
NAPS
|
Apoptosis
|
Cancer
|
|
N-Acetylphytosphingosine (NAPS) is a sphingolipid derivative. N-Acetylphytosphingosine induces mitochondria-dependent Apoptosis by activating Bak. N-Acetylphytosphingosine has antitumor activity .
|
-
- HY-139796
-
|
|
HDAC
|
Cancer
|
|
ZYJ-34v is an orally active histone deacetylase inhibitor. ZYJ-34v has antitumor activity .
|
-
- HY-B0063
-
|
ST1481
|
Topoisomerase
|
Cancer
|
|
Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity .
|
-
- HY-116786
-
|
|
Drug Derivative
|
Cancer
|
|
11-Hydroxycanthin-6-one, a canthin-6-one (HY-N3536) alkaloid, is an antitumor agent which shows potent cytotoxic activity .
|
-
- HY-176708
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
ISM5939 is an orally active and selective ENPP1 inhibitor with an IC50 of 0.63 nM for 2,3-cGAMP degradation and 9.28 nM for ATP hydrolysis. ISM5939 has antitumor activity .
|
-
- HY-142035
-
|
|
Mitochondrial Metabolism
|
Neurological Disease
Cancer
|
|
N-Propargylglycine is an orally active irreversible inhibitor of proline dehydrogenase (PRODH). N-Propargylglycine has antitumor activity and can be used in the study of neurodegenerative diseases .
|
-
- HY-164402
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
NSC-124854 is a DNA polymerase β (Pol-β) inhibitor with an IC50 of 5.3 μM. NSC-124854 has antitumor activity .
|
-
- HY-123135
-
|
|
Fungal
|
Infection
Cancer
|
|
Scirpusin B (compound 5) is a dimeric antioxidant isolated from Scirpus maritimus L.. Scirpusin B exhibits antitumor, antifungal, insecticidal, and plant growth inhibitory activities.
|
-
- HY-130115A
-
|
|
STING
|
Cancer
|
|
IACS-8803 disodium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 disodium has a robust systemic antitumor efficacy .
|
-
- HY-P99539
-
|
REGN4018
|
CD3
|
Cancer
|
|
Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity .
|
-
- HY-130115B
-
|
|
STING
|
Cancer
|
|
IACS-8803 diammonium is a highly potent cyclic dinucleotide STING agonist. IACS-8803 diammonium has a robust systemic antitumor efficacy .
|
-
- HY-N10174
-
|
|
Antibiotic
|
Infection
|
|
Tomaymycin is an antitumor antibiotic. Tomaymycin has antimicrobial activity against Grampositive bacteria .
|
-
- HY-Q25865
-
|
|
VISTA
|
Cancer
|
|
MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC50 value of 121 nM. MG-V-53 has antitumor activity .
|
-
- HY-145923
-
|
ABBV-CLS-484
|
Phosphatase
|
Cancer
|
|
Osunprotafib (ABBV-CLS-484) is a potent PTPN1 and PTPN2 inhibitor with subnanomolar activity. Osunprotafib has antitumor activity, enhances the immune response and increases the sensitivity of tumors to immune-mediated killing .
|
-
- HY-125135
-
|
β-Peltatin
|
Drug Isomer
|
Cancer
|
|
(-)-β-Peltatin is an organic heterotetracyclic compound with antitumor activity and phytometabolite effects that are functionally related to α-peltatin .
|
-
- HY-142458
-
|
|
Ras
|
Cancer
|
|
KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737) .
|
-
- HY-142457
-
|
|
Ras
|
Cancer
|
|
KRAS G12C inhibitor 26 is a KRAS G12C inhibitor with antitumor effects (WO2021109737) .
|
-
- HY-162314
-
|
|
Wnt
|
Cancer
|
|
TNIK-IN-8 (Compound 35b) is a potent, orally active TNKI inhibitor with a IC50 value of 6 nM. TNIK-IN-8 has antitumor activity .
|
-
- HY-N2493
-
Lawsone
1 Publications Verification
|
Fungal
Apoptosis
|
Infection
Cancer
|
|
Lawsone is an orally active naphthoquinone dye that can be isolated from the leaves of Lawsonia inermis. Lawsone can induce apoptosis. Lawsone has antibacterial, antitumor and antioxidant activities. Lawsone can be used in anti-tumor drug research .
|
-
- HY-121785
-
|
|
Bacterial
|
Infection
Cancer
|
|
10-Thiofolic acid is a potent antibacterial and antitumor agent. 10-Thiofolic acid inhibits the growth of Streptococcus faecium (ATCC 8043) and Lactobacillus casei (ATCC 7469). 10-Thiofolic acid has the potential for the research of leukemia .
|
-
- HY-162960
-
|
|
Ras
|
Cancer
|
|
pan-KRAS degrader 1 (Compound 1) is a panKRAS degrader with a surface plasmon resonance (SPR) dissociation constant Ki value of 25 nM for KRAS G12V .pan-KRAS degrader 1 has antitumor activity .
|
-
- HY-122152
-
|
APY-606; Clospirazine hydrochloride
|
Ras
|
Neurological Disease
Cancer
|
|
Spiclomazine hydrochloride (APY-606) is an antipsychotic and antitumor agent. Spiclomazine hydrochloride inhibits KRas. Spiclomazine hydrochloride induces cancer cell apoptosis .
|
-
- HY-125158A
-
|
|
Aurora Kinase
|
Cancer
|
|
(E/Z)-HOI-07 is a potent and selective Aurora B inhibitor. HOI-07 has antitumor activity .
|
-
- HY-163365
-
-
- HY-152245
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Physachenolide C is a potent and selective BET inhibitor that induces apoptosis and arrests the cell cycle in the G0-G1 phase, with antitumor activity .
|
-
- HY-144817
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 27 (DYT-1) is a tubulin polymerisation inhibitor with an IC50 of 25.6 μM. Tubulin inhibitor 27 shows anti-angiogenesis and antitumor activities .
|
-
- HY-156780
-
|
|
Cuproptosis
|
Cancer
|
|
NSC 689534 can form copper chelate with Cu 2+. NSC 689534/Cu 2+ complex is a potent oxidative stress inducer, and has antitumor activity .
|
-
- HY-138645A
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
5-Iminodaunorubicin hydrochloride is a quinone-modified anthracycline that retains antitumor activity . 5-Iminodaunorubicin hydrochloride produces protein-concealed DNA strand breaks in cancer cells .
|
-
- HY-138645
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
5-Iminodaunorubicin is a quinone-modified anthracycline that retains antitumor activity . 5-Iminodaunorubicin produces protein-concealed DNA strand breaks in cancer cells .
|
-
- HY-160414
-
|
(R,R)-TRX-COBI; TRX-cobimetinib
|
MEK
|
Cancer
|
|
TRX-COBI ((R,R)-TRX-COBI; Trx-cobimetinib) is a MEK inhibitor targeting TRX fragments based on Fe 2+. TRX-COBI has antitumor activity .
|
-
- HY-132891
-
-
- HY-121245
-
-
- HY-105463
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Saptomycin D is an antibiotic with antitumor activity isolated from the Streptomyces sp. HP530 strain. Saptomycin D exhibits potent inhibitory effects against Gram-positive bacteria, while demonstrating weaker inhibitory activities against certain Gram-negative bacteria and yeasts. Saptomycin D also displays remarkable antitumor properties. Saptomycin D is applicable in research within the field of oncology .
|
-
- HY-123191
-
|
|
PAI-1
|
Cancer
|
|
CJ-463 is a potent and selective uPA inhibitor. CJ-463 has antitumor activity .
|
-
- HY-148059
-
|
B-Raf IN 10
|
Raf
|
Cancer
|
|
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC50 between 50 and 100 nM. Uplarafenib shows antitumor activity .
|
-
- HY-132001
-
|
KO-539
|
Epigenetic Reader Domain
|
Cancer
|
|
Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151) .
|
-
- HY-161326
-
|
|
FGFR
|
Cancer
|
|
CXF-007 is a potent and specific FGFR4 inhibitor with a IC50 value of 7 nM. CXF-007 has antitumor activity .
|
-
- HY-158346
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Polθ-IN-3 (Compound 113) is an orally active inhibitor of Polymerase Theta (Polθ). Polθ-IN-3 has antitumor activity .
|
-
- HY-W048303
-
|
|
Antibiotic
|
Infection
Cancer
|
|
L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes .
|
-
- HY-168847
-
|
|
Ras
|
Cancer
|
|
INCB159020 is an orally active KRAS G12D inhibitor with a KRAS G12D SPR value of 2.2 nM. INCB159020 has antitumor activity .
|
-
- HY-119789
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Albofungin (Antibiotic P-42-1) is isolated from the culture filtrate of Actinomyces tumemacerans strain INMI.P-42. Albofungin shows highly active on a wide variety of gram-positive bacteria and fungi. Albofungin shows cytotoxic to HeLa cell cultures and exhibited antitumor activity on EHRLICH ascites tumor in mice.
|
-
- HY-101647
-
|
RP 60475
|
Topoisomerase
|
Cancer
|
|
Intoplicine (RP 60475), an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine strongly binds DNA (KA = 2 x 10 5 /M) and thereby increases the length of linear DNA .
|
-
- HY-144804
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-17 (Compound 15a) is a potent VEGFR-2 inhibitor with an IC50 of 67.25 nM. VEGFR-2-IN-17 shows antitumor activities .
|
-
- HY-160549
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 14 (Compound 13A) is a c-Myc protein inhibitor. The IC50 value of HL60 inhibitor is <100 nM. c-Myc inhibitor 14 shows antitumor activity .
|
-
- HY-132891A
-
-
- HY-146014
-
-
- HY-147993
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC50 of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .
|
-
- HY-122356
-
|
|
Bacterial
|
Cancer
|
|
Ambazone monohydrate is an orally active membrane active antitumor agent. Ambazone monohydrate also shows antibacterial and weak antiviral activities .
|
-
- HY-122356A
-
|
|
Bacterial
|
Cancer
|
|
Ambazone is an orally active membrane active antitumor agent. Ambazone also shows antibacterial and weak antiviral activities .
|
-
- HY-N12534
-
|
|
Apoptosis
|
Cancer
|
|
Monaspin B is a natural product produced by the co-culture of Monascus purpureus and Aspergillus oryzae. Monaspin B exerts anti-proliferation activity by inducing apoptosis of HL-60 cells, IC50 160 nM. Monaspin B has antitumor activity .
|
-
- HY-156467A
-
|
NVL-655 TFA
|
Anaplastic lymphoma kinase (ALK)
Apoptosis
|
Cancer
|
|
Neladalkib TFA is the TFA salt form of Neladalkib (HY-156467). Neladalkib (NVL-655) is an oral ALK inhibitor, the IC50 for Neladalkib in inhibiting ALK is 2.8 nM. Neladalkib promotes cell apoptosis and has anti-tumor activity .
|
-
- HY-113799
-
-
- HY-161695
-
|
|
VEGFR
|
Cancer
|
|
Angiogenesis inhibitor 6 (Compound 8) is a non-tyrosine kinase inhibitor with effective antiangiogenic properties. Angiogenesis inhibitor 6 has antitumor activity .
|
-
- HY-10084
-
|
|
Kinesin
|
Cancer
|
|
CK0106023 is a potent and specific allosteric inhibitor of KSP with a Ki value of 12 nM, showing antitumor activity. CK0106023 causes mitotic arrest and growth inhibition in several tumor cell lines. CK0106023 exhibits antitumor activity in tumor-bearing mice .
|
-
- HY-101647A
-
|
RP 60475 dimesylate
|
Topoisomerase
|
Cancer
|
|
Intoplicine (RP 60475) dimesylate, an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine dimesylate strongly binds DNA (KA = 2 x 10 5 /M) and thereby increases the length of linear DNA .
|
-
- HY-169326S
-
-
- HY-W141127
-
|
|
Biochemical Assay Reagents
|
Cancer
|
|
1-(Bromomethyl)pyrene is a Br compound with antitumor activity. 1-(Bromomethyl)pyrene is widely used in the synthesis of fluorophores for the fluorescent sensing of variety of analytes. 1-(Bromomethyl)pyrene can be also used in the synthesis of photoinitiators (PIs) .
|
-
- HY-158195
-
|
|
Others
|
Cancer
|
|
DPP23 exerts antitumor activity through ROS-mediated apoptosis in cancer cells, but does not play a role in healthy cells. DPP23 can up-regulate the expression of ATF4 .
|
-
- HY-144803
-
|
|
VEGFR
|
Cancer
|
|
VEGFR-2-IN-16 (Compound 15b) is a potent VEGFR-2 inhibitor with an IC50 of 86.36 nM. VEGFR-2-IN-16 shows antitumor activities .
|
-
- HY-131345
-
|
|
PI3K
|
Cancer
|
|
PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα, with an IC50 of 1.8 nM. PI3Kα-IN-4 has antitumor activity .
|
-
- HY-169106
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase inhibitor 4 (compound 45) is a potent Topoisomerase1/2 inhibitor. Topoisomerase inhibitor 4 causes cell cycle arrest in the G2/M phase by inducing Apoptosis. Topoisomerase inhibitor 4 has antitumor activity .
|
-
- HY-103694
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Nebularine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-125132
-
|
(-)-Agelastatin A; AglA
|
Apoptosis
|
Cancer
|
|
Agelastatin A ((-)-Agelastatin A; AglA), a tetracyclic alkaloid isolated from the sponge Agelas dendromorpha, induces apoptosis and arrests cells in the G2/M phase of the cell cycle, exhibiting antitumor activity .
|
-
- HY-113431
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Arabinosylhypoxanthine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152995
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Confidential is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-132262
-
|
IMGN-901; BB-1090
|
Antibody-Drug Conjugates (ADCs)
|
Cancer
|
|
Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity .
|
-
- HY-162301
-
-
- HY-154269
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confiden is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162849
-
|
|
Wee1
|
Cancer
|
|
PKMYT1-IN-3 (compound 8ma) is a potent and selective PKMYT1 inhibitor with an IC50 value of 16.5 nM. PKMYT1-IN-3 has antitumor activity .
|
-
- HY-154270
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confident is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-124092
-
|
935U83
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Raluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N9971
-
-
- HY-136293
-
|
|
Apoptosis
|
Cancer
|
|
Mechercharmycin A is a cytotoxic substance isolated from marine-derived Thermoactinomyces sp. YM3-251. Mechercharmycin A exhibits relatively strong antitumor activity .
|
-
- HY-128798
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor 20 is an irreversible menin-MLL interaction inhibitor with antitumor activities (WO2020142557A1, Intermediate 6) .
|
-
- HY-P3917
-
|
LfcinB (20–30)
|
Bacterial
|
Infection
|
|
LfcinB (20–30) is a fragment of bovine lactoferricin. LfcinB (20–30) has bactericidal, antifungal, antiparasitic, antitumor, antiviral and immunomodulatory activities.
|
-
- HY-153544
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy .
|
-
- HY-P99778
-
|
MORAb-004
|
EGFR
|
Cancer
|
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer .
|
-
- HY-12019
-
|
|
c-Met/HGFR
|
Cancer
|
|
SGX523 is a exquisitely selective and ATP-competitive MET inhibitor. SGX523 potently inhibits MET with an IC50 of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity .
|
-
- HY-169111
-
|
|
SHP2
|
Cancer
|
|
SHP2-IN-32 (compound C6) is an orally active, allosteric SHP2 inhibitor with an IC50 value of 0.13 nM. SHP2-IN-32 exhibits antitumor activity .
|
-
- HY-161927
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-TK-IN-4 (compound 10k) is a potent and selective EGFR-TK inhibitor. EGFR-TK-IN-4 can induce apoptosis . EGFR-TK-IN-4 has antitumor activity .
|
-
- HY-154668
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'- Homocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P9922
-
|
IMC-3G3; LY3012207
|
PDGFR
|
Cancer
|
Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
|
-
- HY-143460
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CAXII-IN-1 (Compound 17) is a selective CA XII inhibitor with Ki values of 3.8 nM and 56.0 nM against hCA XII and hCA IX, respectively. CAXII-IN-1 shows antitumor activity .
|
-
- HY-126878
-
|
|
Antifolate
|
Infection
Cancer
|
|
11-Oxahomoaminopterin shows antifolate activity and inhibits Lactobacillus casei DHFFZ with antimicrobial and antitumor activities .
|
-
- HY-15493
-
|
NRC-AN-019
|
Bcr-Abl
|
Cancer
|
|
AN-019 is a Bcr-Abl kinase inhibitor. AN-019 has antitumor activity .
|
-
- HY-169232
-
|
|
PROTACs
|
Cancer
|
|
PCC16 chloride is a CRBN-based cp-PCC with an IC50 value of 102 nM for the degradation of DHHC3. PCC16 chloride has antitumor activity. (Target protein ligand: HY-169235, linker: HY-169236, E3 ligase ligand: HY-10984) .
|
-
- HY-129071
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo .
|
-
- HY-N14180
-
|
|
Antibiotic
|
Infection
Cancer
|
|
6-Deoxyilludin M is an antitumor antibiotic possessing antileukemic activity. 6-Deoxyilludin M can be isolated from the culture broth of the Basidiomycota Pleurotus japonicas .
|
-
- HY-152314
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Cyanoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152599
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152546
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Allyloxyguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-164497
-
|
|
DNA/RNA Synthesis
Histone Methyltransferase
|
Cancer
|
|
NSC 641396 is a ribonucleotide reductase (RNR) inhibitor with an IC50 value of 1.2 μM. NSC 641396 is also a protein arginine N-methyltransferase 9 (PRMT9) inhibitor. NSC 641396 has antitumor activity .
|
-
- HY-152654
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4′-Thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-134295
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152617
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-Thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154732
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-141598
-
-
- HY-112581
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152462
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Azaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W602640
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxyisoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152296
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W011079
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154242
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152643
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161696
-
|
|
Apoptosis
|
Cancer
|
|
AN5777 is a GSPT1 degrader. AN5777 significantly reduces GSPT1 through the ubiquitin-proteasome system. AN5777 induces G1 block and Apoptosis. AN5777 has antitumor activity .
|
-
- HY-154535
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154329
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W244398
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W587829
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152615
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131795
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methylthioadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W576440
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
α-Cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152383
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Difluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152682
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
5-Ethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152368
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Hydrazinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W022290
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-134294
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloroguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154536
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-Guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152544
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Allylthioguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152807
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Thioadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W609639
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxyisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154268
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Confidential-2 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154670
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Homoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154534
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-Adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W048500
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Thiothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-118712
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor WYE-23 is a mTOR inhibitor, and IC50 is 0.45 nM. It is selective to PI3Kα and IC50 is 661 nM. mTOR inhibitor WYE-23 has antitumor activity .
|
-
- HY-145856
-
|
|
VEGFR
Apoptosis
|
Cancer
|
|
VEGFR-2-IN-11 (Compound 8h) is a potent VEGFR-2 inhibitor with an IC50 of 60.27 nM. VEGFR-2-IN-11 shows antitumor activity and induces cell apoptosis .
|
-
- HY-151414
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-Deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131792
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W100215
-
|
5-Methylcyclocytidine hydrochlorine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methylcyclocytidine hydrochloride is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152800
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154275
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’-Methylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152740
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Pyrrolidinomethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W009163
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-164376
-
|
|
CDK
|
Cancer
|
|
CDK4/6-IN-21 (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 has antitumor activity .
|
-
- HY-164376A
-
|
|
CDK
|
Cancer
|
|
CDK4/6-IN-21 maleate (compound I-52) is a CDK4/6 inhibitor with IC50 values of 3.88 and 3.31 nM for CDK4 and CDK6, respectively. CDK4/6-IN-21 maleate has antitumor activity .
|
-
- HY-131194
-
|
|
Interleukin Related
|
Cancer
|
|
JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC50 of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .
|
-
- HY-145483
-
|
KYM-001; PROTAC IRAK4 degrader-7
|
PROTACs
IRAK
Apoptosis
|
Cancer
|
|
KT-474 (KYM-001) is an orally active PROTAC IRAK4 degrader with antitumor activities . KT-474 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-B0431A
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity .
|
-
- HY-123291
-
-
- HY-B0431
-
-
- HY-130806
-
|
H2dUrd
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Dihydrodeoxyuridine (H2dUrd) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W014306
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-130805
-
|
OHUrd
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
5-Hydroxyuridine (OHUrd) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154421
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,5’-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149072
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 11 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N8525
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-O-Acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149071
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 10 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152869
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(Trifluoromethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152656
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Hydrazinyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152510
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Aminomethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152794
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Methyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-105006
-
|
2-Methoxyadenosine; 2-O-Methylisoguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Spongosine (2-Methoxyadenosine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152420
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Trifluoromethyl adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154474
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,4-Dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W013259
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methylmercaptopurine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152375
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-xyloguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152327
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methylthio isopentenyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W154568
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
6-Methylpurine riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-168097
-
|
|
Ferroptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Ferroptosis inducer 6 (6d) is a ferroptosis inducer with high potency for type I/-II photodynamic therapy by inducing ROS generation, oxidative stress and mitochondrial damage. Ferroptosis inducer 6 has anti-tumor activity .
|
-
- HY-152602
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,3'-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152854
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
5-(Hydroxymethyl)cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152441
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Aminomethyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152387
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Chloro-arabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154131
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Deaza-xylouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W412546
-
|
4-[1-[(2-Methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152321
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxy-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152586
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′,3′-Anhydroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152867
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(Trifluoromethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N9292
-
|
|
Others
|
Cancer
|
|
Friedelin-3,4-lactone (Compound 4) is a triterpene can be isolated from the leaves of Garcia parViflora with weak antitumor activity .
|
-
- HY-134900
-
-
- HY-136718
-
|
|
Apoptosis
|
Cancer
|
|
CLEFMA is a curcuminoid with antitumor activity. CLEFMA inhibits tumor growth is associated with NF-κB-regulated anti-inflammatory and anti-metastatic effects .
|
-
- HY-149240
-
|
|
P-glycoprotein
|
Cancer
|
|
Anticancer agent 108 (Compound 3.10) is a potent P-gp inhibitor with significant antitumor activity and less toxicity to normal and pseudonormal cells. Anticancer agent 108 (Compound 3.10) had no acute toxic effect on С57BL/6 mice .
|
-
- HY-117280
-
|
|
MDM-2/p53
|
Cancer
|
|
GN25 is a specific p53-Snail binding inhibitor with antitumor effects .
|
-
- HY-N15371
-
|
|
Others
|
Infection
Inflammation/Immunology
Cancer
|
|
Barbinine is a diterpene alkaloid with antibacterial, antioxidant, anti-inflammatory and antitumor activities. Barbinine is a phytotoxin found in several Delphinium species .
|
-
- HY-157133
-
-
- HY-158845
-
|
|
Apoptosis
|
Cancer
|
|
8Br-HA is a potent FHIT inhibitor with an IC50 of 0.12 μM. 8 BR-HA can induceApoptosis. 8Br-HA has antitumor activity .
|
-
- HY-162274
-
|
|
Hedgehog
Antibiotic
|
Infection
Cancer
|
|
Oxazepine (compound 4a) has antimicrobial viability via binding OMPA/ exo-1,3-beta-glucanase proteins. Oxazepine is a hedgehog signaling inhibitor with antitumor viability .
|
-
- HY-145859
-
-
- HY-169129
-
|
ILX-295501
|
Drug Derivative
|
Cancer
|
|
LY-295501 is a sulfonylurea compound that has demonstrated in-vivo antitumor activity against a broad spectrum of solid tumors. LY-295501 can be utilized in cancer research .
|
-
- HY-145688
-
|
|
HDAC
|
Cancer
|
|
HDAC-IN-33 is a potent HDAC inhibitor with IC50s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .
|
-
- HY-163469
-
|
|
Src
|
Cancer
|
|
SRC-3-IN-2 (SI-12 6c)is an orally active steroid receptor coactivator 3 (SRC-3) inhibitor. SRC-3-IN-2 has antitumor activity .
|
-
- HY-152871
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine 5-oxyacetic acid methyl ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161116
-
|
|
Acetyl-CoA Carboxylase
|
Cancer
|
|
AD-5584 is an ACSS2 inhibitor with blood-brain permeability. AD-5584 can significantly reduce lipid storage, reduce colony formation, and increase cell death. AD-5584 has antitumor activity .
|
-
- HY-154537
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154616
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Phthalimidopropyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154356
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(alpha-L-Threofuranosyl)cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W556301
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-O-Isopropylideneisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152313
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Bromoadenosine, antimalarial agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W108399
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-t-Bulyldimethylsilylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152594
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine-5-oxyacetic acid is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154530
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-TNA-C(Bz)-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152318
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Adenosine-2-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152613
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-Ethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152649
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Cyclopropylmethylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154620
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-O-Hexadecyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149959
-
|
|
Mps1
|
Cancer
|
|
Mps1-IN-6 is a potent Mps1 inhibitor with an IC50 value of 2.596 nM. Mps1-IN-6 shows antiproliferative activity. Mps1-IN-6 shows antitumor activity .
|
-
- HY-154674
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Allylpseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154626
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Hexadecanyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152384
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152837
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,3-Dimethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154109
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154528
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Phthalimidopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W550365
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(alpha-L-Threofuranosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154110
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Aminopseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154453
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154187
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Pivaloyloxymethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W128112
-
|
alpha-D-Ribofuranoside,2,4(1H,3H)-pyrimidinedione-1
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(a-D-ribofuranosyl)uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163308
-
|
|
Bcl-2 Family
|
Cancer
|
|
Bcl-2-IN-18 (Compound 23) is a breast cancer Bcl-2 inhibitor with a IC50 value of 4.7 μM for MCF-7. Bcl-2-IN-18 has antitumor activity .
|
-
- HY-152454
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-α-C-Methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137589
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Dimethyldeoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154398
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-xylo-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152767
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Ethylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154621
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Hexadecanyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-129046E
-
|
Ribonuclease A (DNase & Protease Free), Recombinant
|
DNA/RNA Synthesis
|
Others
|
|
RNase A (DNase & Protease Free), Recombinant is an endonuclease, that can be found in bovine pancreas. RNase A (DNase & Protease Free), Recombinant purifies DNA by hydrolyzing cytosine or uracil residues in RNA. RNase A (DNase & Protease Free), Recombinant regulates cell growth, proliferation, differentiation, and migration, and exhibits antitumor efficacy .
|
-
- HY-150570
-
|
|
Carbonic Anhydrase
CDK
|
Cancer
|
|
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .
|
-
- HY-N7153
-
|
|
Others
|
Cancer
|
|
10-Hydroxycanthin-6-one is an antileukemic canthin-6-one alkaloid from Brucea antidysenterica. Antitumor agent .
|
-
- HY-147426A
-
|
ADS-007 sodium; ARO HIF2 sodium
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran sodium shows antitumor activities and can be used in advanced renal cell carcinoma research .
|
-
- HY-149290
-
|
|
Prostaglandin Receptor
|
Cancer
|
|
AMX12006 is a potent, selective and orally active EP4 antagonist with an IC50 value of 4.3 nM. AMX12006 shows cytotoxic and antitumor activity .
|
-
- HY-147426
-
|
ADS-007; ARO HIF2
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
Zifcasiran is a hypoxia-inducible factor (HIF) synthesis reducer. Zifcasiran shows antitumor activities and can be used in advanced renal cell carcinoma research .
|
-
- HY-119113
-
|
|
Drug Derivative
|
Cancer
|
|
C 175 is a nitroacridine derivative with antitumor activity. C 175 inhibits the growth of HeLa cells monolayer (ED50=0.49 μM) .
|
-
- HY-150036
-
|
|
Antibiotic
Cholecystokinin Receptor
|
Cancer
|
|
Anthramycin, a member of the pyrolobenzodiazepine (PBD) family, is a potent antibiotic. Anthramycin has potent antitumor activity. Anthramycin can act as an potent antagonist of cholecystokinin in the central nervous system in mice .
|
-
- HY-N8873
-
|
|
Others
|
Cancer
|
|
Silychristin B is an antitumor promoter. Silychristin B inhibits TPA induced Epstein-Barr virus early antigen (EBV-EA) induction. Silychristin B can be isolated from milk thistle .
|
-
- HY-144697
-
-
- HY-27787
-
|
cis-Eleostearic acid
|
Apoptosis
Ferroptosis
|
Metabolic Disease
Cancer
|
|
α-Eleostearic acid (cis-Eleostearic acid), a conjugated linolenic acid, is an apoptosis inducer. α-Eleostearic acid is also a ferroptosis inducer. α-Eleostearic acid exhibits antioxidant and antitumor activity .
|
-
- HY-152417
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N3-Ethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152344
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152795
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Desmethyl wyosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W130204
-
|
N4-Acetyl-2'-deoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-Acetyl-2′-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152609
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Cyanomethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154553
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetylthymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152411
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Beta-C-Methyl-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152323
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Methylsulfonyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152608
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-iso-Propyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152814
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-β-C-Methyl isoguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152725
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Benzyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154354
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 3’-O-benzyl xyloriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-20142
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(t-Butyldiphenylsilyl) thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152345
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Ethoxymethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152464
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-arabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137848
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Thymine 1-β-D-arabinofuranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152598
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methylxylo-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154722
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Dimethylaminomethylidene isoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152346
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Benzoyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152459
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-(n-Propylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152342
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Methoxymethyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152385
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5,6-Dihydro-ara-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-101007A
-
|
Tyrphostin AG 835; Tyrphostin B 50
|
EGFR
|
Cancer
|
|
(+)-Tyrphostin B44 (Tyrphostin AG 835) (Compound B50) is an EGRF inhibitor with antitumor activities .
|
-
- HY-144102
-
|
|
HDAC
|
Cancer
|
|
HDAC-IN-29 (compound 13b) is a potent pan-HDAC inhibitor. HDAC-IN-29 shows antitumor activity .
|
-
- HY-145687
-
|
|
HDAC
|
Cancer
|
|
HDAC-IN-32 is a potent HDAC inhibitor with IC50s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .
|
-
- HY-10204
-
OSI-930
4 Publications Verification
|
c-Kit
VEGFR
c-Fms
Apoptosis
|
Cancer
|
|
OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .
|
-
- HY-174161
-
|
|
Trk Receptor
|
Cancer
|
|
Type II TRK inhibitor 3 (Compound 18d) is a Type II TRK inhibitor with IC50 values of 0.82, 1.82, and 0.12 nM for TRKAWT/G595R/G667C, respectively. Type II TRK inhibitor 3 exhibits antitumor activity .
|
-
- HY-176142
-
|
|
CDK
c-Myc
Apoptosis
Bcl-2 Family
|
Cancer
|
|
YX0798 is a selective and orally active CDK9 inhibitor (Kd: 0.28 nM). YX0798 downregulates the oncoprotein c-MYC and pro-survival protein MCL-1. YX0798 disrupts the cell cycle and results in transcriptomic reprogramming, eventually leading to cell apoptosis. YX0798 has antitumor activity .
|
-
- HY-N11777
-
|
NHAP
|
NF-κB
|
Cancer
|
|
(−)-N-Hydroxyapiosporamide (NHAP), an alkaloid, is an NF-κB inhibitor with potent antitumor activity in vitro and in vivo. (−)-N-Hydroxyapiosporamide can be used for the research of colorectal cancer (CRC) .
|
-
- HY-N9460
-
|
|
DNA Alkylator/Crosslinker
Antibiotic
|
Cancer
|
|
Sibiromycin is a naturally produced glycosylated pyrrolobenzodiazepines (PBDs). Sibiromycin is also a potent antitumor antibiotic that binds covalently to DNA in the minor groove at the NH2 of guanine .
|
-
- HY-149856
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 33, a tubulin polymerization inhibitor, inhibits tubulin polymerization in a dose-dependent manner with an IC50 of 9.05 μM. Tubulin inhibitor 33 has antitumor effects and induces cell apoptosis that can be used for antitumor research .
|
-
- HY-102018
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
3'-Deoxy-3'-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152771
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-Deoxy-3′-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154364
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154327
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-dH2U-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152821
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154540
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Alpha-5-Methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152628
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3-deazauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152465
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Carboxymethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152710
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxycarbonylmethyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-77644
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Deoxy-5'-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154717
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxy-2’-fluoroisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152298
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Fluoro-4’-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152701
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Aminocarbonylmethyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152743
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-7-deazguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-482934
-
|
2'-Fluoro-2'-deoxyinosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152622
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154559
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-hydrazinyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152351
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154001
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-8-methylthioguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149220
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Protected 2,2'-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W011168
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-2'-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154114
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-iodoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W013330
-
|
Guanosine, 3'-deoxy-
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Deoxyguanosine (Guanosine, 3'-deoxy-) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152295
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-2’-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152334
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Chloro-2’-deoxyadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W141338
-
|
2'-Bromo-2'-deoxy-D-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Bromo-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-113041
-
|
PGA2; Medullin
|
Endogenous Metabolite
Apoptosis
|
Infection
Cancer
|
|
Prostaglandin A2 (PGA2), a human endogenous metabolite of PGE2, is an antitumor agent. Prostaglandin A2 induces p53-dependent apoptosis. Prostaglandin A2 also has antiviral activity .
|
-
- HY-154324
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154241
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154347
-
|
|
Apoptosis
|
Cancer
|
|
5′-Deoxy-5′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152540
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152505
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152731
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3′-Deoxy-3′-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154491
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154011
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Amino-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152666
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-4’-thiocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154153
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154088
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Deoxy-3′-iodothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W460267
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2,2'-O-Dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-149160
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Amino-5′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152367
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-119969
-
|
NSC 182986
|
DNA Alkylator/Crosslinker
|
Cancer
|
|
Diaziquone (NSC 182986), an aziridinylbenzoquinone, is a DNA alkylating agent. Diaziquone shows a broad antitumor activity against numerous transplantable murine tumors including curative activity against several intracerebrally implanted tumors. Diaziquone crosses the blood brain barrier .
|
-
- HY-176495
-
|
|
DNA Alkylator/Crosslinker
DNA/RNA Synthesis
|
Cancer
|
|
SG3683 is a DNA-targeted cytotoxic agent belonging to pyrrolobenzodiazepine (PBD) dimers. SG3683 exerts antitumor activity with an IC50 value of 0.74 nM in MDA-MB-436 cells. SG3683 is promising for research of cancers, such as breast cancer .
|
-
- HY-152630
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154214
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-(3-Methyln-propylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154025
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Azido-2′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154589
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Di-O-benzoyl fialuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154520
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-3′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154467
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-6-thioinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154243
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Methyl-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152445
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152354
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Benzyloxy-3’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154200
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-5-methycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99306
-
|
DS 1024
|
EGFR
|
Cancer
|
|
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .
|
-
- HY-152452
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Amino-2′-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154554
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-benzoyl thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152700
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methoxy-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154215
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-(P-Cyanophenyl methylidene hydrazino) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152320
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Adenosine-2-carboxy methyl amide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154087
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Bromo-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152519
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Aminomethyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154443
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev dC(Bz)-5'-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154300
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-Benzoyl-3′-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W154172
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Chloro-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152533
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Ethyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137600
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Ethenoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152631
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154470
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-2’-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152591
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-Methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152730
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoroinosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154740
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Chloro-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W039275
-
|
5'-Iodo-5'-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Deoxy-5'-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152765
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
3′-Deoxy-3′-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154692
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-5-methylisocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152440
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxycytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152793
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Cyano-7-deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154294
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154120
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Aza-2'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W251781
-
|
2′-Deoxy-4-thiouridine; 4-Thiodeoxyuridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Thio-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W013052
-
|
8-Bromo-9-(2-deoxypentofuranosyl)-9H-purin-6-amine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152739
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(N-Isopentenyl-N-trifluoroacetyl) aminomethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154399
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-163270
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
PM534, tubulin targeting agent, inhibits tubulin assembly with IC50 values of 0.8-3.2 nM. PM534 binds to the colchicine site of tubulin, which has high antitumor activity .
|
-
- HY-145989
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-162249
-
|
|
Ras
|
Cancer
|
|
ASP6918 is a potent and orally active KRAS G12C inhibitor with an IC50 value of 0.028 µM. ASP6918 inhibits cell growth. ASP6918 shows antitumor activity .
|
-
- HY-B1793
-
|
|
Potassium Channel
|
Neurological Disease
Cancer
|
|
Tetraethylammonium chloride is a non-selective potassium channel blocker. Tetraethylammonium chloride is a good substrate for organic cation transporter (OCTN1). Tetraethylammonium chloride antitumor properties .
|
-
- HY-147317
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Epothilone E is a related compound of epothilone, which inhibits microtubule protein function and blocks cell division, and has anti-tumor activity .
|
-
- HY-13550
-
|
NSC 196473; NSC 290813
|
DNA/RNA Synthesis
|
Cancer
|
|
Ametantrone (NSC 196473) is an antitumor agent that intercalates into DNA and induces topoisomerase II (TOP2)-mediated DNA break .
|
-
- HY-107769
-
-
- HY-P10550
-
|
|
VEGFR
|
Cancer
|
|
VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .
|
-
- HY-155647
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Microtubule stabilizing agent-1 (compound 3l) is a Paclitaxel derivative that efficiently promotes tubulin polymerization. Microtubule stabilizing agent-1 shows antitumor efficacy .
|
-
- HY-152377
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxy-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152865
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-(N-Acetylaminomethyl)-7-deazaguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154697
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-epi-Azido-3-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-77645
-
|
1-(5-Deoxy-beta-D-erythro-pent-4-enofuranosyl)uracil
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4',5'-Didehydro-5'-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154564
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N-methylaminothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152836
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-5-hydroxymethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154289
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Isopropylidene-5-hydroxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152336
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(2-Methyl)propyl pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152590
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154232
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-5′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152759
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-xylocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154012
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-8-methylamino-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152308
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’,5-difluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154248
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-3’,2-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154147
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154624
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Hexadecanyl-2-aminoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152662
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Dideoxy-5-fluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154038
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-3′-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-133117
-
BAY-985
1 Publications Verification
|
IKK
|
Cancer
|
|
BAY-985 is a highly potent, orally active and selective ATP-competitive dual inhibitor of TBK1 and IKKε with IC50s of 2/30 and 2 nM for TBK1 (low/high ATP) and IKKε, respectively. Antitumor efficacy .
|
-
- HY-154392
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-2’-deoxy inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W392809
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-2′-O-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154533
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Acetyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154456
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N6-cyclopentyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154237
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154556
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152548
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152640
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Fluoro-4’-thio-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154400
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Aza-3’-beta-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152707
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-2′-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N0530
-
|
Dryocrassin
|
Apoptosis
Influenza Virus
|
Cancer
|
|
Dryocrassin ABBA (Dryocrassin) is an orally active phloroglucinol derivative that can be extracted from Phyllopteris officinalis. Dryocrassin ABBA has antitumor and antiviral activity. Dryocrassin ABBA induced apoptosis of human hepatocellular carcinoma cells through mitochondrial pathway mediated by Caspase .
|
-
- HY-154239
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Triphenylmethyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152593
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152379
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154374
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Azido-2’,5’-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W603690
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-N6-phenoxyacetyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W550918
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromo-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152433
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(1,1-Difluoroethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152752
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’,3’-Dideoxy-3’-fluorocytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154333
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-8-(phenylmethoxy)guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W560803
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-DMTr-2,2'-anhydrothymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154625
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Hexadecanyl-2-aminoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152551
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4’-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154569
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-furfurylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152516
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-(2-Methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154420
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis-(O-t-butyldimethylsilyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154026
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Amino-2'-deoxyuridine (monohydrochloride) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152717
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152499
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-Methyl-2'-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154303
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Levulinyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154204
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroarabino inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152996
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-8-(methylthio)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154602
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-dG (iBu)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152584
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-xyloguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154372
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,5′-Dideoxy-5′-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154496
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N3-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154558
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-6-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152316
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-isopropyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W700392
-
|
|
IMPDH
|
Cancer
|
|
IMPDH-IN-2 (compound 2) is an inhibitor of inosine monophosphate dehydrogenase (IMPDH) with IC50Values are 0.15 and 0.17 μM, respectively. IMPDH-IN-2 has antitumor activity .
|
-
- HY-152866
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N,N-Dimethyl-2’-O-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154052
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Amino-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W415119
-
|
acetic acid 4-acetoxy-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-hydroxymethyl-tetrahydrofuran-3-yl ester
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Di-O-acetyl-D-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152607
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N,N-Dimethyl-2′-O-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152307
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154293
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-ethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-137548
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-3′-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152577
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(2-Methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152554
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-xyloadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154510
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N4-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152638
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-3’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152588
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152325
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(N,N-Dimethylaminocarbonyl)-pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W347492
-
|
O6-Methyl-2′-deoxyguanosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
O6-Methyldeoxy guanosine; DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152425
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Methylamino-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152513
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-112582S
-
|
1-Methylpseudouridine-d3; N1-methyl-pseudouridine-d3
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methylpseudouridine-d3 is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-160409
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with PARP inhibitors. TopBP1-IN-1 has antitumor activity .
|
-
- HY-139784
-
|
(R)-2-Hydroxyoleic acid; (R)-2-OHOA; (R)-LAM561
|
Endogenous Metabolite
|
Cancer
|
|
Idroxioleic acid ((R)-2-Hydroxyoleic acid; (R)-2-OHOA), the R enantiomer of (Rac)-Idroxioleic acid, is an orally active fatty acid that modulates the lipid composition and structure of the membranes. Idroxioleic acid has antitumor activities .
|
-
- HY-132175
-
|
|
Casein Kinase
|
Cancer
|
|
CK2 inhibitor 2 is a potent, selective and orally active inhibitor of CK2, with an IC50 of 0.66 nM. CK2 inhibitor 2 shows high selectivity for Clk2 (IC50=32.69 nM)/CK2. CK2 inhibitor 2 exhibits favorable antiproliferative and antitumor activity .
|
-
- HY-144793
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Deac-SS-Biotin is a potent antitumor agent with improved tumor targeting effects and reduced off-target toxicities. Deac-SS-Biotin uptakes into the cells through biotin-mediated internalization. Deac-SS-Biotin combined with DTT (Glutathione mimetic) can effectively inhibit microtubule assembly and displays greater antitumor activity .
|
-
- HY-106218
-
|
5-Fluorocyclocytidine; 5'-Fluorocyclocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Flurocitabine (5-Fluorocyclocytidine) is a fluorinated anlydride analog of cytosine arabinoside, partially hydrolysecl in vivo into two active antitumor substances (arabinosyl-tluorocytosine (ara-FC) and arabinosyl-fluorouracil (ara-FU)). Flurocitabine (5-Fluorocyclocytidine) has antitumor activity during phase I studies in acute leukemia and solid tumors .
|
-
- HY-148019
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Deoxy-2′-fluoro-N-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154472
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Ethyl-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154233
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-TBDPS-2,2’-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154018
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154161
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2-Hydroxyethyl)-2’-deoxy uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W010681A
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-DMTr-thymidine 5’-CE phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152863
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N6-Furfuryl-2-aminoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154544
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-MOE-U-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152561
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5’(R)-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W357202
-
|
PMO Thymidine Precusor
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7’-OH-N-trityl morpholinothymine (PMO Thymidine Precusor) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152397
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-isopentenyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152317
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Methyl-2-thio-xylo-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154136
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Fluoro-3’-beta-C-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154201
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-O6-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W011725
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
Cancer
|
|
N-6-Methyl-2-deoxyadenosine is an adenine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W013728
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,3,5-Tri-O-benzoyl-a-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152326
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154568
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-(4-morpholinyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154428
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2-isopropyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-105064C
-
|
CP-597396 dihydrochloride
|
Na+/H+ Exchanger (NHE)
|
Cancer
|
|
Zoniporide dihydrochloride (CP-597396 dihydrochloride) is a potent and selective inhibitor of highly water-soluble sodium hydrogen exchange type 1 (NHE-1). Zoniporide dihydrochloride inhibits NHE1 dependent 22Na + uptake in vitro with an IC50 of 14 nM. Zoniporide has antitumor activity .
|
-
- HY-152715
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-C-β-Methyl-4-deoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152749
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-methyl-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154130
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-5-trifluoromethyluracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154292
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N1-Methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154262
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W570891
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-LNA-C(Bz)-3-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152635
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-O-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152467
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-2’-beta-C-methylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152880
-
|
T 70179
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-arabino-tubercidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154468
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-O-Methyl-2’-O-methylinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154129
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-5-methoxyuracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154348
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-5’-deoxy thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152530
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-beta-C-Methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154296
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152729
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-(2-Amino-2-oxoethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152721
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-O-Methyl-4-deoxy uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152497
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-C-Methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152629
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152428
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methylguanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154600
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-3’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152768
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-(1,1,1-Trifluoroethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152651
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’(R)-C-Methyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152745
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154430
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2-cyclopentyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W008615
-
|
5-Iodo-D-cytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-cytidine (5-Iodo-D-cytidine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W394419
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-dC(Bz)-2’-phosphor amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152322
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-iso-pentenyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161136
-
|
|
EGFR
STAT
|
Cancer
|
|
EGFR/STAT3-IN-1 (Compound 5k) is a dual inhibitor of EGFR/STAT3 with IC50 values for EGFR and STAT3 are 41 and 3.34 nM, respectively. EGFR/STAT3-IN-1 has antitumor activity .
|
-
- HY-154373
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-2′,5′-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154138
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-C-Methyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152501
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-O-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-19137
-
|
KW 2189 free base
|
Antibiotic
|
Infection
Cancer
|
|
Pibrozelesin (KW 2189 free base) is the derivative of antibiotic Duocarmycin B2. Pibrozelesin exhibits antitumor activity, inhibits proliferation of cell H69 with an IC50 of 1.9 μM. Pibrozelesin induces the DNA strand breaks upon activation via carboxyl esterase .
|
-
- HY-152500
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-3’-β-C-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-49200
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMT-2'-F-dC(Bz)-CE-Phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154496A
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N3-methylcytidine hydriodide is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154128
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-5-fluorouracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154495
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3-Methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W377454
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-Beta-D-arabinofuranosyl-5-iodouracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152369
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Etheno-ara-adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154330
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-beta-Azido-2',3'-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W048512
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-Didehydro-2',3'-dideoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152741
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991141
-
|
|
VEGFR
|
Cancer
|
|
Inlecitug is a chimeric monoclonal antibody targeting human KDR (kinase insert domain receptor). Inlecitug specifically binds to KDR, blocking the binding of vascular endothelial growth factor (VEGF) to KDR and inhibiting angiogenesis, thus exerting antitumor activity. Inlecitug is promising for research of cancers .
|
-
- HY-152644
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-5-methoxyuridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N8473
-
|
(+)-Pericosine A
|
Topoisomerase
|
Cancer
|
|
Pericosine A ((+)-Pericosine A) is a topoisomerase II (Topoisomerase II) inhibitor that can be isolated from the Periconia byssoides strain. Pericosine A has significant antitumor activity in vitro and in vivo and can be used in cancer research. Pericosine A also inhibits the protein kinase epidermal growth factor receptor .
|
-
- HY-154432
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152415
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152466
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Methyl-N1-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152343
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-(β-D-Xylofuranosyl)-2-thiouracil is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-117481
-
|
|
Apoptosis
|
Cancer
|
|
NSC-639829 is a Benzoylphenylurea (BPU) analogue which has antitumor activity. NSC-639829 is promising for research of refractory metastatic cancer .
|
-
- HY-10824B
-
|
PT523 ammonium
|
Dihydrofolate reductase (DHFR)
Antifolate
|
Cancer
|
|
Talotrexin ammonium is a nonpolyglutamatable antifolate. Talotrexin ammonium improves antitumor activity in a broad spectrum of cancer models by targeting DHFR to inhibit tumor growth .
|
-
- HY-138799
-
|
|
HDAC
|
Cancer
|
|
KA2507 is a potent, orally active and selective HDAC6 inhibitor, with an IC50 of 2.5 nM. KA2507 shows antitumor activities and immune modulatory effects in preclinical models .
|
-
- HY-125633
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Kapurimycin A3 is an antitumor and antibacterial antibiotic. Kapurimycin A3 has DNA binding and breakage activity. Kapurimycin A3 can be isolated from Streptomyces .
|
-
- HY-101162
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala .
|
-
- HY-16111A1
-
|
|
Farnesyl Transferase
|
Cancer
|
|
BMS-214662 mesylate is a potent and selective farnesyl transferase inhibitor with an IC50 of 1.35 nM. BMS-214662 mesylate exhibits potent antitumor activity and can be utilized in cancer research .
|
-
- HY-14429
-
|
MGI 114; 6-Hydroxymethylacylfulvene; NSC 683863
|
DNA Alkylator/Crosslinker
Apoptosis
|
Cancer
|
|
(-)-Irofulven (MGI 114), an Illudin S analog, is a DNA alkylating agent. (-)-Irofulven inhibits the replication of DNA, induces tumor cells apoptosis, and has potent antitumor activity .
|
-
- HY-13598
-
|
CKD-516
|
Microtubule/Tubulin
|
Cancer
|
|
Valecobulin (CKD516) is a valine proagent of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .
|
-
- HY-142460
-
|
|
Ras
|
Cancer
|
|
KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC50 of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1) .
|
-
- HY-164484
-
|
|
Raf
|
Cancer
|
|
IHMT-RAF-128, a highly potent pan-RAF inhibitor. IHMT-RAF-128 shows potent antitumor efficacy in xenograft mouse tumor models without causing any apparent toxicities .
|
-
- HY-145989A
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E TFA is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E TFA has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-154198
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine](//file.medchemexpress.com/product_pic/hy-154198.gif)
- HY-154257
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyryl-8-azaguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152872
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine-5-oxo-acetyl-(9-fluorenylmethyl) ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154261
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-A(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152413
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Furfuryl-2’-C-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W047393
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 2,3,5-tri-O-benzyl-D-ribofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154231
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-alpha-D-arabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154081
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-2’-OMeU-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154457
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N6-(4-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154064
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-MOE-A(Bz)-2’-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146574
-
|
|
Aldose Reductase
17β-HSD
|
Cancer
|
|
AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.19 μM. AKR1C3-IN-7 shows antitumor activity .
|
-
- HY-152805
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(2-β-C-Methyl-β-D-ribofuranosyl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154529
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-3’-O-phthalimidopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154406
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2-methylguanosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146575
-
|
|
Aldose Reductase
17β-HSD
|
Cancer
|
|
AKR1C3-IN-8 (Compound 5) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.069 μM. AKR1C3-IN-8 shows antitumor activity .
|
-
- HY-152650
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N6-Methyl-2-methyl thioadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152400
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Bromo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157750
-
|
|
MEK
Raf
|
Cancer
|
|
MEK1/C-Raf-IN-1 (Compound 14d) is a MEK1/C-Raf inhibitor with IC50 values of 97 and 23 nM, respectively. MEK1/C-Raf-IN-1 has antitumor activity .
|
-
- HY-152675
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152624
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152508
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-beta-C-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154323
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-DMTr-3’dA(Bz)-methylphosphonami dite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154566
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N,N-diethylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152339
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Amino-2'-C-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152606
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-C-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154516
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-9-(beta-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152621
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152461
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-(3-Trifluoromethylbenzyl)-3’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154458
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N6-(3-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152738
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-β-C-Methyl-3-deazauri dine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152648
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Ethyl-2’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154481
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Me-C(Bz)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152324
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-(2-hydroxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-117813
-
|
|
Nucleoside Antimetabolite/Analog
Apoptosis
DNA/RNA Synthesis
|
Cancer
|
|
2-Thiouridine (2-Thioxo-2-deoxouridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154565
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N,N-dimethylamino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154395
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-2′-deoxy-N,N-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152421
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
8-Benzyloxy-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154297
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Dimethylamino methylidene-2’-deoxyisoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145791
-
|
2′,3′-Didehydro-2′,3′-dideoxycytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Dideoxycytidinene (2′,3′-Didehydro-2′,3′-dideoxycytidine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W128788
-
|
4-amino-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)pyrimidin-2(1H)-one
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-b-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152494
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methyl-9-(β-D-xylofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154082
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Caroxy uracil-1-yl acetic acid benzyl ester is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152804
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-2’-β-C-methyl cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W046353
-
|
o-Methoxycinnamaldehyde
|
Apoptosis
NF-κB
Topoisomerase
Mitochondrial Metabolism
Caspase
|
Cancer
|
|
2-Methoxycinnamaldehyde (o-Methoxycinnamaldehyde) is a natural compound that can be isolated from Cinnamomum cassia. 2-Methoxycinnamaldehyde inhibits topoisomerase-I/II and NF-κB signaling pathway, causes mitochondrial dysfunction, induces lysosomal vesiculation, thereby leading to DNA damage and cell apoptosis. 2-Methoxycinnamaldehyde exhibits antitumor effects .
|
-
- HY-N0379
-
|
|
Endogenous Metabolite
|
Others
Cancer
|
|
D-Mannose is a C-2 superpolymer of glucose that occurs naturally in many plants and fruits. D-Mannose has anti-inflammatory and antitumor activity. D-Mannose plays an important role in immune regulation .
|
-
- HY-148810
-
|
BI 1810631
|
c-Met/HGFR
|
Cancer
|
|
Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors .
|
-
- HY-161075
-
|
|
Microtubule/Tubulin
Ferroptosis
|
Cancer
|
|
Microtubule inhibitor 8 (MP-HJ-1b) is a potent inhibitor of microtubule. Microtubule inhibitor 8 triggers cell death through ferroptosis. Microtubule inhibitor 8 has anti-tumor effect .
|
-
- HY-138799A
-
|
|
HDAC
|
Inflammation/Immunology
Cancer
|
|
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects .
|
-
- HY-13810
-
|
|
Raf
|
Cancer
|
|
PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .
|
-
- HY-152337
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(4-trifluoromethyl)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154066
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-flluoro-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W054074
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromo-2',3',5'-tri-O-acetyluridine diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154156
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroadenosine 5’-monophosphate (triethylammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152712
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Bromo-3’-deoxy-3’-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152653
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-iso-Propyl-2’-O-methyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154578
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2'-deoxyadenosine, DNA adduct is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152457
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-beta-D-xylo-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154417
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis(O-t-butyldimethylsilyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154170
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-acetyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152873
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Uridine-5-(N-Fmoc-methylamino)-acetyl (9-fluorenylmethyl) ester is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152747
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-β-D-Ribofuranosyl-2(1H)-pyridinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152332
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(4-methoxy)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154418
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis(O-(t-butyldimethylsilyl)-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154595
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-4-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154344
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Deoxy-5′-iodo-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W342664
-
|
FIRU
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-2'-fluoro-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154609
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Bromo-2’-deoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152754
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152487
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-3’-deoxy-3’-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152753
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152760
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W539754
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2'-Deoxy-2'-fluoro-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154230
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-C(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152664
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(2,3-Dideoxy-β-D-erythro-hexo pyranosyl)cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152778
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-3’-deoxy-3’-fluoroadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154646
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-4’-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152723
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-N,N-dimethyl-2′-C-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152330
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(3-methoxy)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152302
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154396
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-deoxy-2’-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152362
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Hydroxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154599
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Me-3’-dU-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152803
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Iodo-3’-deoxy-3’-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W010917
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′,5′-Tri-O-acetyl-6-chloroguanosine diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154288
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154573
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine](//file.medchemexpress.com/product_pic/hy-154573.gif)
- HY-152761
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-methoxyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154642
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Bromo-2’-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152359
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Benzyloxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152335
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Chloro-N6-(3-trifluoromethyl)benzyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152439
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxy-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154513
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-5,N4-dimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152482
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(2-Methoxyethyl)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152329
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152757
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-trifluoromethyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W551974
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154415
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154213
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-5-MedC (Ac)-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154085
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(2’,3’,5’-Tri-O-acetyl)uridine 5-carboxylic acid is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W048487
-
|
N6-Benzoyl-7'-OH-Morpholino adenosine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-7’-OH-morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152455
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6-(m-methoxy benzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152549
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-(2-Methoxyethyl)-2-aminoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152693
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Methyl-2’-O-methyl-cytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152611
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-5-methyl ara-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152356
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Bromo-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152306
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1,N3-Bis(cyanomethyl)pseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154190
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-benzoyl-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154259
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-G(iBu)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152456
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Amino-2’-deoxy-5-methylcytidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152733
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Aza-7-bromo-7-deazaguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154271
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
TLR7 agonist 12 (example 20) is a TLR7 agonist, also is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162608
-
|
|
PROTACs
|
Cancer
|
|
PROTAC JAK1 degrader 1 degrader 1 (compound 10c) is an effective and selective PROTAC JAK1 degrader with a DC50 of 214 nM. PROTAC JAK1 degrader 1 has antitumor activity. (Structure Note: PINK, JAK1 ligand 1 (HY-10961); Blue, VHL ligand Thalidomide (HY-14658); Black, linker) .
|
-
- HY-170806
-
|
|
Estrogen Receptor/ERR
|
Cancer
|
|
ERα degrader 12 (Compound RA3) is an estrogen receptor α (ERα) degrader with antitumor properties. ERα degrader 12 induces pronounced tumor growth inhibition in a breast cancer xenograft mouse model .
|
-
- HY-147057A
-
|
FAP-2286 acetate
|
FAP
|
Cancer
|
|
Rofapitide tetraxetan (FAP-2286) acetate is a potent and selective FAP-binding peptide with a mean IC50 value of 2.7 nM for binding to FAP. Rofapitide tetraxetan acetate can be labeled with radionuclides for diagnostic applications. Rofapitide tetraxetan acetate has antitumor activity .
|
-
- HY-P10656
-
|
|
Apoptosis
Pyroptosis
|
Cancer
|
|
Ac-DEVDD-TPP is a porphyrin derivative that can be converted into D-TPP by caspase-3 cleavage and laser irradiation. The formed porphyrin nanofibers can effectively induce Apoptosis and Pyroptosis. Ac-DEVDD-TPP has antitumor activity .
|
-
- HY-15866
-
|
|
Others
|
Cancer
|
|
FR901465 is a potent anti-cancer and anti-tumor agent. FR901465 can be used for cancer research .
|
-
- HY-115937
-
|
|
c-Met/HGFR
Apoptosis
|
Cancer
|
|
c-Met-IN-9, a 4-phenoxypyridine derivative, is a c-Met kinas inhibitor with an IC50 of 12 nM. c-Met-IN-9 induces cells apoptosis, and has antitumor activities .
|
-
- HY-116592
-
|
|
c-Met/HGFR
|
Cancer
|
|
SOMCL-863 is a selective and orally active c-Met inhibitor with antitumor activity in vitro and in vivo. SOMCL-863 can be utilized in cancer research .
|
-
- HY-152088
-
-
- HY-152618
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-N-Acetyl-3’-amino-3’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154319
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine](//file.medchemexpress.com/product_pic/hy-154319.gif)
- HY-152633
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-N6,N6-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152403
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-118474
-
|
NSC 721648
|
Aryl Hydrocarbon Receptor
Cytochrome P450
|
Cancer
|
|
GW 610 (NSC 721648), an antitumor agent, is a potent AhR ligand with a Ki of 6.8 nM. GW 610 induces CYP1A1 expression in MCF-7 cells. GW 610 shows potent and selective anticancer activity against lung, colon, and breast cancer cell lines .
|
-
- HY-152504
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N1-methyladensoine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P99470
-
|
GEN1029
|
TNF Receptor
Apoptosis
|
Cancer
|
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .
|
-
- HY-154121
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-(2-Methoxyethyl)guanosine 5’-triphosphate (ammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W397503
-
|
2'-Deoxy-5'-O-DMT-5-iodouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-5-iodo-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154167
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152566
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N7-Methyl-2’-beta-C-methyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154526
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3’-O-[4,4’-dimethoxytrityl]-alpha-L-threofuranosyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)uridine](//file.medchemexpress.com/product_pic/hy-154526.gif)
- HY-149070
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Azido-2′,3′-dideoxy-5-hydroxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152813
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Deoxy-2′-fluoro-4-deoxy-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154218
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-O-Benzoyl-3-O-t-butyldiphenylsilyl-L-threono lactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152435
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Amino-2’-deoxy-5-methyl uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152509
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-beta-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152424
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-(4-Methoxybenzyl)-2’-C-methyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154545
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-MOE-5MeU-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154473
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N4-ethyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152563
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-beta-C-methyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154291
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-N1-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154133
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154059
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluorouridine 5’-monophosphate triethyl ammonium is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131818
-
|
NH2dAdo; Nsc 238990
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-Amino-5'-deoxyadenosine (NH2dAdo; Nsc 238990) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152340
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-5-fluoro-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152507
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-beta-C-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154465
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-F-3’-dG(iBu)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154394
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-methyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154407
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2,N2-dimethylguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154511
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N4,N4-dimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154295
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N1-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154159
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O,4’-C-Methyleneadenosine 5’-monophosphate (triethylammonium) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154391
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-(tert-Butyldiphenylsilyl)-2,3-isopropylidene-D-ribonolactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-131847
-
|
2,6-Dichloro-9-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)purine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,6-Dichloro-2',3',5'-triacetyl-purine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152518
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-5-methyl-4-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152817
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-β-C-Methyl-beta-D-6-methylpurine riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152301
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-N6-methyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152489
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-deoxy-2’-fluoro inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154370
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Bis-O-(t-butyldimethylsilyl)-N1-methylpseudouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154355
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-cyclopentyl 2’-deoxy- adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152444
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Hydroxymethyl-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154531
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Dideoxy-3′-fluoro-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154203
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Deoxy-3’-deoxy-3’-fluoro uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161348
-
|
|
Indoleamine 2,3-Dioxygenase (IDO)
|
Cancer
|
|
AT-0174 is an orally active dual inhibitor of IDO1/TDO2 (tryptophan 2,3-dioxygenase-2) with IC50 values of 0.17 and 0.25 μM, respectively. AT-0174 has antitumor activity .
|
-
- HY-152815
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2′-Deoxy-2′-fluoro-3-deaza-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147656
-
|
|
ATTECs
NAMPT
Autophagy
|
Cancer
|
|
NAMPT degrader-1 (Compound A3), an autophagosome-tethering compound (ATTEC), is an nicotinamide phosphoribosyltransferase (NAMPT) degrader with an IC50 of 0.023 μM. NAMPT degrader-1 significantly induces the degradation of NAMPT through the autophagy-lysosomal pathway and shows excellent cellular antitumor potency .
|
-
- HY-154132
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(b-D-Xylofuranosyl)-N6-(p-methoxybenzyl) adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154246
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Fluoro-2’-deoxy-arabinoadenosine 5’-triphosphate (triethylamine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152311
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6,N6-dimethyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154404
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzyl-4’-thio-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154345
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-5′-deoxy-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154134
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154158
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroguanosine 5’-monophosphate triethyl ammonium is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154306
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152390
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Fluoro-2’-deoxy-N6-methylarabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154238
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-3’-deoxyuridine 2’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N9971R
-
|
|
Reference Standards
NF-κB
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
|
Hentriacontane (Standard) is the analytical standard of Hentriacontane. This product is intended for research and analytical applications. Hentriacontane is a long-chain alkane. Hentriacontane exerts anti-inflammatory effects by inhibiting the NF-κB pathway. Hentriacontane has anti-inflammatory, antitumor and antibacterial activities .
|
-
- HY-117361
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
LY207702 is a difluorinated purine nucleoside with antitumor activity and cardiotoxicity. LY207702 is cytotoxic to CEA-positive LS174T cells (IC50=0.302 μg/mL). LY207702 can be used in the study of colon cancer .
|
-
- HY-N15458
-
|
|
Apoptosis
|
Cancer
|
|
5,6,7,8,4'-Pentahydroxyflavone (Compound 2b) is a flavonoid with antitumor activity. 5,6,7,8,4'-Pentahydroxyflavone exerts cytotoxic effects via inhibiting cell proliferation and inducing apoptosis .
|
-
- HY-17422B
-
|
|
HSV
Antibiotic
|
Infection
Cancer
|
|
Acyclovir monophosphate is a potent anti-herpes simplex virus (HSV) agent. Acyclovir monophosphate blocks DNA synthesis through the inhibition of the viral DNA polymerase and terminates the chain elongation of the viral DNA. Acyclovir monophosphate shows antitumor activity .
|
-
- HY-154408
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Me-5-I-U-3’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154382
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W357200
-
|
N-[9-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-9H-purin-6-yl]-benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-7’-OH-N-trityl morpholino adenine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154575
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine](//file.medchemexpress.com/product_pic/hy-154575.gif)
- HY-154660
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-5-iodocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154266
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-2’-deoxy-N6-ethyl-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152484
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N7-Methyl-2’-deoxy-2’-fluoroarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154205
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoroarabino-O6-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154235
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iBu-2’,3’-bis-O-TBDMS guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154371
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Benzoyl-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152486
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxy-2’-fluoroarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152736
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-5-methyl-xylo-uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152481
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-deoxy-2’-fluoroarabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-41793
-
|
2'-Deoxy-3'-O-[(1,1-dimethylethyl)dimethylsilyl]-2'-fluorouridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-O-(t-Butyldimethylsilyl)-2'-deoxy-2'-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W457757
-
|
1,2-O-Isopropylidene-3-O-Methyl-D-ribofuranose
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-isopropylidene-3-O-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-I0100
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 2-deoxy-3,5-di-O-toluoyl-D-ribofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152634
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
8-Chloro-2’-deoxy-2’-fluoro-arabino adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154307
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4′,5′-Didehydro-5′-deoxy-2′-O-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W357201
-
|
N-[1-(6-Hydroxymethyl-4-trityl-morpholin-2-yl)-2-oxo-1,2-dihydro-pyrimidin-4-yl]-benzamide
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-7’-OH-N-trityl morpholino cytosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154050
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Chloro-3′-deoxy-5′-O-(triphenylmethyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154331
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(5-O-Methoxytrityl-2-deoxy-β-D-xylofuranosyl)uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154343
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3′-Azido-3′-deoxy-5′-O-(triphenylmethyl)thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W045998
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-O-Isopropylidene-5-O-p-toluoyl-a-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152647
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methoxypurine-9-beta-D-(3-methoxy riboside) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152412
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyl-5-fluorouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152492
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N1-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152393
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyl-5-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W555976
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Hydroxymethyl-2',3'-O-isopropylidene-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W564313
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3'-O-Isopropylidene-5-pyrrolidinomethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154557
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′,3′-Didehydro-2′,3′-dideoxy-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154234
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-TBDPS-5-methyl-2,2’-anhydrouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154376
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W342904
-
|
5'-O-[Bis(4-methoxyphenyl)phenylmethyl]-5-iodo-2'-O-methyl-uridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Methyl-5’-O-DMTr-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154304
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’,5’-dideoxy-2’-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154429
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-N2,N2-diethyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154612
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-4’-thio-a-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152796
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Furan-2-yl-2’-O-methyl uridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154258
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-5MeU-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154677
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Aminopurine-9-beta-D-(2’-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154123
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-2’-chloro-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154263
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-N6-ethyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154567
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-N-(2-chloroethyl)amino thymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154086
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-2’,2’-difluoro-dC(Bz)-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991468
-
|
|
Interleukin Related
|
Cancer
|
|
IMM20324 is a human monoclonal antibody (mAb) targeting IL38. IMM20324 inhibits the interaction of IL-38 with human IL1RAPL1-Fc and human IL-36R-Fc with IC50 values of 1.267 nM and 1.4667 nM, respectively. IMM20324 has antitumor activity in the B16.F10 syngeneic mouse model. IMM20324 can be used in antitumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-105672
-
|
|
Adrenergic Receptor
|
Cancer
|
|
Cafaminol (Methylcoffanolamine) is a vasoconstrictor and anticatarrhal that selectively binds to alpha-1 receptors, causing blood vessels to constrict. Cafaminol is an xanthine derivative which can be utilized in decongestant and antitumor research .
|
-
- HY-N4058
-
|
|
Apoptosis
|
Cancer
|
|
Helichrysetin is isolated from the flower Helichrysum odoratissimum. Helichrysetin is an ID2 (DNA binding inhibitor 2) inhibitor. Helichrysetin induces apoptosis. Helichrysetin has anti-tumor and antioxidant activity .
|
-
- HY-147337
-
MeTC7
1 Publications Verification
|
VD/VDR
|
Cancer
|
|
MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC50 value of 2.9 μM. MeTC7 shows good antitumor effects .
|
-
- HY-19474
-
|
Ansamitocin P-0
|
Microtubule/Tubulin
ADC Cytotoxin
Apoptosis
|
Cancer
|
|
Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research .
|
-
- HY-139132
-
|
|
Apoptosis
|
Cancer
|
|
Met-F-AEA is a metabolically stable anandamine analogue. Met-F-AEA inhibits cell growth by activating apoptosis. Met-F-AEA has antitumor activity .
|
-
- HY-120448
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
QTX125 is a potent and highly selective HDAC6 inhibitor. QTX125 exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects .
|
-
- HY-162938
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Skp2 inhibitor 3 (E35), an antitumor agent, is a potent S‑Phase Kinase-associated Protein 2 (SKP2) inhibitor, with an IC50 of 4.86 μM for Skp2-Cks1 binding. Skp2 inhibitor 3 (E35) significantly inhibits colony formation and migration, as well as arrests the cell cycle at the S-phase .
|
-
- HY-136582
-
|
Androgen receptor-IN-2
|
Androgen Receptor
|
Cancer
|
|
Masofaniten (Androgen receptor-IN-2) is a potent and orally active androgen receptor inhibitor. Masofaniten has antitumor activity against prostate cancer .
|
-
- HY-N10391
-
|
Cleistenolide
|
Bacterial
|
Infection
Cancer
|
|
(-)-Cleistenolide is a α,β-unsaturated δ-lactone isolated from Cleistochlamys kirkii Oliver. (-)-Cleistenolide has antibacterial and antitumor activity .
|
-
- HY-W553730
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-iodouridine; 2’-Iodo-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W394293
-
|
2-Thio-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Methyl-2-thiouridine (2-Thio-5-methyluridine) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152568
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N7-Methyl-2’-O-(2-methoxyethyl) guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154779
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine](//file.medchemexpress.com/product_pic/hy-154779.gif)
- HY-152503
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N6-Benzoyl-3’-O-(2-methoxyethyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152706
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-O-Methyl-N2,N2-dimethyl-guanosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154442
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Rev 2’-O-MOE-5MeC(Bz)-5’-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154037
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-3'-fluoro-2',3'-dideoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152571
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154309
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3'-O-tert-Butyldimethylsilyl-5'-O-DMT-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154251
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Methoxy-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162318
-
|
|
Molecular Glues
c-Myc
|
Cancer
|
|
MYC degrader 1 (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .
|
-
- HY-154605
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyroyl-2’-fluoro-2’-deoxyarabinoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152769
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Methoxy-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154729
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Methyl-2’-O-acetyl-5’-O-benzoyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152575
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-3’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152378
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-β-D-arabino-6-azauridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152569
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154024
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-O-(2-methoxyethyl)cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154148
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Isopentenyl-2’-deoxy adenosine, 2’-deoxy riboprine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154240
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-2’,3’-bis-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152350
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-4’-thio-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152570
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Methyl-2’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152864
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methylpurine-2’-deoxy-2’-fluoro-beta-D-arabinoriboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W395015
-
|
5'-O-(DIMETHOXYTRITYL)-2'-O-METHYLINOSINE
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4-Dimethoxytrityl)-2’-O-methyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152567
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-2’-O-(2-methoxyethyl) guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154587
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](//file.medchemexpress.com/product_pic/hy-154587.gif)
- HY-154546
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-MOE-5Me-C(Bz)-2’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154325
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(2-Deoxy-β-D-erythro-pentofuranosyl)-4(1H)-pyrimidinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154499
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Methyl 4-C-hydroxymethyl-2,3-O-isopropylidene-beta-D-ribofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154220
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-2’,2’-diflurocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152349
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-β-D-arabino-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154454
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-2’,5’-di-O-acetyl-8-hydroxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-43426A
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-Benzoyl-1,2-di-O-isopropylidene-alpha-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152619
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6,N6-Dimethyl-4’-thio-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154588
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](//file.medchemexpress.com/product_pic/hy-154588.gif)
- HY-N9351
-
|
Diphyllin O-glucoside
|
SARS-CoV
|
Infection
Cardiovascular Disease
Metabolic Disease
Cancer
|
|
Cleistanthin B (Diphyllin O-glucoside) is an orally active arylnaphthalene lignan lactone glycoside. Cleistanthin B exhibits anti-SARS-CoV-2 effects in Vero cells, with EC50 of 6.51 µM. Cleistanthin B also exhibits antitumor, diuretic and antihypertensive effects in vivo .
|
-
- HY-154680
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154727
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(3-aminopropyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154541
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2,N2-Dimethylamino-6-deamino adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154363
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Cyanovinyl-9-(5’-O-DMT-2’-deoxyribofuranosyl)carbazole is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161275
-
|
|
EGFR
|
Cancer
|
|
BI-4732 a potent inhibitor EGFR-activating (E19del and L858R) and T790M mutations, with high blood-brian barrier penetration, targeting a broad range of EGFR mutations, including C797S. BI-4732 has anti-tumor activity .
|
-
- HY-152587
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-3’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152874
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-N-(t-Butyloxycarbonylmethyl)-N-trifluoro acetyl-aminomethyl-2’-O-methyluridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152371
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,N6-Etheno-9-(β-D-xylofuranosyl)adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154224
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Me-2-thio-U-3’-phos phoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154682
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(n-dodecyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154489
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Bromo-2’-deoxy-2’-fluoro-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154723
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(4-hydroxybenzyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154326
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Deoxy-2’-deoxy-5’-(4,4’-dimethoxytrityl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152426
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-Amino-8-benzyloxy-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152573
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Methyl-3’-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152527
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-4-thio-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-23790
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-2'-O-(2-methoxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W565157
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-O-Ditoluoyl 6-chloropurine-9-β-D-deoxyriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-13598A
-
|
CKD-516 hydrochloride
|
Microtubule/Tubulin
|
Cancer
|
|
Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine proagent of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .
|
-
- HY-P991125
-
|
|
TNF Receptor
|
Inflammation/Immunology
Cancer
|
|
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
|
-
- HY-171443
-
|
Lyso-GM3
|
EGFR
Drug Derivative
|
Cancer
|
|
Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analogue of Ganglioside GM3 (HY-114456) with antitumor activities. Lyso-Monosialoganglioside inhibits EGF-induced increases in EGFR kinase activity in A431 epithelial cancer cells .
|
-
- HY-110156
-
|
|
Phosphatase
|
Cancer
|
|
Y29 is a potent PFKFB3 inhibitor with an IC50 of 0.183 µM, and acts as a competitive inhibitor against Fru-6-P with a Ki value of 0.094 µM. Y29 exhibits antitumor effects against cervical cancer .
|
-
- HY-168440
-
|
|
Ligands for Target Protein for PROTAC
Aurora Kinase
|
Cancer
|
|
Aurora-A ligand 1 is a high-affinity and specific Aurora-A inhibitor with a dissociation constant (Kd) value of 0.85 nM. Aurora-A ligand 1 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC Aurora-A degraders with antitumor activity. Aurora-A ligand 1 can be used for the synthesis of HLB-0532259 (HY-168439). HLB-0532259 shows anti-tumor activity against neuroblastoma .
|
-
- HY-148127
-
|
|
Drug-Linker Conjugates for ADC
|
Cancer
|
|
TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .
|
-
- HY-N0114A
-
-
- HY-131994
-
|
|
STING
|
Infection
Cancer
|
STING agonist-16 (1a) is a specific stimulator of interferon genes (STING) agonist. STING agonist-16 (1a) can be used as a potential antiviral and antitumor tool .
|
-
- HY-106689
-
-
- HY-169763
-
|
|
IRE1
Apoptosis
|
Cancer
|
|
D-F07 is a prodrug with an aldehyde shielding group and an IRE-1 inhibitor that induces Apoptosis. D-F07 has antitumor activity .
|
-
- HY-158230
-
|
|
Topoisomerase
|
Cancer
|
|
SN-398 is a derivative of Camptothecin (HY-158230), which is an antitumor drug. Acting by inhibiting mammalian DNA topoisomerase I (Topo I), stabilizing the Topo I-DNA complex prevents DNA rewiring to induce Topo I mediated DNA breaks. In Hela cell tests, SN-398 shows stronger antitumor activity than SN-38 (HY-13704) (IC50=1.562 μM). SN-398 can be used to study the anti-proliferation and growth inhibition of Topo I in cancer cells .
|
-
- HY-154561
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetyl-2’-deoxy-N3-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154340
-
|
2’-Deoxy-3’,2-anhydro-5-methyluridine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,3’-Anhydrothymidine; 2’-Deoxy-3’,2-anhydro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154627
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154437
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-Amino-2’,3’-dideoxy-5’-O-methoxy trityluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152785
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-beta-D-ribofuranosyl)-9H-Purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154360
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152831
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-8-aza-7-deaza-7-iodoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152735
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine](//file.medchemexpress.com/product_pic/hy-152735.gif)
- HY-154023
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Benzoyl-2’,3’-di-O-acetyl-4’-C-fluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154514
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-5,N4,N4-trimethylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154667
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3,5-di-O-benzyl-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W340190
-
|
5-Iodo-2'-O-methyluridine
|
Nucleoside Antimetabolite/Analog
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
2’-O-Methyl-5-iodouridine (5-Iodo-2'-O-methyluridine) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154594
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Aminomethyl)-2′,3′-O-(1-methylethylidene)-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154725
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine](//file.medchemexpress.com/product_pic/hy-154725.gif)
- HY-152374
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-fluoro-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154366
-
|
N1-Methylpseudouridine CEP
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-DMT-2'-O-TBDMS-N1-Methyl-PseudoUridine-CE-Phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154160
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2-Hydroxyethyl)-2’,3’-di-O-toluoyl-2’-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154267
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-O-DMT-2-thio-2'-dU-3'-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152808
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(2-Furanyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154385
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4’,5’-Didehydro-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-139279
-
|
TPX-0131
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). Zotizalkib has strong antitumor activities .
|
-
- HY-154469
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-2’-O-MOE inosine 3’-P-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-P991142
-
|
|
MHC
|
Inflammation/Immunology
Cancer
|
|
Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
|
-
- HY-154610
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine](//file.medchemexpress.com/product_pic/hy-154610.gif)
- HY-152994
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3,5-di-O-benzoyl-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154412
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-2’-fluoro-β-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154622
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152877
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-1-β-D-ribofuranosyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154206
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzo yl-5’-O-(4,4’-dimethoxytrityl)-aracytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152555
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-β-D-arabino-5-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152661
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Hydroxy-2’-de oxy-2’-fluoro-beta-D-arabino adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154276
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-O-Acetyl-2-O-benzoyl-3-O-tert-butyldiphenylsilyl-L-threofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152660
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-O-methyl-2’-O-methyl purine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W354644
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(β-D-Ribofuranosyl)-5-nitropyrine-2(1H)-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154607
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-5’-O-(4,4’-dimethoxytrityl)-3’-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-49198
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-Deoxy-2'-fluoro-N4-benzoyl-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154381
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152392
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Fluoro-2’-deoxy-N6,N6-dimethylarabinoadenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162318A
-
|
|
Molecular Glues
c-Myc
|
Cancer
|
|
MYC degrader 1 TFA (compound A80.2HCl) is an orally available MYC molecular glues degrader with anti-tumor activity. MYC degrader 1 TFA restores pRB1 protein activity and re-establishes sensitivity of MYC overexpressing cancer cells to CDK4/6 inhibitors .
|
-
- HY-152998
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-acetyl-5-methoxycarbonylmethyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152655
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Ethoxy-9-beta-D-(2-C-methyl-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152711
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-2’-β-C-methyl-6-N,N-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154478
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-Acetyl-N2-iso-Butyroyl-2’-deoxy-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-157888
-
|
|
SHP2
Phosphatase
|
Cancer
|
|
SHP2-IN-26 (Compound 4b) is a highly selective SHP2 allosteric inhibitor with a IC50 value of 3.2 nM. SHP2-IN-26 inhibits the phosphorylation of ERK and AKT in NCI-H358 cells. SHP2-IN-26 has antitumor activity .
|
-
- HY-152689
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-(4-nitrobenzyl)-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154463
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iso-Butyroyl-3’-deoxy-3’-fluoro guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-161239A
-
|
|
Antibiotic
|
Infection
Cancer
|
|
IB-96212 (compound 5) is a member of oligomycin class which can be extracted ftom the marine Micromonospora sp. L-25-ES25-008 ref. IB-96212 is an antitumor antibiotic against P-388, it also exhibits antimicrobial activity against Micrococcus luteus .
|
-
- HY-W559353
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3-Beta-amino-2,3-dideoxy-beta-d-threopenta-furanosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152762
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-phenylpurine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154298
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine](//file.medchemexpress.com/product_pic/hy-154298.gif)
- HY-152780
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(2’-Deoxy-2’-fluoro-β-D-arabinofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W007791
-
|
6-Chloropurine riboside
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Chloropurine riboside (6-Chloropurine riboside) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Purine nucleoside analogs represent cytotoxic agents with established activity in hematological malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152437
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Amino-3’-deoxy-5-methyl uridine, Anticancer antiviral agent is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154135
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-N6-(p-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154375
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-methyl-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152404
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-3’-fluoro-xylo-N6-(m-methoxybenzyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154236
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-3’,5’-bis-O-TBDMS-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154045
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-Deoxy-1,2-O-isopropylidene-5-O-(p-toluoyl)-L-arabinofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154290
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N3,5-Dimethyl-2’-O-(2-methoxyethyl) uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-43426
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(R)-5-O-Benzoyl-1,2-di-O-isopropylidene-alpha-D-xylofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152380
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1,2,4-Triazine-3,5-dione 2-β-D-xylopyranoside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154512
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-N4,N4-dimethyl-5-fluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152347
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-Amino-3’-deoxy-7,8-dihydro-8-oxoguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152579
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(1-Piperazinyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154542
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146697
-
|
|
Trk Receptor
c-Fms
PDGFR
Bcr-Abl
c-Kit
Apoptosis
|
Cancer
|
|
IHMT-TRK-284 (Compound 34) is a potent, orally active type II TRK kinase inhibitor with IC50 values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies .
|
-
- HY-152878
-
|
NSC 529488
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-1-β-D-arabinofuranosyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152572
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(4-Morpholinyl)-9-β-D-ribofuranosyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154222
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-2’,2’-difluoro-dC(Bz)-3’-CED-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-B0431AR
-
|
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Phenoxybenzamine (hydrochloride) (Standard) is the analytical standard of Phenoxybenzamine (hydrochloride). This product is intended for research and analytical applications. Phenoxybenzamine hydrochloride is a nonselective, irreversible, orally active α-adrenoceptor antagonist that is commonly used for the research of hypertension, specifically caused by pheochromocytoma. Phenoxybenzamine hydrochloride also shows antitumor activity .
|
-
- HY-146438
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .
|
-
- HY-N4251
-
|
(-)-Periplocoside M
|
Others
|
Cancer
|
|
Periplocoside M (compound 8) is a natural product isolated from the root bark of Periploca sepium. Periplocoside M shows antitumor activity against human A-549 and HepG2 cell lines, with the IC50 of 4.84 and 7.06 μM .
|
-
- HY-126534
-
-
- HY-156244
-
|
|
PROTACs
|
Cancer
|
|
PROTAC GDI2 Degrader-1 (compound 21) is a potent PROTAC GDI2 degrader. PROTAC GDI2 Degrader-1 exhibits excellent in vivo antitumor activity in the GDI2-overexpressing pancreatic xenograft models .
|
-
- HY-155950
-
|
|
Methylenetetrahydrofolate Dehydrogenase (MTHFD)
Apoptosis
|
Cancer
|
|
TH9619 is a potent inhibitor of dehydrogenase and cyclohydrolase activities in both MTHFD1 and MTHFD2 with a IC50 value of 47 nM, and selectively kills cancer cells. TH9619 induces apoptosis by blocking the S phase. TH9619 has antitumor activity .
|
-
- HY-156275
-
|
|
Others
|
Cancer
|
|
OSBP-IN-1(compound 12) is a Schweinfurthins analogues targeted of oxysterol-binding protein (OSBP). OSBP-IN-1 has antitumor activity .
|
-
- HY-144497
-
-
- HY-N2279
-
-
- HY-106052
-
|
ICIG 1105; NSC 279194; RFCNU
|
DNA/RNA Synthesis
|
Cancer
|
|
Bofumustine (ICIG 1105) is a nitrosourea compound with antitumor activity. Bofumustine can interfere with the replication and division of tumor cell DNA through alkylation, leading to the death of tumor cells. Bofumustine can be used in the field of cancer research .
|
-
- HY-16478
-
|
TAS-102; FTD/TPI
|
Nucleoside Antimetabolite/Analog
Thymidylate Synthase
|
Cancer
|
|
Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA .
|
-
- HY-162569
-
|
|
Apoptosis
Necroptosis
|
Cancer
|
|
Ru-TRZ2 is a potent ruthenium-based chemotherapeutic agent. Ru-TRZ2 induces apoptosis and necroptosis. Ru-TRZ2 shows antitumor activity .
|
-
- HY-120448A
-
|
|
HDAC
Apoptosis
|
Cancer
|
|
QTX125 TFA is a potent and highly selective HDAC6 inhibitor. QTX125 TFA exhibits excellent selectivity over other HDACs. QTX125 has antitumor effects .
|
-
- HY-N0878
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Bufotalin is a steroid lactone isolated from Venenum Bufonis with potently antitumor activities. Bufotalin induces cancer cell apoptosis and also induces endoplasmic reticulum (ER) stress activation .
|
-
- HY-N10387
-
|
|
Others
|
Cancer
|
|
Glucodichotomine B (Compound 13) is a natural product which can be isolated from the roots of Chinese medicinal plant Stellaria dichotoma L. var. lanceolata. Glucodichotomine B shows antitumor activity .
|
-
- HY-146439
-
|
|
PPAR
|
Cancer
|
|
PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ. PPARγ agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib .
|
-
- HY-N7850
-
|
1-Hydroxy-8-methoxyanthraquinone
|
Endogenous Metabolite
|
Cancer
|
|
6PGD-IN-1 (compound S3) is an inhibitor of 6-phosphogluconate dehydrogenase (6PGD). IC50 and Kd the value of 17.8μM and 17.1 μM respectively. 6PGD-IN-1 has antitumor activity .
|
-
- HY-129071R
-
|
|
Reference Standards
Microtubule/Tubulin
|
Cancer
|
|
Vindesine (sulfate) (Standard) is the analytical standard of Vindesine (sulfate). This product is intended for research and analytical applications. Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo .
|
-
- HY-168845
-
|
|
CDK
Apoptosis
|
Cancer
|
|
CDK2/9-IN-1 (compound 20a) is an orally active dual inhibitor of CDK2 and CDK9 with IC50 values are 0.004 μM and 0.009 μM respectively. CDK2/9-IN-1 induces apoptosis by regulating G2/M cell cycle arrest. CDK2/9-IN-1 has antitumor activity .
|
-
- HY-N8646
-
|
|
Others
|
Cancer
|
|
Isodonal is a N-pentane diterpene compound with potential cytotoxic, antitumor, inhibitory oxidative phosphorylation and antiingestion activities. Isodonal can be isolated from the leaves of Isodon wikstroemioides and is used in the study of gastrointestinal diseases, anti-tumor and anti-inflammatory .
|
-
- HY-144121
-
|
|
Bacterial
Fungal
Apoptosis
|
Infection
Cancer
|
|
Ph-Ph+ is a hemiprotonic compound, which is produced from phenanthroline (ph) dimerization. Ph-Ph+ has antitumor, antibacterial and antifungal activities .
|
-
- HY-N0661
-
-
- HY-152532
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-6-S-Methyl-6-thio-ara-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154571
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-acetyl-6-S-methyl-6-thio-guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154611
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-5-methyl-4’-thio-a-D-arabino uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152423
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3’-Deoxy-3’-α-C-methyl-N6,N6-dimethyladenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W555583
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetyl-2’-deoxy-2’-fluoro-5-iodouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W556276
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,4-Anhydro-2,3-di-O-isopropylidene-4-thio-D-ribitol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152824
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(R)-N-(2,3-Dihydro-1H-indenyl)-2-amino adenosine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W394793
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-44220
-
|
5-O-Benzoyl-1,2-O-(1-methylethylidene)pentofuranos-3-ulose
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-Benzoyl-1,2-di-O-isopropylidene-3-keto-alpha-D-xylofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154057
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154145
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-methoxy uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154264
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-N6-ethyl-2’-deoxyadenosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154424
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine](//file.medchemexpress.com/product_pic/hy-154424.gif)
- HY-154490
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154683
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Di-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabinocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154654
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2-β-C-Methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154583
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Bis-O-benzoyl-2’-deoxy-2’-fluoro-β-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154154
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-Bis-O-(4-methylbenzoyl)-2-C-methyl-D-ribonic acid gama-lactone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-121893
-
|
|
MDM-2/p53
NF-κB
|
Cancer
|
|
p53-MDM2-IN-3 (Compound 5s) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .
|
-
- HY-154229
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-DMT-N2-isobutyryl-2’-O-(2-methoxyethyl)guanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154543
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-(2-methoxyethyl) uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154681
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine](//file.medchemexpress.com/product_pic/hy-154681.gif)
- HY-154721
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-DMTr-5-iodo-2’-dU-3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154720
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-O-Benzoyl-1,2: 5,6-bis(di-O-isopropylidene)-alpha-D-galactofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154117
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2',3',5'-Tri-O-benzoyl-2'-beta-C-methyl-6-azauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152695
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Methoxy purine-9-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154562
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-acetyl-2’-deoxy-5,N3-dimethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154223
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5'-O-(4,4'-Dimethoxytrityl)-2'-O-methyl-2-thiouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154365
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl) inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152604
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3,4-Dihydro-3-oxo-4-β-D-ribofuranosyl-2-pyrazinecarboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154449
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-3’-O-(2-methoxyethyl)-5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W357137
-
|
(3R,4S)-3,4-Dihydroxyoxolan-2-one
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
L-Threonolactone ((3R,4S)-3,4-Dihydroxyoxolan-2-one) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154718
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine-3’,5’-di-O-acetyl-2’-deoxyriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154592
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
DMTr-TNA-G(O6-CONPh2)(N2Ac)-amidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154030
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-3'-deoxy-5'-O-DMT-3'-fluoroadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154061
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154581
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(Furan-2-yl)-2’-O-methyl-5’-O-DMTr-cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154035
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154302
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(4,4’-Dimethoxytrityl)-3’-O-levulinyl-2’-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154359
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-3’,5’-bis-O-benzoyl-6-aza-xylo uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154426
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’-Di-O-acetyl-8-benzyloxy-3’-deoxy-3’-fluoroguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152605
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-6-S-methyl-6-thio-arabino-inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154056
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’,3’,5’-Tri-O-benzoyl-2’-β-C-methyl-3-deazauridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-116052
-
|
|
MDM-2/p53
NF-κB
|
Cancer
|
|
p53-MDM2-IN-2 (Compound 5q) is an orally active p53-MDM2 inhibitor with a Ki value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .
|
-
- HY-152521
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-meThythio-9-(β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W601637
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-5-Benzoyl-3-O-Methyl-D-ribofuranose diacetate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-N9470
-
|
|
Others
|
Inflammation/Immunology
Cancer
|
|
λ-Carrageenan is a seaweed polysaccharide which has been generally used as proinflammatory agent in the basic research. λ-Carrageenan is a potent antitumor agent .
|
-
- HY-168566
-
|
|
HSP
|
Cancer
|
|
EV206 is a potent Hsp70 inhibitor. EV206 shows antiproliferative activity. EV206 induces apoptosis and increases the protein expression of cleaved PARP and caspase-3. EV206 shows antitumor activity .
|
-
- HY-P5020
-
|
|
Bacterial
|
Infection
Cancer
|
|
Crotalicidin is an antimicrobial peptide and anti-tumor peptide that can effectively inhibit the activity of Gram-negative bacteria and tumor cells. Crotalicidin can be obtained from rattlesnake venom. Crotalicidin can be used in the study of microbial infections and cancer .
|
-
- HY-124439
-
|
|
Antibiotic
Bacterial
SARS-CoV
|
Infection
Cancer
|
|
Setomimycin is a potent antibiotic. Setomimycin inhibits the SARS-CoV-2 Mpro enzyme with an IC50 value of 12.02 µM. Setomimycin shows anti-inflammatory and antioxidant properties. Setomimycin shows antiproliferative and antitumor activity .
|
-
- HY-100846
-
JQEZ5
3 Publications Verification
|
Histone Methyltransferase
|
Cancer
|
|
JQEZ5 is a potent and selective EZH2 lysine methyltransferase inhibitor. JQEZ5 SAM-competitively inhibits polycomb repressive complex 2 (PRC2) with an IC50 of 80 nM. JQEZ5 has anti-tumor effects .
|
-
- HY-103682A
-
|
|
Histone Methyltransferase
|
Cancer
|
|
PF-06726304 acetate is a potent and selective EZH2 inhibitor. PF-06726304 acetate inhibits wild-type and Y641N mutant EZH2 with Kis of 0.7 and 3.0 nM, respectively. PF-06726304 acetate displays robust antitumor growth activity .
|
-
- HY-103682
-
|
|
Histone Methyltransferase
|
Cancer
|
|
PF-06726304 is a potent and selective EZH2 inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with Kis of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity .
|
-
- HY-172104
-
|
|
EGFR
Apoptosis
|
Cancer
|
|
EGFR-IN-143 (Compound 5f) is a potent EGFR inhibitor with an IC50 value of 0.15 μM. EGFR-IN-143 induces apoptosis by arresting the cell cycle in the G2/M phase. EGFR-IN-143 has antitumor activity .
|
-
- HY-N15337
-
|
OS-4742 A1
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Vineomycin A1 (OS-4742 A1) is an antibiotic against Gram-positive bacteria, which is found in Streptomyces matensis subsp. vineus. Vineomycin A1 also shows antitumor activity in mice. Vineomycin A1 is promising for research of skin fibrosis .
|
-
- HY-101160
-
|
DRG16
|
DNA Alkylator/Crosslinker
ADC Cytotoxin
|
Cancer
|
|
SG2057 (DRG16) is a PBD dimer containing a pentyldioxy linkage which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts. SG2057 is a highly active antitumor agent .
|
-
- HY-14526
-
|
543U76; 5,11-Methenyltetrahydrohomofolate
|
DNA/RNA Synthesis
|
Cancer
|
|
5-DACTHF (543U76) is an inhibitor of purine de novo biosynthesis. 5-DACTHF is a GAR-TFase and AICAR-TFase inhibitor (IC50: 3 and 94 μM). 5-DACTHF is a potent antitumor agent .
|
-
- HY-N10131
-
|
(+)-Biatractylolide
|
Apoptosis
|
Neurological Disease
Cancer
|
|
Biatractylolide is a compound isolated from the ethyl acetate extract of Atractylodes macrocephala. Biatractylolide has antitumor and antioxidant activities. Biatractylolide improves cell viability, inhibits the apoptosis of cells induced by glutamate, and reduces the activity of LDH. Biatractylolide has neuroprotective effects .
|
-
- HY-163374
-
|
|
CDK
|
Cancer
|
|
Cdc7-IN-20 (EP-05) is an orally effective and selective Cdc7 inhibitor with IC50 and Ki values of 0.93 and 0.11 nM, respectively. Cdc7-IN-20 has antitumor activity .
|
-
- HY-N3561
-
|
|
Apoptosis
|
Cancer
|
|
Cedrelone, a limonoid, is a Phenazine biosynthesis-like domain-containing protein (PBLD) activator. Cedrelone induces cancer cell apoptosis, and possess antitumor effects .
|
-
- HY-N14959
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Deacetylravidomycin N-oxide is an antibiotic that can be produced by Streptomyces ravidus S50905. Deacetylravidomycin N-oxide is active against Gram-positive bacteria but inactive against Gram-negative bacteria. Deacetylravidomycin N-oxide has antitumor activity against P388 leukemia and methamphetamine A fibrosarcoma .
|
-
- HY-152727
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(naphthalen-1-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-50866B
-
|
AEW541 dihydrochloride
|
IGF-1R
Insulin Receptor
Autophagy
|
Cancer
|
|
NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity .
|
-
- HY-154003
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-154003.gif)
- HY-152853
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3-Methyl-5-β-D-ribofuranosyl-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154379
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Di-O-acetyl-2'-O-methyl-6-chloro-2-aminopurine riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154089
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Deoxy-1,2:5,6-bis-O-(1-methylethylidene)-α-D-ribo-hexofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154221
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2'-deoxy-5'-O-DMT-2',2'-difluorocytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152372
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Methyl 6-amino-9-β-D-ribofuranosyl-9H-purine-2-carboxylate is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152348
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-5-methyl-4’-thio-β-D-arabino uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154601
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-5’-O-(4,4-dimethoxytrityl)-3’-deoxy cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154628
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-iBu-5’-O-DMTr-2’-O-hexadecanyl guanosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152734
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(pyridine-4-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152491
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-ribofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154555
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Acetyl-2’,3’-dideoxy-2’,3’-didehydro-5-fluoro-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154384
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-Deoxy-5’-iodo-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154532
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(5(R)-C-Methyl-2,3,5-tri-O-benzoyl-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152333
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-n-Butyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154477
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloro-9-(3-deoxy-beta-D-ribofuanosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154439
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-β-Amino-2’,3’-dideoxy-5’-O-trityl-5-methyl uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154416
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-(2,3,5-Tri-O-benzyl-beta-D-ribofuranosyl)-3-methyl-2-benzyloxypyridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154260
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-3'-O-DMT-2'-O-(2-methoxyethyl) adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154342
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N1-Ethyl-2’-O-TBDMS-5’-O-DMTr-3’-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152809
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(furan-2-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152331
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-n-Propyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152328
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
7-Ethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154328
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-Azido-2’,3’-dideoxy-5’-O-(4-methoxy-trityl)uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154315
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-4-deoxy-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152531
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-allyl thio-9-(beta-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154422
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Amino-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152766
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-(Thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-21286
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N2-Isobutyryl-2'-O-methylguanosine (N2-IBU-2'-OME-RG) is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152297
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(1S)-1,4-Anhydro-1-C-(2,4-difluorophenyl)-D-ribitol is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154593
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-5’-O-DMTr-2’-O-(N3-trifluoroacetyl) aminopropyl cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-170812
-
|
|
Aurora Kinase
|
Cancer
|
|
BET/Aurora kinase-IN-1 (Compound 38) is a dual BET/Aurora kinase inhibitor. BET/Aurora kinase-IN-1 shows antiproliferative activities on diverse cancer cell lines and favorable antitumor efficacy in renal cell cancer and colon cancer xenograft models with tumor growth inhibition (TGI) of 45.99% and 53.06%, respectively .
|
-
- HY-154686
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3-β-Azido-2,3-dideoxy-5-O-trityl-D-threopenta-furanosyl)thymine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W010757
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-2-iodo-9-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154501
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-Benzoyl-1,2,3-tri-O-acetyl-4-C-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152460
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-N6-cyclopentyl-2’-deoxy-2’-fluoro-beta-D-arabinoadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154207
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-N4-benzoyl-5’-O-DMT arabinocytidine 3’-O-phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154403
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Azido-2’-deoxy-5’-O-(4,4’-dimethoxytrityl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152436
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Cyclopropylmethyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154658
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine](//file.medchemexpress.com/product_pic/hy-154658.gif)
- HY-152381
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,9-Dihydro-9-β-D-xylofuranosyl-6H-purin-6-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154623
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Bz-5’-O-DMTr-2’-O-hexadecanyl adenosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154643
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154515
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine](//file.medchemexpress.com/product_pic/hy-154515.gif)
- HY-152810
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Ami no-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154570
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-N-Acetyl-3’-amino-3’-deoxy-2’,5’-di-O-acetyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152776
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154316
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-3-Deaza-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154265
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-2’-deoxy-N6,N6-dimethyl-2’-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152791
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-methyl-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W061531
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-O-TBDPS-1,2-di-O-isopropy lidene-3-keto-alpha-D-xylofuranoside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![(3aR,5R,6aS)-5-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-dimethyldihydrofuro[2,3-d][1,3]dioxol-6(3aH)-one](//file.medchemexpress.com/product_pic/hy-w061531.gif)
- HY-154116
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-2-hydroxy-9-(2',3',5'-tri-O-acetyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154663
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-β-D-Arabinofuranosyl-5-bromo-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152690
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine](//file.medchemexpress.com/product_pic/hy-152690.gif)
- HY-154312
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-Di-O-benzoyl-2-deoxy-2-fluoro-5-trifluoromethyl-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152603
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-1-β-D-arabinofuranosyl-5-methyl-4(1H)-pyrimidinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152407
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-Allyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152431
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-Amino-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl) guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154029
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one](//file.medchemexpress.com/product_pic/hy-154029.gif)
- HY-153215
-
|
|
Ligands for E3 Ligase
|
Cancer
|
|
MEL24 is an Mdm2 E3 ligase inhibitor that reduces cell survival and increases sensitivity to DNA damaging agents in a p53-dependent manner for in vitro antitumor studies .
|
-
- HY-N10093
-
|
Chamaejasmin
|
Apoptosis
AMPK
Autophagy
Reactive Oxygen Species (ROS)
|
Cancer
|
|
Chamaejasmine is a biflavonoid that can be isolated from the roots of Stellera chamaejasme L. Chamaejasmine has antitumor activity. Chamaejasmine induces cell apoptosis, autophagy and ROS production, and activates the activity of AMPK/mTOR signal pathway .
|
-
- HY-129292
-
|
Quinocarmycin; DC-52; KW2152 free base
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Quinocarcin (DC-52) is a potent antitumor antibiotic. Quinocarcin inhibits Bacillus subtilis DNA, RNA and protein syntheses .
|
-
- HY-129545
-
|
|
Isocitrate Dehydrogenase (IDH)
|
Cancer
|
|
DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity .
|
-
- HY-131611
-
-
- HY-144069
-
|
|
Trk Receptor
Apoptosis
|
Cancer
|
|
Pan-Trk-IN-3 (Compound 11g) is a potent inhibitor of pan-Trk and their drug-resistant mutants with IC50 values of 2, 3, 2, 21, 26, 5, 7 and 6 nM against TrkA, TrkB, TrkC, TrkA G595R, TrkA G667C, TrkA G667S, TrkA F589L and TrkC G623R, respectively. Pan-Trk-IN-3 displays excellent antitumor activity and induces apoptosis .
|
-
- HY-119016
-
SK1-I
1 Publications Verification
BML-258
|
SphK
|
Cancer
|
|
SK1-I (BML-258), an analog of sphingosine, is an isozyme-specific competitive SPHK1 inhibitor with a Ki value of 10 μM . SK1-I shows no activity at SPHK1 PKCα, PKCδ, PKA, AKT1, ERK1, EGFR, CDK2, IKKβ or CamK2β. SK1-I enhances autophagy and has antitumor activity .
|
-
- HY-N12537
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/ PD-L1-in-38 is a PD-1/PD-L1 inhibitor, which can inhibit the proliferation of tumor cells, promote the secretion of INF-γ by CD8 + T cells, and inhibit the ability of PD-1/PD-L1 signal transduction. PD-1/PD-L1-IN-38 has antitumor activity .
|
-
- HY-146153
-
|
|
HDAC
|
Cancer
|
|
HDAC-IN-40 is a potent alkoxyamide-based HDAC inhibitor with Ki values of 60 nM and 30 nM for HDAC2 and HDAC6, respectively. HDAC-IN-40 had antitumor effects .
|
-
- HY-P9956
-
|
CNTO-328
|
Interleukin Related
|
Cancer
|
|
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research .
|
-
- HY-147812
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
POLA1 inhibitor 1 (Compound 12) is an orally active POLA1 inhibitor. POLA1 inhibitor 1 shows antitumor activity against several tumor histotypes and Adarotene-resistant cell line .
|
-
- HY-125117
-
|
|
DNA/RNA Synthesis
Bacterial
|
Infection
Cancer
|
|
Simocyclinone D8 is an anthracycline antibiotic with antibacterial and antitumor activity against Gram-positive bacteria. Simocyclinone D8 inhibits DNA gyrase and thus has an inhibitory effect on a variety of tumor cell lines .
|
-
- HY-P3365
-
|
|
Bacterial
|
Inflammation/Immunology
Cancer
|
|
Cecropin D is an antimicrobial peptide with a MIC of 4.55 μg/mL. Cecropin D is effective against both Gram-negative and Gram-positive bacteria. Cecropin D has antiviral, antifungal, antitumor, and immunomodulatory .
|
-
- HY-133141
-
|
TRE-515
|
DNA/RNA Synthesis
|
Cancer
|
|
DI-87 is an orally active and selective deoxycytidine kinase (dCK) inhibitor with an EC50 of 10.2 nM. DI-87 has antitumor activity and is used in combination therapy against tumors expressing dCK .
|
-
- HY-W048245
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(2R,3S,4R)-2-(Hydroxymethyl)tetrahydrothiophene-3,4-diol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152709
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-(5-phenylpyridin-3-yl)purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W556327
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5-Nitro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152408
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](//file.medchemexpress.com/product_pic/hy-152408.gif)
- HY-154078
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-fluorouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154459
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Benzoyl-2’-deoxy-5’-O-DMTr-2’-fluoro- 5-methylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154726
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro- N3-(2S)-(2-amino-3-carbonyl)-propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W102981
-
|
7-Oxanorborna-2-ene-5,6-dicarboxylic anhydride
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione](//file.medchemexpress.com/product_pic/hy-w102981.gif)
- HY-152876
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Chloro-9-(2-O-methyl-beta-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154118
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3',5'-Bis-O-benzoyl-2'-deoxy-2'-fluoro-beta-D-arabino-6-azidouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154498
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3,5-di-O-benzoyl-3-beta-C-methyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W547585
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Hydroxy-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-111783G
-
|
|
DNA-PK
ATM/ATR
PI3K
Apoptosis
|
Cancer
|
|
AZD-7648 (GMP) is AZD-7648 (HY-111783) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity .
|
-
- HY-76574
-
|
|
Drug Intermediate
|
Cancer
|
|
3-(Trifluoromethyl)benzaldehyde is a key intermediate in organic synthesis. 3-(Trifluoromethyl)benzaldehyde can be used to synthesize 2,3-di- and 2,2,3-trisubstituted-3-methoxycarbonyl-γ-butyrolactones. 3-(Trifluoromethyl)benzaldehyde derivatives have antitumor effects against nasopharyngeal carcinoma, leukemia, and breast cancer .
|
-
- HY-161828
-
|
|
PROTACs
CDK
|
Cancer
|
|
JWZ-5-13 is a potent CDK7 PROTAC degrader that significantly degrades CDK7 via the ubiquitin-proteasome system. JWZ-5-13 has antitumor activity. (Pink: Target protein ligand (HY-161830); Black: linker (HY-Y0925); Blue: E3 ligase ligand (HY-112078)) .
|
-
- HY-154369
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,4-Anhydro-2,3-O-isopropylidene-5-O-t-butyldiphenylsilyl-4-thio-D-ribitol is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154655
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Methyl-9-(2-β-C-methyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154212
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N4-Acetyl-5’-O-(4,4’-dimethoxytrityl)-5-methyl-2’-deoxycytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154633
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine](//file.medchemexpress.com/product_pic/hy-154633.gif)
- HY-154185
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’,5’-Di-O-benzoyl-2’-deoxy-2’-fluoro-5-methyl-β-D-arabino-uridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154286
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-O-Acetyl-2,3,5-tri-O-benzoyl-5(R)-C-methyl-D-ribo furanose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154228
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-O-(4,4’-Dimethoxy trityl)-2’-O-(2-methoxyethyl)-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154040
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-Benzoyl-3’-O-(4-methoxybenzyl)-2’-O,4’-C-methyleneuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154440
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloro-9-(3’-O-methyl-beta-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154676
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Purine-9-b-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154503
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-O-(4-Methoxybenzyl)-4-C-hydroxymethyl-1,2-O-isopropylidine-alpha-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154071
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147798
-
|
|
EGFR
CDK
|
Cancer
|
|
EGFR/HER2/CDK9-IN-3 (Compound 10) is a potent inhibitor of EGFR/HER2/CDK9 with IC50s of 191.08, 132.65, and 113.98 nM, respectively. EGFR/HER2/CDK9-IN-3 exhibits remarkable antitumor activity .
|
-
- HY-147796
-
|
|
EGFR
CDK
|
Cancer
|
|
EGFR/HER2/CDK9-IN-1 (Compound 4) is a potent inhibitor of EGFR/HER2/CDK9 with IC50s of 90.17, 131.39, and 67.04 nM, respectively. EGFR/HER2/CDK9-IN-1 exhibits remarkable antitumor activity .
|
-
- HY-154335
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-(3-Deoxy-3-fluoro-β-D-xylofuranosyl)-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154083
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-methoxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154730
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152858
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
Methyl 1,2,3,4-tetrahydro-2,4-dioxo-1-β-D-ribofuranosyl-5-pyrimidineacetate is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154124
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-2'-chloro-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154072
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-O-Acetyl-5’-O-(p-toluoyl)-3’-deoxy-3’-fluoro-5-trifluoromethyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152828
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](//file.medchemexpress.com/product_pic/hy-152828.gif)
- HY-154475
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2'-O-Acetyl-5'-O-benzoyl-3'-deoxy-beta-D-ribofuranosyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154447
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
5’-O-(p-Toluoyl)-2’-O-acetyl-3’-deoxy-3’-fluoro-6-chloroinosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152772
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy-2’-fluoro)-arabinoriboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-147797
-
|
|
EGFR
CDK
|
Cancer
|
|
EGFR/HER2/CDK9-IN-2 (Compound 9) is a potent inhibitor of EGFR/HER2/CDK9 with IC50s of 145.35, 129.07, and 117.13 nM, respectively. EGFR/HER2/CDK9-IN-2 exhibits remarkable antitumor activity .
|
-
- HY-152806
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino -6-chloro-9-(2-β-C-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154044
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3-Deoxy-1,2-O-isopropylidene-5-p-toluoyl-a-D-glycero-pent-3-enofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-145989S
-
|
|
Drug-Linker Conjugates for ADC
Microtubule/Tubulin
|
Cancer
|
|
Aminobenzenesulfonic auristatin E-d8 is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic .
|
-
- HY-161141
-
|
|
c-Met/HGFR
|
Cancer
|
|
EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity .
|
-
- HY-131349
-
|
|
CCR
|
Cancer
|
|
CCR4-351 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity .
|
-
- HY-131349A
-
|
|
CCR
|
Metabolic Disease
Cancer
|
|
CCR4-351 hydrochloride is an orally active, potent and selective CCR4 antagonist. CCR4-351 hydrochloride, featuring a novel piperidinyl-azetidine motif, has IC50s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 hydrochloride has antitumor activity .
|
-
- HY-162003A
-
|
|
Histone Methyltransferase
|
Cancer
|
|
DCPT1061 hydrochloride has a strong inhibitory effect on PRMT1, PRMT6, and PRMT8 in vitro, The epigenetic enzymes such as PRMT3, PRMT4 and PRMT5 had little inhibitory effect. DCPT1061 hydrochloride has antitumor effects .
|
-
- HY-W029411
-
|
|
Drug Derivative
|
Cancer
|
|
4-(Benzo[d]oxazol-2-yl)aniline is a potent antitumor agent. 4-(Benzo[d]oxazol-2-yl)aniline has inhibitory activity against mammary carcinoma cell lines .
|
-
![4-(Benzo[d]oxazol-2-yl)aniline](//file.medchemexpress.com/product_pic/hy-w029411.gif)
- HY-N0697
-
-
- HY-126643
-
|
|
Mitochondrial Metabolism
|
Others
Cancer
|
|
Wedeloside is a diterpenoid amino glycoside isolated from the plant Wedelia asperrima. Wedeloside is capable of inhibiting ADP-stimulated respiration in mitochondria and possesses potential anti-tumor activity. Wedeloside is applicable in drug development and toxicological research .
|
-
- HY-N10542
-
|
|
Others
|
Cancer
|
|
Aplyronine C is an active compound. Aplyronine C shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 22 nM. Aplyronine C can be used for the research of cancer .
|
-
- HY-12941
-
|
|
MDM-2/p53
|
Cancer
|
|
AM-7209 is a potent and selective MDM2-p53 interaction inhibitor with a Kd of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC50 of 1.6 nM. AM-7209 shows antitumor activities .
|
-
- HY-B1610
-
|
Trisodium citrate dihydrate; Citric acid trisodium salt dihydrate
|
Bacterial
Endogenous Metabolite
Apoptosis
|
Infection
Cardiovascular Disease
Cancer
|
|
Sodium citrate dehydrate (Trisodium citrate dihydrate) is a natural product with oral activity that can be found in citrus fruits. Sodium citrate dehydrate can inhibit the proliferation of tumor cells and induce apoptosis. Sodium citrate dehydrate has antibacterial, anti-tumor and antioxidant activities. Sodium citrate dehydrate can be prepared as a cosolvent or buffer .
|
-
- HY-120882
-
|
UBX1967
|
Bcl-2 Family
|
Cancer
|
|
BM-1197 (UBX1967) is a potent and selective inhibitor of dual Bcl-2/Bcl-xL, with IC50s of 3.5 nM and 5.2 nM for Bcl-2 and Bcl-xL, respectively. BM-1197 exhibits antitumor effects both in vitro and in vivo .
|
-
- HY-158412
-
|
|
Proteasome
Apoptosis
|
Cancer
|
|
BT317 is a blood-brain transmissible mitochondrial Lon peptidase I (LonP1) and CT-L proteasome inhibitor. BT317 can increase the production of reactive oxygen species (ROS) and induce apoptosis in astrocytoma cells. BT317 has antitumor activity .
|
-
- HY-126534A
-
|
LSN3106729 hydrochloride
|
Ligands for Target Protein for PROTAC
CDK
|
Cancer
|
|
Abemaciclib metabolite M18 (LSN3106729) hydrochloride, the metabolite of Abemaciclib (HY-16297A), is a CDK inhibitor with antitumor activity. Abemaciclib metabolite M18 hydrochloride and a CRBN ligand have been used to design PROTAC CDK4/6 degrader .
|
-
- HY-152680
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](//file.medchemexpress.com/product_pic/hy-152680.gif)
- HY-152305
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
(1S)-1,4-Anhydro-1-C-(2,4-difluoro-5-methylphenyl)-D-ribitol is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154112
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Bromo-6-chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152685
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Amino-1-(β-D-ribofurano syl)-7H-pyrrolo [2.3-d] pyrimidine-5-carboxamide is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-1-(β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine-5-carboxamide](//file.medchemexpress.com/product_pic/hy-152685.gif)
- HY-152398
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152398.gif)
- HY-152485
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-N6,N6-dimethyl-2’-deoxy-2’-fluoro-beta-D-arabino-adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152410
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152410.gif)
- HY-152657
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine](//file.medchemexpress.com/product_pic/hy-152657.gif)
- HY-152432
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
1-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(β-D-xylofuranosyl)guanine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154380
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-9-(3,5-di-O-acetyl-2-O-methyl-β-D-ribofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154679
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Chloro-6-(thiophen-3-yl)purine-beta-D-(3’-deoxy-3’-fluoro)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-146573
-
|
|
Aldose Reductase
17β-HSD
|
Cancer
|
|
AKR1C3-IN-6 (Compound 1) is a potent, selective AKR1C3 inhibitor with IC50 values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. AKR1C3-IN-6 shows antitumor activity .
|
-
- HY-152414
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152414.gif)
- HY-152582
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](//file.medchemexpress.com/product_pic/hy-152582.gif)
- HY-163273
-
|
|
FGFR
|
Cancer
|
|
FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a FGFR inhibitor with IC50 values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity .
|
-
- HY-154731
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2’-O-Acetyl-5’-O-benzoyl-3’-O-methyl-beta-D-ribofuranosyl)-2,6-dichloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152687
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine](//file.medchemexpress.com/product_pic/hy-152687.gif)
- HY-152827
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine](//file.medchemexpress.com/product_pic/hy-152827.gif)
- HY-152578
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](//file.medchemexpress.com/product_pic/hy-152578.gif)
- HY-152704
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine](//file.medchemexpress.com/product_pic/hy-152704.gif)
- HY-154617
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-S-(2-Cyanoethyl)-2’-deoxy-5’-O-DMTr--6-thioguanosine 3’-CED phosphoramidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W544504
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,6-Dichloro-9-(2-c-methyl-2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)purine dibenzoate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152818
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](//file.medchemexpress.com/product_pic/hy-152818.gif)
- HY-154675
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Aminopurine-9-beta-D-(3’,5’-di-O-benzoyl-2’-deoxy-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154572
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2-O-Acetyl-3,5-di-O-benzoyl-β-D-xylofuranosyl)-6-chloro-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154669
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2,3-Di-O-acetyl-6-O-benzoyl-5-deoxy-D-ribo-exofuranoyl)-6-chloropurine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152686
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-6-methoxy-9H-purine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152788
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Chloro-6-(furan-2-yl) purine-beta-D-(3’-deoxy-3’-fluoro)-riboside is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154060
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-3'-O-(2-methoxyethyl)adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-113649
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects .
|
-
- HY-N0379R
-
|
|
Reference Standards
Endogenous Metabolite
|
Others
|
|
D-Mannose (Standard) is the analytical standard of D-Mannose. This product is intended for research and analytical applications. D-Mannose is a C-2 superpolymer of glucose that occurs naturally in many plants and fruits. D-Mannose has anti-inflammatory and antitumor activity. D-Mannose plays an important role in immune regulation .
|
-
- HY-P99202
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
|
-
- HY-N10541
-
|
|
Others
|
Cancer
|
|
Aplyronine B is an active compound. Aplyronine B shows potent antitumor activity and has cytotoxicity against HeLa-S3 cells with an IC50 values of 2.9 nM. Aplyronine B can be used for the research of cancer .
|
-
- HY-132003
-
|
|
Akt
|
Cancer
|
|
Wortmannin-Rapamycin Conjugate 1 (compound 7c) is a furan ring-opened derivative of wortmannin-rapamycin conjugate with potent antitumor activities and a fine water solubility. Wortmannin-Rapamycin Conjugate 1 can inhibit the AKT phosphorylation in the tumor and can be used for cancer research .
|
-
- HY-103266
-
|
|
Aurora Kinase
|
Cancer
|
|
TC-A 2317 hydrochloride is an orally active Aurora A kinase inhibitor (Ki=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (Ki=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity .
|
-
- HY-162326
-
|
|
VEGFR
Apoptosis
|
Cancer
|
|
VEGFR-2 IN-41 (Compound 8) is a VEGFR-2 inhibitor with an IC50 of 0.0554 μM. VEGFR-2 IN-41 can induce apoptosis. VEGFR-2-IN-41 has antitumor activity .
|
-
- HY-134900R
-
|
|
Reference Standards
Reactive Oxygen Species (ROS)
|
Infection
Metabolic Disease
|
|
Allyl methyl trisulfide (Standard) is the analytical standard of Allyl methyl trisulfide. This product is intended for research and analytical applications. Allyl methyl trisulfide is a volatile organic compound and a component of garlic (Allium sativum L.) essential oil, which has antibacterial, antioxidant and antitumor activities[1].
|
-
- HY-147710
-
|
|
MicroRNA
|
Cancer
|
|
PIN1 inhibitor 2 (compound 12) is a potent PIN1 inhibitor. PIN1 inhibitor 2 shows antitumor activity with an IC50 of 9.55 µM for MCF7 cells. PIN1 inhibitor 2 has the potential for the research of breast cancer .
|
-
- HY-N0326
-
|
|
Endogenous Metabolite
Keap1-Nrf2
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
L-Methionine is an L-isomer of orally active Methionine, an essential amino acid. Methionine is a strong liver antidote that acts as a liver protector. L-Methionine can inhibit cell proliferation and induce cell apoptosis. L-Methionine has antitumor and antioxidant activity .
|
-
- HY-136499
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
DI-82 is a potent deoxycytidine kinase (dCK) inhibitor with an IC50 app of 27.8 nM and Ki app of 9.2 nM. DI-82 has antitumor activity .
|
-
- HY-172133
-
-
- HY-W020361
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2'-C-Ethynyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2'-C-Ethynyluridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-154662
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine](//file.medchemexpress.com/product_pic/hy-154662.gif)
- HY-W551230
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine-9-beta-D-(2’-deoxy-3’,5’-di-O-(p-toluoyl))riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154653
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
9-(2,3,5-Tri-O-benzoyl-2-C-methyl-β-D-ribofuranosyl)-9H-purin-2-amine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162848
-
|
|
PI3K
|
Cancer
|
|
IHMT-PI3K-315 (20e) is a potent and selective PI3Kγ/δ inhibitor with IC50 values for PI3Kγ and PI3Kδ of 4.0 and 9.1 nM, respectively. IHMT-PI3K-315 has antitumor activity .
|
-
- HY-154362
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
1,2-Di-O-acetyl-3-deoxy-3-fluoro-5-O-(4-methyl)benzoyl-D-ribofuranose is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-154724
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine](//file.medchemexpress.com/product_pic/hy-154724.gif)
- HY-154125
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-2-fluoropurine-9-b-D-(3,5-bis-O-(p-toluoyl)-2-deoxy)riboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W544503
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine dibenzoate is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-153543
-
|
|
Toll-like Receptor (TLR)
|
Cancer
|
|
TLR7/8 agonist 8 (compound 24m) is a potent toll-like receptor 7/8 (TLR7/8) dual agonist, with EC50s of 27 and 12 nM for hTLR7 and hTLR8, respectively. TLR7/8 agonist 8 can improve the antitumor activity of PD-1/PD-L1 blockade .
|
-
- HY-135751
-
|
|
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Holomycin is a secondary metabolite of the dithiolopyrrolone class. Holomycin also is a broad spectrum antibiotic. Holomycin has antitumor activity and can act in vivo on RNA synthesis .
|
-
- HY-N0611
-
|
α-Boswellic acid
|
Others
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
alpha-Boswellic acid (α-Boswellic acid) is an orally active pentacyclic triterpenoid compound that can be extracted from frankincense. alpha-Boswellic acid has anti-inflammatory and antitumor activities. alpha-Boswellic acid can be used in Alzheimer's disease (AD) research .
|
-
- HY-147981
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin polymerization-IN-31 (Compound 4c) is a tubulin polymerization inhibitor with an IC50 of 3.64 μM. Tubulin polymerization-IN-31 induces cancer cell apoptosis and shows antitumor activity .
|
-
- HY-N6952
-
-
- HY-148128
-
|
|
Microtubule/Tubulin
ADC Cytotoxin
|
Cancer
|
|
TAM470 is a novel cytolysin, inhibiting tubulin polymerization and microtubule depolymerization. TAM470 can be used in the synthesis of OMTX705 as payload molecule, OMTX705 is a novel FAP-targeting antibody-drug conjugates (ADCs) with antitumor activity .
|
-
- HY-N2682
-
|
|
Others
|
Cancer
|
|
(7R,8S)-Dehydrodiconiferyl alcohol is a natural product that can be isolated from the thorns of Gleditsia sinensis. (7R,8S)-Dehydrodiconiferyl alcohol shows antitumor activity .
|
-
- HY-W005824
-
|
|
Biochemical Assay Reagents
|
Infection
Cancer
|
|
2,6-Dichloropurine riboside is an antitumor and antiviral agent, which can be used for infections caused by mycoplasma. 2,6-Dichloropurine riboside also can be used to synthesize the photoaffinity probes for nucleotide binding sites in proteins .
|
-
- HY-108713
-
|
SHR1020
|
VEGFR
PDGFR
Apoptosis
|
Cancer
|
|
Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively . Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis .
|
-
- HY-N6074
-
|
|
Autophagy
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Soyasapogenol B is a component of soy that has oral activity. Soyasapogenol B promotes autophagy and apoptosis. Soyasapogenol B has anti-inflammatory, antioxidant and antitumor activities .
|
-
- HY-P10128
-
-
- HY-114233
-
|
MC-GGFG-DX8951
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
|
MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .
|
-
- HY-122753
-
|
|
MDM-2/p53
|
Cancer
|
|
SLMP53-1 is a wild-type and mutant p53 reactivator with promising antitumor activity. SLMP53-1 mediates the reprograming of glucose metabolism in cancer cells. SLMP53-1 depletes angiogenesis, decreasing endothelial cell tube formation and vascular endothelial growth factor (VEGF) expression levels .
|
-
- HY-150072
-
|
|
PKA
|
Cancer
|
|
DS89002333 is an orally active and potent PRKACA inhibitor, with an IC50 of 0.3 nM. DS89002333 shows good anti-tumor activity in an FL-HCC patient-derived xenograft model (expressing the DNAJB1-PRKACA fusion gene). DS89002333 can be used in study of fibrolamellar hepatocellular carcinoma (FL-HCC) .
|
-
- HY-137377
-
|
|
Aurora Kinase
|
Cancer
|
|
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC50 of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC50 of 95 nM). TAS-119 has potent antitumor activites .
|
-
- HY-N4058R
-
|
|
Reference Standards
Apoptosis
|
Cancer
|
|
Helichrysetin (Standard) is the analytical standard of Helichrysetin. This product is intended for research and analytical applications. Helichrysetin is isolated from the flower Helichrysum odoratissimum. Helichrysetin is an ID2 (DNA binding inhibitor 2) inhibitor. Helichrysetin induces apoptosis. Helichrysetin has anti-tumor and antioxidant activity .
|
-
- HY-B1320
-
-
- HY-15337
-
|
Hesperetin 7-rutinoside
|
Apoptosis
Autophagy
Reactive Oxygen Species (ROS)
Endogenous Metabolite
|
Cancer
|
|
Hesperidin (Hesperetin 7-rutinoside), a flavanone glycoside, is isolated from citrus fruits. Hesperidin has numerous biological properties, such as decreasing inflammatory mediators and exerting significant antioxidant effects. Hesperidin also exhibits antitumor and antiallergic activities .
|
-
- HY-129441
-
|
BW 197U
|
Histone Methyltransferase
Antifolate
|
Neurological Disease
Cancer
|
|
Metoprine (BW 197U) is a potent histamine N-methyltransferase (HMT) inhibitor. Metoprine, a diaminopyrimidine derivative, can cross the blood-brain barrier and increase brain histamine levels by inhibiting HMT . Metoprine is an antifolate and antitumor agent .
|
-
- HY-113574
-
|
|
HSP
|
Cancer
|
|
HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective HSP-90 inhibitor with an IC50 value of 30 nM. HSP90-IN-29 has antitumor activity .
|
-
- HY-152819
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152819.gif)
- HY-152474
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Ethynylcytidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-21978
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
9H-Purine, 6-chloro-2-iodo-9-β-D-ribofuranosyl- (6-CHLORO-2-IODOPURINE-9-RIBOSIDE) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-W605935
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2-Amino-6-chloropurine -9-beta-D-(2’-deoxy-3’,5’-di-O-benzoyl-2’-fluoro)arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152475
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-β-C-Ethynyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-β-C-Ethynyladenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-W020420
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
6-Chloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152718
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
4-Amino-5-cyano-1-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![4-Amino-1-(2-C-methyl-β-D-ribofuranosyl)-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile](//file.medchemexpress.com/product_pic/hy-152718.gif)
- HY-W550484
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2,6-Dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-arabinofuranosyl)-9H-purine arabinoriboside is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152556
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
3-Deaza-4’-C-methyluridine, 4-Hydroxy-1-β-D-(4-C-methylribofuranosyl)-2(1H)-pyridinone is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-129577
-
|
|
Necroptosis
|
Inflammation/Immunology
Cancer
|
|
Aplysin is a brominated sesquiterpene with an isoprene backbone that exhibits hepatoprotective, immunomodulatory, and antitumor activities. Aplysin effectively prevents spontaneous pancreatic necrosis and inflammatory responses in NOD mice .
|
-
- HY-143296
-
|
|
SphK
|
Cancer
|
|
SphK1-IN-1 (compound 48) is a SphK1 inhibitor with effective antitumor activity. SphK1-IN-1 inhibits SphK1 ATPase with an IC50 value of 4.02 μM. SphK1-IN-1 can be used for the research of cancer .
|
-
- HY-129252
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Prothracarcin is an antibiotic with antitumor activity that exerts its tumor cell toxicity by covalently binding to the C-2 amino group of guanine residues in the minor groove of DNA. Prothracarcin also shows antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria such as Escherichia coli .
|
-
- HY-19474R
-
|
Ansamitocin P-0 (Standard)
|
Reference Standards
Microtubule/Tubulin
ADC Cytotoxin
Apoptosis
|
Cancer
|
|
Maytansinol (Standard) is the analytical standard of Maytansinol. This product is intended for research and analytical applications. Maytansinol (Ansamitocin P-0) is a derivative of Maytansine. Maytansinol can inhibit tubulin polymerization and induce apoptosis. Maytansinol has antitumor activity. Maytansinol can be used in cancer drug research[1][2].
|
-
- HY-W778423
-
|
Dihydroxy Oxaliplatin-Pt(IV)
|
Drug Intermediate
|
Cancer
|
|
[Pt(DACH)(OH)2(ox)] (Dihydroxy Oxaliplatin-Pt(IV)) is a Oxaliplatin (HY-17371)-based Pt(IV) scaffold. [Pt(DACH)(OH)2(ox)] reacts with N-hydroxysuccinimide (NHS) ester of Pyropheophorbide-a (HY-128973) to yield phorbiplatin. Phorbiplatin is a highly potent Pt(IV) antitumor prodrug .
|
-
![[Pt(DACH)(OH)2(ox)]](//file.medchemexpress.com/product_pic/hy-w778423.gif)
- HY-W014395
-
|
|
Reactive Oxygen Species (ROS)
Apoptosis
|
Cancer
|
|
Dithiodipropionic acid can interact with CPUL1 (HY-151802, a TrxR inhibitor) to form nanoaggregates (CPUL1-DA NAs). CPUL1-DA NAs generates more abundant ROS to induce cell apoptosis than that of free CPUL1, and improves antitumor efficacy against HUH7 cancer cells .
|
-
- HY-14721A
-
|
EMD-1214063 hydrochloride
|
c-Met/HGFR
Autophagy
|
Cancer
|
|
Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC50 of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects .
|
-
- HY-N0035
-
-
- HY-12457
-
|
CC-1065; NSC 298223
|
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
|
Rachelmycin (CC-1065) is an antitumor antibiotic and a DNA-alkylating agent. Rachelmycin has cytotoxic potency that can be used as a cytotoxin to synthesis ADC. Rachelmycin effectively inhibits DNA synthesis. Rachelmycin can be used for cancer and infection research .
|
-
- HY-N10950
-
|
|
Dopamine Receptor
|
Cancer
|
|
Vanicoside E is an antioxidant and antitumor agent. Vanicoside E inhibits L-Tyrosine (HY-N0473) and L-DOPA (HY-N0304) with IC50s of 45.23 μM and 189.96 μM, respectively .
|
-
- HY-111207
-
|
|
CDK
Apoptosis
|
Cancer
|
|
CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC50 of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity .
|
-
- HY-137193
-
|
|
Drug Metabolite
|
Cancer
|
|
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .
|
-
- HY-N15579
-
|
|
Phytohormone
|
Cancer
|
|
Fujenal is a kaurene-type diterpenoid found in Gibberella fujikuroi. Fujenal shows moderate inhibition against HeLa tumor cells and acts as a gibberellin biosynthesis inhibitor. Fujenal is promising for research of plant growth regulators and antitumor agents .
|
-
- HY-132295
-
|
ZN-c3
|
Wee1
|
Cancer
|
|
Azenosertib (ZN-c3) is a selective, orally active inhibitor for Wee1 inhibitor (IC50=3.9 nM). Azenosertib exhibits antitumor activity .
|
-
- HY-162085
-
|
|
TAM Receptor
|
Cancer
|
|
Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .
|
-
- HY-124944
-
|
|
Ras
|
Cancer
|
|
APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity .
|
-
- HY-152405
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one](//file.medchemexpress.com/product_pic/hy-152405.gif)
- HY-159893
-
|
|
Smo
Hedgehog
Apoptosis
|
Cancer
|
|
SMO-IN-5 ((Compound 25(B31)) is a potent and competitive inhibitor of smoothened (SMO) that can inhibit Hedgehog (Hh) signaling. SMO-IN-5 interacts with Smo through hydrogen bonds, hydrophobic interactions, and electrostatic forces. SMO-IN-5 inhibits PC cell proliferation, migration, and induces apoptosis by suppressing Gli1 expression. SMO-IN-5 exhibits antitumor activity in pancreatic cancer. .
|
-
- HY-154740R
-
|
|
Nucleoside Antimetabolite/Analog
Reference Standards
|
Cancer
|
|
3′-Chloro-3′-deoxythymidine (Standard) is the analytical standard of 3′-Chloro-3′-deoxythymidine. This product is intended for research and analytical applications. 3′-Chloro-3′-deoxythymidine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-152447
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
3’-beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 3’-beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152625
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
2’-Beta-C-Ethynyl inosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . 2’-Beta-C-Ethynyl inosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-120041
-
|
|
IRAK
|
Cancer
|
|
ND-2158 is a competitive IRAK4 inhibitor, with the Ki of 1.3 nM. ND-2158 suppresses LPS-induced TNF production in human white blood cells, alleviated collagen-induced arthritis, and blocked gout formation in mouse models. ND-2158 has antitumor activity in vivo .
|
-
- HY-P5702
-
|
|
Bacterial
Apoptosis
Fungal
|
Infection
|
|
EP3 is an antimicrobial peptide. EP3 has antibacterial and antifungal activities. EP3 inhibits E. gallinarum, P. pyocyanea, A. baumanii, K. terrigena with a MIC value of 12.85 μg/mL. EP3 also shows antitumor activity against cancer cells, and induces cell apoptosis .
|
-
- HY-147021
-
|
|
ADC Linker
|
Cancer
|
|
MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.
|
-
- HY-N0114AR
-
|
|
Topoisomerase
Apoptosis
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
(±)-Evodiamine (Standard) is the analytical standard of (±)-Evodiamine. This product is intended for research and analytical applications. (±)-Evodiamine, a quinazolinocarboline alkaloid, is a Top1 inhibitor. Evodiamine exhibits anti-inflammatory, antiobesity, and antitumor effects. (±)-Evodiamine inhibits the proliferation of a wide variety of tumor cells by inducing their apoptosis .
|
-
- HY-12743A
-
|
|
Proteasome
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
K-7174 dihydrochloride is an orally active proteasome and GATA inhibitor. K-7174 dihydrochloride is a cell adhesion inhibitor. K-7174 dihydrochloride induces cell apoptosis. K-7174 dihydrochloride shows antitumor activities, it can be used for the research of cancer .
|
-
- HY-12743
-
|
|
Proteasome
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
K-7174 is an orally active proteasome and GATA inhibitor. K-7174 is a cell adhesion inhibitor. K-7174 induces cell apoptosis. K-7174 shows antitumor activities, it can be used for the research of cancer .
|
-
- HY-134673A
-
UZH1a
2 Publications Verification
|
Apoptosis
|
Cancer
|
|
UZH1a is a potent and selective METTL3 inhibitor, with an IC50 of 280 nM. UZH1a can be used for epitranscriptomic modulation of cellular processes. UZH1a has antitumor activity. UZH1a also can be used as a chemical probe for studying METTL3 .
|
-
- HY-147834
-
|
|
STING
|
Cancer
|
|
STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity .
|
-
- HY-167860
-
|
|
Others
|
Cancer
|
|
BE-12406B is an antitumor agent that can be found in the culture broth of a streptomycete. BE-12406B can inhibit the growth of Vincristine (HY-N0488)-resistant or Doxorubicin (HY-15142A)-resistant P388 murine leukemia cell lines as well as their parent sensitive cell line .
|
-
- HY-162065
-
|
|
Ferroptosis
|
Cancer
|
|
N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8 + T cells .
|
-
- HY-N7449
-
-
- HY-152616
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one](//file.medchemexpress.com/product_pic/hy-152616.gif)
- HY-154613
-
|
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
(2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![(2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione](//file.medchemexpress.com/product_pic/hy-154613.gif)
- HY-106263B
-
|
|
PTEN
PDK-1
MDM-2/p53
Apoptosis
Akt
|
Cancer
|
|
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .
|
-
- HY-152659
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N1-Propargylpseudouridine (see GL102032) is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc . N1-Propargylpseudouridine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-152443
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
![6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine](//file.medchemexpress.com/product_pic/hy-152443.gif)
- HY-152703
-
|
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
2-Amino-7-cyclopropyl methyl-7,8-dihydro-8-oxo-9-(beta-D-xylo furanosyl)purine (G159-82) PTPD-2 Confidential is a purine nucleoside analogue. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc .
|
-
- HY-162101
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase inhibitor 3 (compound 9) is a potent Topoisomerase inhibitor. Topoisomerase inhibitor 3 shows antiproliferative and anti-tumor activity .
|
-
- HY-123979
-
ζ-Stat
1 Publications Verification
NSC37044
|
PKC
Apoptosis
|
Cancer
|
|
ζ-Stat (NSC37044) is a specific and atypical PKC-ζ inhibitor, with an IC50 of 5 μM. ζ-Stat can reduce melanoma cell lines proliferation and induce apoptosis, and has antitumor activity in vitro .
|
-
- HY-N8394
-
|
|
Others
|
Cancer
|
|
Eupatolide is an antitumor agent that can be isolated from Eupatorium formosanum. Eupatolide has cytotoxic activity and inhibits human epidermoid carcinoma of larynx cell growth in vitro .
|
-
- HY-163357
-
|
|
CDK
MDM-2/p53
|
Cancer
|
|
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC50 value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .
|
-
- HY-158109
-
|
|
Antibody-Drug Conjugates (ADCs)
CD2
|
Cancer
|
|
M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody and has anti-tumor activity. The cytotoxicity of M3554 against the GD2-positive neuroblastoma cell line CHP134 was in the subnanomolar IC50 range.
|
-
- HY-147202
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC50 values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A) .
|
-
- HY-116532
-
|
|
Bcl-2 Family
|
Cancer
|
|
YCW-E11 is a Bcl-2, and Mcl-1 inhibitor with Ki values of 0.83 and 0.33 μM, respectively. YCW-E11 induces cell apoptosis through the mitochondrial pathway and exhibits antitumor activity. YCW-E11 can be utilized in cancer research .
|
-
- HY-108553
-
|
|
Proteasome
Apoptosis
|
Cancer
|
|
Dihydroeponemycin, an analogue of the antitumor and antiangiogenic natural product eponemycin, selectively targets the 20S proteasome. Dihydroeponemycin covalently modifies a subset of catalytic proteasomal subunits, binding preferentially to the IFN-gamma-inducible subunits LMP2 and LMP7. Dihydroeponemycin-mediated proteasome inhibition induces a spindle-like cellular morphological change and apoptosis .
|
-
- HY-123325
-
|
|
Antibiotic
Bacterial
|
Infection
Cancer
|
|
Kapurimycin A1 is an anbitiotic that can be isolated from Streptomyces. Kapurimycin A1 has a significant inhibitory effect on Gram-positive bacteria, exhibits cytotoxicity to cultured mammalian cells, and shows strong antitumor activity against the mouse leukemia P388 cell line .
|
-
- HY-144617
-
|
|
DYRK
|
Cancer
|
|
JH-XIV-68-3 is a selective macrocyclic inhibitor of DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines .
|
-
- HY-123269
-
-
- HY-163195
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 40 (compound 45) is a tubulin inhibitor with IC50 of 1.2 μM. Tubulin inhibitor 40 shows selective cytotoxicity towards cancer cells. Tubulin inhibitor 40 processes antitumor activity .
|
-
- HY-19825
-
|
|
Topoisomerase
ADC Cytotoxin
Antibiotic
|
Cancer
|
|
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin appears to exert its primary antineoplastic effect by poisoning topoisomerase I and has negligible effect on protein kinase C and topoisomerase II .
|
-
- HY-123542
-
|
|
Ser/Thr Protease
Apoptosis
|
Cancer
|
|
ONO-3403 is an orally active serine protease inhibitor. ONO-3403 inhibits the production of TNF-α and nitric oxide induced by LPS. ONO-3403 inhibits the cell growth and induces the apoptosis, and has an antitumor effect on malignant tumors .
|
-
- HY-P99633
-
|
BGB-A333
|
PD-1/PD-L1
Apoptosis
|
Cancer
|
|
Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
|
-
- HY-141514
-
|
|
STING
|
Inflammation/Immunology
Cancer
|
|
MSA-2 dimer is a selective, orally active non-nucleotide STING agonist (Kd=145 μM) with long-term antitumor and immunogenic activity. MSA-2 dimer is bound to STING as a non-covalent dimer exhibiting higher permeability than cyclic dinucleotide .
|
-
![β-Glucuronide-NB-bis[N(Me)-methyl ester]-MMAE](http://file.medchemexpress.com/product_pic/hy-155313.gif)
![5′-O-[Bis(4-methoxyphenyl)phenylmethyl]cytidine](http://file.medchemexpress.com/product_pic/hy-154198.gif)
![2’-Deoxy-O6-[2-(4-nitrophenylethyl)]guanosine](http://file.medchemexpress.com/product_pic/hy-154573.gif)
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)-thymine](http://file.medchemexpress.com/product_pic/hy-154319.gif)
![1-(3’-O-[4,4’-Dimethoxytrityl]-alpha-L-threofuranosyl)uridine](http://file.medchemexpress.com/product_pic/hy-154526.gif)
![2-[(3-Pyridyl) pyrrolidin-1-yl]-2’-deoxyinosine](http://file.medchemexpress.com/product_pic/hy-154575.gif)
![5′-Deoxy-5-fluoro-N-[(2-methylbutoxy)carbonyl]cytidine](http://file.medchemexpress.com/product_pic/hy-154779.gif)
![1-[6-(Diethoxyphosphinyl)-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](http://file.medchemexpress.com/product_pic/hy-154587.gif)
![1-[6-Phosphono-2-O-methyl-β-D-ribo-hexofuranosyl]uracil](http://file.medchemexpress.com/product_pic/hy-154588.gif)
![5-[[Methyl(2,2,2-trifluoroacetyl)amino]methyl]-2-thiouridine](http://file.medchemexpress.com/product_pic/hy-152735.gif)
![2’-Deoxy-2’-fluoro-N3-[3-(tert-butoxycarbonyl) amino]propyluridine](http://file.medchemexpress.com/product_pic/hy-154725.gif)
![6-Amino-9-[2-deoxy-β-D-ribofuranosyl]-9H-purine](http://file.medchemexpress.com/product_pic/hy-154610.gif)
![N-Benzoyl-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-3′-deoxyadenosine](http://file.medchemexpress.com/product_pic/hy-154298.gif)
![2′-Amino-5′-O-[bis(4-methoxyphenyl)phenylmethyl]-2′-deoxyuridine](http://file.medchemexpress.com/product_pic/hy-154424.gif)
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]uridine](http://file.medchemexpress.com/product_pic/hy-154681.gif)
![7-(2-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-154003.gif)
![2’-Deoxy-2’-fluoro-N3-[(pyrid-4-yl)methyl]-beta-D-arabinouridine](http://file.medchemexpress.com/product_pic/hy-154658.gif)
![2-Chloro-9-[(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)]-9H-purine](http://file.medchemexpress.com/product_pic/hy-154515.gif)
![(3aR,5R,6aS)-5-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-dimethyldihydrofuro[2,3-d][1,3]dioxol-6(3aH)-one](http://file.medchemexpress.com/product_pic/hy-w061531.gif)
![2’-Deoxy-2’-fluoro-N3-[(pyrid-2-yl)methyl]-beta-D-arabinouridine](http://file.medchemexpress.com/product_pic/hy-152690.gif)
![3-β-D-Ribofuranosyl-6-hydroxymethyl-furano[2,3-d]-pyrimidin-2-one](http://file.medchemexpress.com/product_pic/hy-154029.gif)
![2-β-D-Ribofuranosyl-2H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](http://file.medchemexpress.com/product_pic/hy-152408.gif)
![4,10-Dioxatri cyclo[5.2. 1.02.6]dec-8-ene-3,5-dione](http://file.medchemexpress.com/product_pic/hy-w102981.gif)
![3,5-O-[1,1,3,3-Tetrakis(1-methylethyl)-1,3-disiloxanediyl] cytidine](http://file.medchemexpress.com/product_pic/hy-154633.gif)
![1-β-D-Ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine](http://file.medchemexpress.com/product_pic/hy-152828.gif)
![4-(Benzo[d]oxazol-2-yl)aniline](http://file.medchemexpress.com/product_pic/hy-w029411.gif)
![4-Amino-5-cyano-1- (β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](http://file.medchemexpress.com/product_pic/hy-152680.gif)
![4-Amino-1-(β-D-ribofuranosyl)-7H-pyrrolo[2.3-d]pyrimidine-5-carboxamide](http://file.medchemexpress.com/product_pic/hy-152685.gif)
![6-Amino-4-methoxy-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152398.gif)
![6-Amino-4-hydrozino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152410.gif)
![N1-Methyl-N3-[(2S)-2-(t-butoxycarbonyl)amino-3-(t-butoxycarbonyl)] propylpseudouridine](http://file.medchemexpress.com/product_pic/hy-152657.gif)
![6-Amino-4-hydroxyamino-2-(β-D-ribofuranosyl)-2H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152414.gif)
![7-(3-Deoxy-β-D-erythro-pentofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](http://file.medchemexpress.com/product_pic/hy-152582.gif)
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-methylpiperazinyl) pyridin-3-yl]purine](http://file.medchemexpress.com/product_pic/hy-152687.gif)
![4-Methoxy-1-β-D-ribofuranosyl-1H-pyrazolo[3,4-d]pyrimidin-6-amine](http://file.medchemexpress.com/product_pic/hy-152827.gif)
![7-(2,3-Anhydro-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine](http://file.medchemexpress.com/product_pic/hy-152578.gif)
![9-(3-Deoxy-3-fluoro-β-D-ribofuranosyl)-6-[6-(4-morpholinyl)pyridin-3-yl]purine](http://file.medchemexpress.com/product_pic/hy-152704.gif)
![4-Chloro-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d] pyrimidine](http://file.medchemexpress.com/product_pic/hy-152818.gif)
![2’-Deoxy-2’-fluoro-N3-(2S)-(2-amino-3-carbonyl] propyl-beta-D-arabinouridine](http://file.medchemexpress.com/product_pic/hy-154662.gif)
![2’-Deoxy-2’-fluoro-N3-(2S)-[2-(tert-butoxy-carbonyl)-amino-3-carbonyl]propyluridine](http://file.medchemexpress.com/product_pic/hy-154724.gif)
![4-Amino-5-iodo-7-(2-β-C-methyl-β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152819.gif)
![4-Amino-1-(2-C-methyl-β-D-ribofuranosyl)-1H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile](http://file.medchemexpress.com/product_pic/hy-152718.gif)
![[Pt(DACH)(OH)2(ox)]](http://file.medchemexpress.com/product_pic/hy-w778423.gif)
![6-Amino-1,2-dihydro-2-β-D-ribofuranosyl-4H-pyrazolo[3,4-d]pyrimidin-4-one](http://file.medchemexpress.com/product_pic/hy-152405.gif)
![2-Amino-3,7-dihydro-5-iodo-7-β-D-ribofuranosyl-4H-pyrrolo[2,3-d]pyrimidin-4-one](http://file.medchemexpress.com/product_pic/hy-152616.gif)
![(2R-cis)-5-[Tetrahydro-5-(hydroxymethyl)-4-oxo-2-furanyl]-2,4(1H,3H)-pyrimidinedione](http://file.medchemexpress.com/product_pic/hy-154613.gif)
![6-Amino-3-(furan-2-yl)-4-methoxy-1-(β-D-ribofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine](http://file.medchemexpress.com/product_pic/hy-152443.gif)
